Matriptase 2 inhibitors and uses thereof
Matriptase 2 inhibitors, such as those defined by formula I, address IRIDA by increasing hepcidin production, effectively treating associated disorders by modulating iron metabolism and improving conditions like iron overload and hematological diseases.
Patent Information
- Application Number
- JP2024127647
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-02
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Matriptase 2 mutations lead to iron-refractory iron deficiency anemia (IRIDA) due to inappropriate high hepcidin levels, as the enzyme suppresses hepcidin expression through BMP/SMAD signaling, necessitating a therapeutic approach to modulate iron metabolism by increasing hepcidin production.
Development of compounds that inhibit matriptase 2 activity, thereby increasing hepcidin production to treat disorders associated with relative or absolute hepcidin deficiency, using specific chemical structures defined by formula I and its pharmaceutically acceptable salts.
The compounds effectively inhibit matriptase 2, leading to increased hepcidin production, which can treat conditions like IRIDA, iron overload disorders, hematological diseases, liver diseases, metabolic diseases, and neurodegenerative diseases by modulating iron metabolism.
Smart Images

Figure 2024156867000001 
Figure 2024156867000002 
Figure 2024156867000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to compounds and methods useful for inhibiting matriptase 2 ("Mat-2") or variants thereof. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. [Background technology]
[0002] Matriptase 2 is a modular cell surface serine protease. Mutations in matriptase 2 cause iron-refractory iron deficiency anemia (IRIDA), a condition characterized by inappropriately high hepcidin levels. Matriptase 2 enzymatic activity reduces hepcidin expression through maternal-son inhibition of bone morphogenetic protein (BMP) / decapentaplegic homolog protein (SMAD) signaling. Loss or inhibition of matriptase 2 activity leads to increased hepcidin production by the liver. Summary of the Invention
[0003] It has now been found that compounds of the present invention and pharmaceutically acceptable compositions thereof are effective as inhibitors of matriptase 2. In one aspect, the present invention provides compounds of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0004] The compounds of the present invention and pharmaceutically acceptable compositions thereof are useful for treating a variety of diseases, disorders, or conditions associated with relative or absolute hepcidin deficiency, or in which modulating iron metabolism by increasing hepcidin production by the liver may be therapeutically beneficial. DETAILED DESCRIPTION OF THE INVENTION
[0005] 1. Overview of Certain Embodiments of the Invention The compounds of the present invention and pharmaceutical compositions thereof are useful as inhibitors of matriptase 2 or variants thereof. Without wishing to be bound by any particular theory, it is believed that the compounds of the present invention and pharmaceutical compositions thereof may inhibit the activity of matriptase 2 or variants thereof and may therefore treat a variety of diseases, disorders, or conditions associated with relative or absolute hepcidin deficiency, such as those described herein, or diseases, disorders, or conditions in which modulating iron metabolism by increasing hepcidin production by the liver may be therapeutically useful.
[0006] It has now been found that compounds of the present invention and pharmaceutically acceptable compositions thereof are effective as inhibitors of matriptase 2. In one aspect, the present invention provides compounds of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: each X is independently C or N; L 1 is a bond or an optionally substituted divalent C 1-8 a saturated or unsaturated, straight or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)2-, -C(O)-, or -O-; R 1 is H or an optionally substituted ring selected from a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic carbocycle, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; L 2 is an optionally substituted divalent C 1-8a saturated or unsaturated, straight or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -NR-C(O)-, -C(O)-NR-, -C(O)-, -S(O)-, -C(O)-O-, -OC(O)-, -NR-S(O)-, -S(O)-NR-, or -Cy-; -Cy- is an optionally substituted divalent ring selected from a 4- to 6-membered monocyclic heterocycle having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, and a 4- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 2 is H or an optionally substituted ring selected from a 4-7 membered monocyclic carbocycle, a 4-7 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered bicyclic carbocycle, a 7-10 membered bicyclic heterocarboxylic acid ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic ring, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and adamantyl; R 3 is H, halogen, -CN, -C(O)H, -NH2, -NO2, -COOH, -CONH2, -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 aliphatic compounds, where C 1-6 The aliphatic compound is optionally substituted; L 3 is a bond or an optionally substituted divalent C 1-8 a saturated or unsaturated, linear or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally replaced by -CO-; R 4is —NHR, —C(NR)—NHR, —NH—C(NR)—NHR, —F, or —OH; and Each R is independently H, -C 1-8 Alkyl, -OC 1-8 Alkyl, -C(O)-C 1-8 Alkyl, -C(O)-OC 1-8 Alkyl, 4- to 7-membered monocyclic carbocyclyl, -O-(4- to 7-membered monocyclic carbocyclyl), -C(O)-(4- to 7-membered monocyclic carbocyclyl), -C(O)-O-(4- to 7-membered monocyclic carbocyclyl), phenyl, -O-phenyl, -C(O)-phenyl, -C(O)-O-phenyl, 8- to 10-membered bicyclic aryl, -O-(8- to 10-membered bicyclic aryl), -C(O)-(8- to 10-membered bicyclic aryl), or -C(O)-O-(8- to 10-membered bicyclic aryl), wherein C 1-8 Each of the alkyl, 4- to 7-membered monocyclic carbocyclyl, phenyl, and 8- to 10-membered bicyclic aryl is optionally and independently substituted.
[0007] 2. Compounds and Definitions The compounds of the present invention include those generally described herein and are further described by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75th Edition. Furthermore, general principles of organic chemistry may be learned from "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry”, 5 th Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001.
[0008] The terms "aliphatic compound" or "aliphatic group," as used herein, refer to a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing one or more units of fully saturated or unsaturated, or a monocyclic or bicyclic hydrocarbon containing one or more units of fully saturated or unsaturated, but which is not aromatic (also referred to herein as "carbocyclic," "alicyclic," or "cycloalkyl") and has a single point of attachment to the rest of the molecule. Unless specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in yet other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, straight-chain or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups, and hybrids thereof, such as, for example, (cycloalkyl)alkyl, (cycloalkynyl)alkyl, or (cycloalkyl)alkenyl.
[0009] As used herein, the term "bicyclic ring" or "bicyclic ring system" refers to any bicyclic ring system, i.e., a carbocyclic or heterocyclic ring having one or more units of saturated or unsaturation with one or more atoms in common between the two rings of the ring system. Thus, the term includes permissible ring fusions, such as ortho-fused or spiro-fused rings. As used herein, "heterobicyclic" is a subset of "bicycle," requiring one or more heteroatoms to be present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions, are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, and the like. In some embodiments, bicyclic groups have 7 to 12 ring members and 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term "bridged bicycle" refers to any bicyclic ring system, i.e., a saturated or partially unsaturated carbocyclic or heterocyclic ring, having at least one bridge. As defined by IUPAC, a "bridge" is an unbranched chain of atoms or an atomic bond or valence bond connecting two bridgeheads, where a "bridgehead" is any skeletal atom of a ring system that is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7 to 12 ring members and 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include groups as described below, where each group is linked to the remainder of the molecule at a substitutable carbon or nitrogen atom. Unless specified, a bridged bicyclic group is optionally substituted with one or more substituents as described for an aliphatic group. Additionally, or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include: [ka] Exemplary bridged bicycles include: [ka] Examples include:
[0010] The term "lower alkyl" refers to C 1-4 " refers to a straight or branched chain alkyl group of the formula: Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
[0011] The term "lower haloalkyl" refers to a C substituted with one or more halogen atoms. 1-4 refers to a straight or branched chain alkyl group.
[0012] The term "heteroatom" means oxygen, sulfur, nitrogen, phosphorus, or silicon (oxidized forms of nitrogen, sulfur, phosphorus, or silicon; quaternized forms of a basic nitrogen; or a substitutable nitrogen of a heterocycle, e.g., N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (including as in N-substituted pyrrolidinyl) means one or more of:
[0013] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.
[0014] As used herein, "divalent C 1-8 (or C 1-6 The term "saturated or unsaturated, straight or branched hydrocarbon chain" refers to divalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
[0015] The term "alkylene" refers to a divalent alkyl group. The alkylene chain is a polymethylene group, i.e., -(CH2) n -, where n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 2 to 3. A substituted alkynylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0016] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0017] As used herein, the term "cyclopropylenyl" refers to the following structure: [ka] refers to a divalent cyclopropyl group of the formula:
[0018] The term "halogen" means F, Cl, Br or I.
[0019] The term "aryl," used alone or as part of a larger moiety such as "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including, but not limited to, phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Also included within the scope of the term "aryl," as used herein, are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as, for example, indanyl, phthalimidyl, naphthimidyl, or tetrahydronaphthyl.
[0020] The terms "heteroaryl" and "heteroar-," used alone or as part of a larger moiety, such as "heteroaralkyl" or "heteroaralkoxy," refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, having 6, 10, or 14 pi-electrons shared in a cyclic arrangement, and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to a group that is heteroatom-free, such as nitrogen, oxygen, or sulfur. " refers to heteroaryl groups, including oxidized forms of nitrogen or sulfur and quaternized forms of basic nitrogens. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroar-," as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic, or heterocyclyl rings, with the radical or point of attachment being on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include optionally substituted rings. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions are independently optionally substituted.
[0021] As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety, saturated or partially unsaturated, having carbon atoms and one or more, preferably 1 to 4, heteroatoms as defined above. When used in reference to a heterocyclic ring atom, the term "nitrogen" includes substituted nitrogen. By way of example, in a saturated or partially unsaturated ring having 0 to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or . + It may also be NR (as in N-substituted pyrrolidinyl).
[0022] A heterocyclic ring can be linked to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical" are used interchangeably herein and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or alicyclic rings, such as, for example, indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. Heterocyclyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl portions independently are optionally substituted.
[0023] As used herein, the term "partially unsaturated" refers to a ring moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0024] As described herein, compounds of the invention may contain "optionally substituted" moieties. The term "substituted," whether preceded by the term "optionally," means that one or more hydrogens in the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable moiety of the group, and when more than one moiety in a given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at each moiety. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to a compound that remains substantially unchanged when subjected to conditions that permit its production, detection, and, in certain embodiments, recovery, purification, and use for one or more of the purposes disclosed herein.
[0025] Each optional substituent at a substitutable carbon is a halogen; -(CH2) 0-4 R*;-( CH2) 0-4 OR°*;-O(CH2) 0-4 R*, -O-(CH2) 0-4 C(O)OR°;-(CH2) 0-4 CH(OR*)2;-(CH2) 0-4 SR*;R* May be replaced by -(CH2) 0-4 Ph; optionally substituted by R* -(CH2)0 -4 O(CH2) 0-1 Ph; optionally substituted by R* -CH=CHPh; optionally substituted by R* -(CH 0-4 O(CH2)0-1 -pyridyl; -NO2; -CN; -N3; -(CH2) 0-4 N(R*)2; -(CH2) 0-4 N(R*)C(O)R*; -N(R*)C(S)R*; -(CH2) 0-4 N(R*)C(O)NR*2; -N( R*)C(S)NR*2; -(CH2) 0-4 N(R*)C(O)OR*; -N(R*)N( R*)C(O)R*; -N(R*)N(R*)C(O)NR*2; -N(R*)N(R*)C( O)OR*; -(CH2) 0-4 C(O)R*; -C(S)R*; -(CH2) 0-4 C( O)OR*; -(CH2) 0-4 C(O)SR*; -(CH) 0-4 C(O)OSiR* 3; -(CH2) 0-4 OC(O)R*; -OC(O)(CH2) 0-4 SR-、SC( S)SR°; -(CH2)[[ID=*]] 0-4 SC(O)R*; -(CH2) 0-4 C(O)NR*2; -C(S)NR*2; -C(S)SR°; -SC(S)SR°、-(CH2) 0-4 OC (O)NR*2; -C(O)N(OR*)R*; -C(O)C(O)R*; -C(O)CH2C(O)R*; -C(NOR*)R*; -(CH2) 0-4 SSR*; -(CH2) 0-4 S(O)2R*; -(CH2) 0-4 S(O)2OR*; -(CH2) 0-4 OS(O)2R*; -S(O)2NR*2; -S(O)(NR°)R°; -S(O)2N=C(NR°2)2; -(CH2) 0-4 S(O)R*; -N(R*)S(O)2NR*2; -N(R*)S(O)2R*; -N(OR*)R*; -C(NH)NR*2; -P(O)2R*; -P(O)R*2; -OP(O)R*2; -OP(O)(OR*)2; SiR*3; -(C 1-4 linear chain or <000126>*is a branched alkylene)ON(R*)2; or -(C 1-4 Linear or branched chain alkane is a monovalent substituent independently selected from alkylene)C(O)ON(R*)2.
[0026] Each R* is independently hydrogen, C 1-6 Aliphatic compounds, -CH2Ph, -O(CH2) 0- 1Ph, -CH2- (5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definition, two independent occurrences of R* may be at a saturated carbon atom of R* selected from =O and =S, together with the intervening atom(s) or each R* forms a 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted by a divalent substituent selected from the group consisting of: halogen, -(CH2) 0-2 R # ,-(Halo R # ), -(CH2) 0-2 OH, -(CH2) 0-2 OR # , -(CH2) 0-2 CH(OR # )2;-O(HaloR # ), -CN, -N3, -(CH2) 0-2 C(O)R # , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR # , -(CH2) 0-2 SR # , -(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR # , -(CH2) 0-2 NR # 2, -NO2, -SiR # 3. -OSi R# 3. -C(O)SR # 、 -(C 1-4 Straight or branched chain alkylene)C(O)OR # , or -SSR # is optionally substituted by a monovalent substituent independently selected from
[0027] Each R # is C 1-4 Aliphatic compounds, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R # is unsubstituted, or, if preceded by halo, is substituted only with one or more halogens; or, if any substituent on a saturated carbon is a divalent substituent, is ═O, ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O- or -S(C(R * 2)) 2-3 A divalent substituent attached to an adjacent substitutable carbon of an "optionally substituted" group is independently selected from -S- or -O(CR * 2) 2-3 O-, where R * each independent occurrence of C has 0 to 4 heteroatoms independently selected from hydrogen, nitrogen, oxygen, or sulfur. 1-6 It is selected from aliphatic compounds or unsubstituted 5- to 6-membered saturated rings, partially unsaturated rings, or aryl rings.
[0028] R * C 1-6 If it is an aliphatic compound, R * is halogen, -R # ,-(Halo R # ), -OH, -OR # , -O(HaloR# ), -CN, -C(O)OH, -C(O)OR # , -NH2, -NHR # , -NR # 2, or -NO2, where R # is C 1-4 Aliphatic compounds, -CH2Ph, -O(CH2) 0-1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; # is unsubstituted or, if preceded by halo, substituted only with one or more halogens.
[0029] Any substituent at a substitutable nitrogen is independently -R $ , -NR $ 2. -C(O)R $ , -C(O)OR $ , -C(O)C(O)R $ , -C(O)CHC(O)R $ , -S(O)2R $ , -S(O)NR $ 2. -C(S)NR $ 2. -C(NH)NR $ 2, or -N(R $ )S(O)2R $ In this case, each R $ are independently hydrogen, C 1-6 an aliphatic compound, an unsubstituted -OPh, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R $ two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; $ is C 1-6 It is an aliphatic compound, R $ is halogen, -R # ,-(Halo R # ), -OH, -OR #, -O(HaloR # ), -CN, -C(O)OH, -C(O)OR # , -NH2, -NHR # , -NR # 2, or -NO2, wherein each R # is C 1-4 Aliphatic compounds, -CH2Ph, -O(CH2) 0-1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; # is unsubstituted or, if preceded by halo, substituted only with one or more halogens.
[0030] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., and which are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Pharmaceutically acceptable non-toxic acid addition salts include those derived from inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or from acids such as, for example, acetic acid. , oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, and the like. Acid salts include, for example, salts of hydroxybenzoates, ...
[0031] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed with counterions such as, for example, halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
[0032] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure: for example, S and R configurations about each asymmetric center, Z and E double bond isomers, and Z and E stereoisomers. Accordingly, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, tautomers of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium, or 13 C or 14 Compounds having the present structure including the replacement of a carbon with a C-enriched carbon are within the scope of the present invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or as therapeutic agents according to the present invention. In certain embodiments, compounds of the present invention include one or more deuterium atoms.
[0033] As used herein, the term "inhibitor" is defined as a compound that binds to and / or inhibits matriptase 2 or a variant thereof with measurable affinity. In certain embodiments, an inhibitor has an IC of less than about 100 μM, less than about 50 μM, less than about 20 μM, less than about 10 μM, or less than about 5 μM. 50 and / or have a binding constant.
[0034] The terms "measurable affinity" and "measurably inhibit" as used herein refer to a measurable change in matriptase 2 or a variant thereof, a measurable change in activity, between a sample containing a compound or composition thereof of the present invention and matriptase 2 or a variant thereof and an equivalent sample containing matriptase 2 or a variant thereof in the absence of said compound or composition thereof.
[0035] 3. Description of Exemplary Embodiments In one aspect, the present invention provides a compound of formula I [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, each X is independently C or N; L 1 is a bond or an optionally substituted divalent C 1-8 a saturated or unsaturated, straight or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)2-, -C(O)-, or -O-; R 1 is H or an optionally substituted ring selected from a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic carbocycle, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; L 2 is an optionally substituted divalent C 1-8 a saturated or unsaturated, straight or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -NR-C(O)-, -C(O)-NR-, -C(O)-, -S(O)-, -C(O)-O-, -OC(O)-, -NR-S(O)-, -S(O)-NR-, or -Cy-; -Cy- is an optionally substituted divalent ring selected from phenyl and a 4-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 2is H or an optionally substituted ring selected from a 4-7 membered monocyclic carbocycle, a 4-7 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered bicyclic carbocycle, a 7-10 membered bicyclic heterocarboxylic acid ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic ring, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and adamantyl; R 3 is H, halogen, -CN, -C(O)H, -NH2, -NO2, -COOH, -CONH2, -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 aliphatic compounds, where C 1-6 The aliphatic compound is optionally substituted; L 3 is a bond or an optionally substituted divalent C 1-8 a saturated or unsaturated, linear or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally replaced by -CO-; R 4 is —NHR, —C(NR)—NHR, —NH—C(NR)—NHR, —F, or —OH; and Each R is independently H, -C 1-8 Alkyl, -OC 1-8 Alkyl, -C(O)-C 1-8 Alkyl, -C(O)-OC 1-8 Alkyl, 4- to 7-membered monocyclic carbocyclyl, -O-(4- to 7-membered monocyclic carbocyclyl), -C(O)-(4- to 7-membered monocyclic carbocyclyl) -C(O)-O-(4- to 7-membered monocyclic carbocyclyl), phenyl, -O-phenyl, -C(O)-phenyl, -C(O)-O-phenyl, 8- to 10-membered bicyclic aryl, -O-(8- to 10-membered bicyclic aryl), -C(O)-(8- to 10-membered bicyclic aryl), or -C(O)-O-(8- to 10-membered bicyclic aryl), wherein C 1-8 Each of the alkyl, 4- to 7-membered monocyclic carbocyclyl, phenyl, and 8- to 10-membered bicyclic aryl is optionally and independently substituted.
[0036] Each X is independently C or N, as generally defined above.
[0037] In some embodiments, X is C. In some embodiments, X is N.
[0038] In some embodiments, [ka] is below [ka] Each X is independently C or N, such that
[0039] In some embodiments, each X is independently selected from those shown in Table A below.
[0040] As generally defined above, L 1 is a bond or an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)2-, -C(O)-, or -O-.
[0041] In some embodiments, L 1 is a bond.
[0042] In some embodiments, L 1is an optionally substituted C 1-8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)-, -C(O)-, or -O-. In some embodiments, L 1 is an optionally substituted C 1-8 It is a divalent hydrocarbon chain, and one methylene unit of the hydrocarbon chain is Optionally substituted by -S(O)-, -C(O)-, or -O-. In some embodiments, L 1 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain, wherein two methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)-, -C(O)-, or -O-. 1 is an optionally substituted C 1-8 It is a divalent hydrocarbon chain in which three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)2-, -C(O)-, or -O-.
[0043] In some embodiments, L 1 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain, wherein one methylene unit of the hydrocarbon chain is replaced by -S(O)-. 1 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain in which one methylene unit is replaced by -C(O)-. 1 is an optionally substituted C 1-8 It is a divalent hydrocarbon chain in which one methylene unit of the hydrocarbon chain is replaced by -O-.
[0044] In some embodiments, L 1 is -(CH2)-. In some embodiments, L 1 is -(CH2)2-. In some embodiments, L 1 is -(CH2)3-. In some embodiments, L 1 is —S(O)2CH2—. In some embodiments, L 1is —S(O)(CH)—. In some embodiments, L 1 is -S(O)-. In some embodiments, L 1 is —CHS(O)—. In some embodiments, L 1 is -(CH2)2S(O)2-.
[0045] In some embodiments, L 1 is selected from those shown in Table A below.
[0046] As generally defined above, R 1 is H or an optionally substituted ring selected from a 5- to 6-membered heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8- to 10-membered bicyclic aromatic carbocycle, and an 8- to 10-membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0047] In some embodiments, R 1 is H. In some embodiments, R 1 is an optionally substituted ring selected from a 5- to 6-membered heteroaromatic ring having 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8- to 10-membered bicyclic aromatic carbocycle, and an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0048] In some embodiments, R 1 is optionally substituted phenyl. In some embodiments, R 1 is unsubstituted phenyl. In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] and halogen is fluorine, chlorine, or bromine. In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] is.
[0049] In some embodiments, R 1 is an optionally substituted 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1is an optionally substituted 5-membered heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1 is an optionally substituted 6-membered heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0050] In some embodiments, R 1 is optionally substituted pyridyl. In some embodiments, R 1 is unsubstituted pyridyl. In some embodiments, R 1 teeth [ka] is.
[0051] In some embodiments, R 1 is.
[0052] In some embodiments, R 1 is an optionally substituted 8-10 membered bicyclic aromatic carbocycle. In some embodiments, R 1 is an optionally substituted 8-membered bicyclic aromatic carbocycle. In some embodiments, R 1 is an optionally substituted 9-membered bicyclic aromatic carbocycle In some embodiments, R 1 is an optionally substituted 10-membered bicyclic aromatic carbocycle. In some embodiments, R 1 Ha-CH2-R 11 , -OR 11 , -NR 11 , -SR 11 , -NR-C(O)-R 11 , -C(O)-NR-R 11 , -C(O)-R 11 , -S(O)2-R 11 , -C(O)-OR 11 , -OC(O)-R 11 , -NR-S(O)2-R 11 , or -S(O)2-NR-R 11is a 10-membered bicyclic aromatic carbocycle optionally substituted by 11 is an optionally substituted phenyl or a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] is.
[0053] In some embodiments, R 1 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1 is an optionally substituted 8-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1 is an optionally substituted 9-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 1 is an optionally substituted 10-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0054] In some embodiments, R 1 teeth [ka] is.
[0055] In some embodiments, R 1 is selected from those shown in Table A below.
[0056] As generally defined above, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -NR-C(O)-, -C(O)-NR-, -C(O)-, -S(O)-, -C(O)-O-, -OC(O)-, -NR-S(O)-, -S(O)-NR-, or -Cy-.
[0057] In some embodiments, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -NR-C(O)-, -C(O)-NR-, -C(O)-, -C(O)-O-, or -OC(O)-. In some embodiments, C 1-8 The divalent hydrocarbon chain is substituted with -OH.
[0058] In some embodiments, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -S(O)2-, -NR-S(O)2-, or -S(O)2-NR-.
[0059] In some embodiments, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -Cy-.
[0060] In some embodiments, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -NR-C(O)-, -C(O)-NR-, -NR-S(O)-, or -S(O)-NR-.
[0061] In some embodiments, L2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -C(O)- or -S(O)2-.
[0062] In some embodiments, L 2 is an optionally substituted C 1-8 A divalent hydrocarbon chain wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently replaced by -C(O)-O- or -OC(O)-.
[0063] In some embodiments, L 2 -CH2-, -NH-, -NH-CH3-, -CH3-NH-, -NH-C(O)-, -N(CH3)-C(O)-, -S(O)2-, -CH2-NH-C(O)-, [ka] -(CH2)2-, -NH-CH(CH3)-, -NH-(CH2)2-, [ka] -NH-(CH2)4-NH-, or -NH-(CH2)3-.
[0064] In some embodiments, L 2 is selected from those shown in Table A below.
[0065] As generally defined above, -Cy- is an optionally substituted divalent ring selected from phenyl, a 4- to 6-membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 4- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0066] In some embodiments, -Cy- is optionally substituted phenylene. In some embodiments, -Cy- is unsubstituted phenylene.
[0067] In some embodiments, -Cy- is optionally substituted pyridylene. In some embodiments, -Cy- is unsubstituted pyridylene.
[0068] In some embodiments, -Cy- is a 4- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is a 4-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is a 5-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is a 6-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0069] In some embodiments, -Cy- is an optionally substituted 4- to 6-membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 4-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 5-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, -Cy- is an optionally substituted 6-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0070] In some embodiments, -Cy- is an optionally substituted divalent ring that is oxadiazole. In some embodiments, -Cy- is an optionally substituted divalent ring that is thiadiazole.
[0071] In some embodiments, -Cy- is selected from those shown in Table A below.
[0072] As generally defined above, R 2 is H, or a 4- to 7-membered monocyclic carbocyclic ring, a 4- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7- to 10-membered bicyclic carbocyclic ring, a 7- to 10-membered bicyclic heterocarboxylic acid ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenyl, nitrogen, an optionally substituted ring selected from a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic aromatic ring; an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and adamantyl.
[0073] In some embodiments, R 2 is H. In some embodiments, R 2 is an optionally substituted ring selected from a 4- to 7-membered monocyclic carbocyclic ring, a 4- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7- to 10-membered bicyclic carbocyclic ring, a 7- to 10-membered bicyclic heterocarboxylic acid ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8- to 10-membered bicyclic aromatic ring, an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and adamantyl.
[0074] In some embodiments, R 2 is an optionally substituted 4- to 7-membered monocyclic carbocyclic ring.
[0075] In some embodiments, R 2 is a 4-7 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2is a 4-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is a 5-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is a 6-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is a 7-membered monocyclic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0076] In some embodiments, R 2 is an optionally substituted 7- to 10-membered bicyclic carbocyclic ring.
[0077] In some embodiments, R 2 is an optionally substituted 7-10 membered bicyclic heterocarboxylic acid ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 7-membered bicyclic heterocarboxylic acid ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 8-membered bicyclic heterocarboxylic acid ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 9-membered bicyclic heterocarboxylic acid ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 10-membered bicyclic heterocarboxylic acid ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0078] In some embodiments, R 2 is optionally substituted phenyl.
[0079] In some embodiments, R 2 is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 5-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 6-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0080] In some embodiments, R 2 is an optionally substituted 8- to 10-membered bicyclic aromatic ring.
[0081] In some embodiments, R 2 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 8-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 9-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 2 is an optionally substituted 10-membered bicyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0082] In some embodiments, R 2 is an optionally substituted adamantyl.
[0083] In some embodiments, R 2 teeth [ka] [ka] [ka] is selected from.
[0084] In some embodiments, R 2 is selected from those shown in Table A below.
[0085] As generally defined above, R 3 are H, -OH, halogen, -CN, -C(O)H, -NH2, -NO2, -COOH, -CONH2, -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 aliphatic compounds, where C 1-6 The aliphatic compounds are optionally substituted.
[0086] In some embodiments, R 3 is H. In some embodiments, R 3 is halogen. In some embodiments, R 3 is -CN. In some embodiments, R 3 is —C(O)H. In some embodiments, R 3 is -NH. In some embodiments, R 3 is —NO. In some embodiments, R 3 is —COOH. In some embodiments, R 3 is -CONH. In some embodiments, R 3 -NH-C(O)-OC 1-6 It is an aliphatic compound, C 1-6 The aliphatic compound is optionally substituted. In some embodiments, R 3 is C 1-6 It is an aliphatic compound, C 1-6 The aliphatic compound is optionally substituted. In some embodiments, R 3is -C(O)-C 1-6 It is an aliphatic compound, C 1-6 The aliphatic compounds are optionally substituted.
[0087] In some embodiments, R 3 is —OH. In some embodiments, R 3 is -NH. In some embodiments, R 3 is —NO. In some embodiments, R 3 is —COOH. In some embodiments, R 3 is NH—C(O)—O—C2H5. In some embodiments, R 3 is -CH2-OCH3.
[0088] In some embodiments, R 3 is selected from those shown in Table A below.
[0089] As generally defined above, L 3 is a bond or an optionally substituted C 1-8 It is a divalent hydrocarbon chain in which one, two or three methylene units of the hydrocarbon chain are optionally replaced by -CO-.
[0090] In some embodiments, L 3 is a bond.
[0091] In some embodiments, L 3 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain in which one, two, or three methylene units are optionally replaced by -CO-. 3 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain, wherein one methylene unit of the hydrocarbon chain is optionally replaced by -CO-. 3 is an optionally substituted C 1-8 In some embodiments, L is a divalent hydrocarbon chain, wherein two methylene units of the hydrocarbon chain are optionally replaced by -CO-. 3 is an optionally substituted C1-8 It is a divalent hydrocarbon chain in which three methylene units of the hydrocarbon chain are optionally replaced by -CO-.
[0092] In some embodiments, L 3 is -CH2-.
[0093] In some embodiments, L 3 is selected from those shown in Table A below.
[0094] As generally defined above, R 4 is —NHR, —C(NR)—NHR, —NH—C(NR)—NHR, —F, or —OH.
[0095] In some embodiments, R 4 is -NHR. In some embodiments, R 4 is —C(NR)—NHR. In some embodiments, R 4 is —NH—C(NR)—NHR. In some embodiments, R 4 is -F. In some embodiments, R 4 is -OH.
[0096] In some embodiments, R 4 is -NH. In some embodiments, R 4 teeth [ka] is selected from.
[0097] In some embodiments, R 4 is selected from those shown in Table A below.
[0098] As generally defined above, R independently represents H, -C 1-8 Alkyl, -OC 1-8 Alkyl, -C(O)-C 1-8 Alkyl, -C(O)-OC 1-8alkyl, 4- to 7-membered monocyclic carbocyclyl, -O-(4- to 7-membered monocyclic carbocyclyl), -C(O)-(4- to 7-membered monocyclic carbocyclyl), -C(O)-O-(4- to 7-membered monocyclic carbocyclyl), phenyl, -O-phenyl, -C(O)-phenyl, -C(O)-O-phenyl, 8- to 10-membered bicyclic aryl, -O-(8- to 10-membered bicyclic aryl), -C(O)-(8- to 10-membered bicyclic aryl), or -C(O)-O-(8- to 10-membered bicyclic aryl), wherein C 1-8 Each of the alkyl, 4- to 7-membered monocyclic carbocyclyl, phenyl, and 8- to 10-membered bicyclic aryl is optionally and independently substituted.
[0099] In some embodiments, R is H. In some embodiments, R is —OH.
[0100] In some embodiments, R is optionally substituted -C 1-8 In some embodiments, R is optionally substituted -OC. 1-8 In some embodiments, R is optionally substituted -C(O)-C 1-8 In some embodiments, R is optionally substituted -C(O)-OC 1-8 In some embodiments, C 1-8 Alkyl is C 1-6 In some embodiments, C 1-8 Alkyl is isopropyl. In some embodiments, C 1-8 The alkyl is tert-butyl. In some embodiments, C 1-8 The alkyl is neopentyl.
[0101] In some embodiments, R is an optionally substituted 4-7 membered monocyclic carbocyclyl. In some embodiments, R is an optionally substituted -O-(4-7 membered monocyclic carbocyclyl). In some embodiments, R is an optionally substituted -C(O)-(4-7 membered monocyclic carbocyclyl). In some embodiments, R is an optionally substituted -C(O)-O-(4-7 membered monocyclic carbocyclyl). In some embodiments, the 4-7 membered monocyclic carbocyclyl is cyclopentyl. In some embodiments, the 4-7 membered monocyclic carbocyclyl is cyclohexyl.
[0102] In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted -O-phenyl. In some embodiments, R is optionally substituted -C(O)-phenyl. In some embodiments, R is optionally substituted -C(O)-O-phenyl.
[0103] In some embodiments, R is an optionally substituted 8-10 membered bicyclic aryl. In some embodiments, R is an optionally substituted -O-(8-10 membered bicyclic aryl). In some embodiments, R is an optionally substituted -C(O)-(8-10 membered bicyclic aryl). In some embodiments, R is an optionally substituted -C(O)-O-(8-10 membered bicyclic aryl).
[0104] In some embodiments, R is selected from those shown in Table A below.
[0105] In some embodiments, the compound of formula I has formula II [ka] wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0106] In some embodiments, the compound of Formula I has the formula II-a to II-f: [ka] or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0107] In some embodiments, the compound of formula I has formula III: [ka] wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0108] In some embodiments, the compound of Formula I has the formula III-a to III-f: [ka] or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0109] In some embodiments, the compound of formula I has formula IV: [ka] wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0110] In some embodiments, the compound of Formula I has the formula IV-a to IV-f: [ka] or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 Each of -Cy-, -Cy-, and R is as defined above and is described in embodiments herein both alone and in combination.
[0111] Exemplary compounds of the present invention are set forth in Table A below. [Table 1] [Table 2] [Table 3] [Table 4]
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11
Table 12
Table 13
Table 14
Table 15
Table 17
Table 18
Table 19
Table 30
Table 50
Table 91
Table 99
Table 100
[0112] In some embodiments, the present invention provides a compound set forth in Table A above, or a pharmaceutically acceptable salt thereof.
[0113] In some embodiments, the present invention provides a compound set forth in the Examples below, or a pharmaceutically acceptable salt thereof.
[0114] In some embodiments, the compound of the invention is not: [ka]
[0115] 4. Use, Formulation and Administration Pharmaceutically acceptable compositions According to another embodiment, the present invention provides a composition comprising a compound of the present invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in the composition of the present invention is effective to measurably inhibit matriptase 2 or a variant thereof in a biological sample or a patient. In certain embodiments, the amount of compound in the composition of the present invention is effective to measurably inhibit matriptase 2 or a variant thereof in a biological sample or a patient. In certain embodiments, the composition of the present invention is formulated for administration to a patient in need of such a composition. In some embodiments, the composition of the present invention is formulated for oral administration to a patient.
[0116] The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[0117] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants, or vehicles that may be used in the compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block copolymers, polyethylene glycol, and wool fat.
[0118] "Pharmaceutically acceptable derivative" means a non-toxic salt, ester, salt of an ester, or other derivative of a compound of the present invention that, upon administration to a recipient, is capable of providing, directly or indirectly, the compound of the present invention or an inhibitory active metabolite or residue thereof.
[0119] As used herein, the term "inhibitory active metabolite or residue thereof" means that the metabolite or residue thereof is also an inhibitor of matriptase 2 or a variant thereof. means.
[0120] The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. The term "parenterally," as used herein, includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present invention may be aqueous or oily suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending media.
[0121] For this purpose, any type of fixed oil may be used, including synthetic monoglycerides or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives, especially in their polyoxyethylated forms, are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils such as olive oil or castor oil. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used in the preparation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween and Span, and other emulsifiers or bioavailability enhancers, commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.
[0122] The pharmaceutically acceptable composition of the present invention can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions.For tablets for oral use, commonly used carriers include lactose and cornstarch.Lubricants, such as magnesium stearate, are also usually added.For oral administration in capsule form, useful diluents include lactose and dried cornstarch.When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents.If desired, certain sweeteners, flavorings or coloring agents can also be added.
[0123] Alternatively, the pharmaceutically acceptable compositions of the present invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.
[0124] The pharmaceutically acceptable compositions of this invention may be administered topically, particularly when the target of treatment includes areas or organs easily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[0125] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical transdermal patches may also be used.
[0126] For topical application, the pharmaceutically acceptable compositions provided herein may be formulated in a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present invention include mineral oil, liquid petrolatum, white petrolatum, propylene glycol, and the like. Examples of suitable carriers include, but are not limited to, glycerin, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the provided pharmaceutically acceptable compositions can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.
[0127] For ophthalmic use, the provided pharmaceutically acceptable compositions may be formulated as a micronized suspension in isotonic, pH-adjusted, sterile saline, with or without a preservative such as benzalkonium chloride, or preferably as a solution in isotonic, pH-adjusted, sterile saline. Alternatively, for ophthalmic use, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
[0128] Pharmaceutically acceptable compositions of the invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0129] Most preferably, the pharmaceutically acceptable compositions of the present invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of the present invention are administered without food. In other embodiments, the pharmaceutically acceptable compositions of the present invention are administered with food.
[0130] The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration, etc. Preferably, the provided compositions should be formulated so that a dosage of between 0.01-100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.
[0131] It should also be understood that the specific dosage and treatment regimen for a particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, body weight, general condition, sex, diet, frequency of administration, rate of excretion, drug combinations, and the judgment of the attending physician and the severity of the particular disease being treated. The amount of a compound of the invention in a composition will also depend on the particular compound in the composition.
[0132] Uses of the Compounds and Pharmaceutically Acceptable Compositions The compounds and compositions described herein are generally useful for inhibiting matriptase 2 or variants thereof.
[0133] The activity of the compounds utilized in the present invention as inhibitors of matriptase 2 or its variants may be assayed in vitro, in vivo, or in a cell line. In vitro assays include assays that determine the inhibition of matriptase 2 or its variants. Alternative in vitro assays quantitate the ability of an inhibitor to bind to matriptase 2 or its variants. Detailed conditions for assaying the compounds utilized in the present invention as inhibitors of matriptase 2 or its variants are described in the Examples below.
[0134] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder as described herein, or one or more symptoms thereof. In embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., taking into account a history of symptoms and / or taking into account genetic or other susceptibility factors). Treatment may be continued after symptoms have resolved, e.g., to prevent or delay recurrence.
[0135] As used herein, the term "hepcidin-low" disorders, diseases and / or conditions as used herein means diseases or other deleterious conditions in which an absolute or relative deficiency of hepcidin is known to play a role or in which increasing hepcidin may be therapeutically beneficial.
[0136] The provided compounds are inhibitors of matriptase 2 or variants thereof and are therefore useful for treating hepcidin-low disorders, diseases, and / or conditions. Accordingly, in certain embodiments, the present invention provides methods for treating hepcidin-low disorders, diseases, and / or conditions, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof.
[0137] Without wishing to be bound by any particular theory, it has been found that inhibition of matriptase 2 leads to increased hepcidin production by the liver. Accordingly, in some embodiments, the present invention provides methods for increasing hepcidin production by the liver in a patient, comprising administering to the patient a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the present invention provides methods for treating absolute and / or relative hepcidin deficiency in a patient, comprising administering to the patient a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the present invention provides methods for treating underproduction of hepcidin in a patient, comprising administering to the patient a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the present invention provides methods for treating excessive or increased iron absorption or accumulation in a patient, comprising administering to the patient a compound of the present invention or a pharmaceutically acceptable composition thereof to increase hepcidin production by the liver. In some embodiments, the present invention provides methods for treating ineffective hematopoiesis in a patient, comprising administering to the patient a compound of the present invention or a pharmaceutically acceptable composition thereof.
[0138] In some embodiments, the present invention provides a method of treating one or more iron overload disorders, diseases and / or conditions, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof.
[0139] As used herein, the term "iron overload disorder, disease, and / or condition" refers to a condition, disease, or disorder associated with excessive iron levels or iron overload. Large amounts of free iron in the bloodstream can cause cellular damage, particularly in the liver, heart, and secretory glands. The cause of excess iron can be genetic; for example, iron overload can be caused by genetic conditions such as hemochromatosis type 1 (classical hemochromatosis), hemochromatosis type 2A or 2B (juvenile hemochromatosis), hemochromatosis type 3, African iron overload, congenital hemochromatosis, aceruloplasminemia, or congenital atransferrinemia. Examples of non-genetic causes of iron overload include dietary iron overload (including African iron overload), transfusional iron overload (from blood transfusions given to patients with thalassemia or other congenital blood disorders), hemodialysis, chronic liver disease (e.g., hepatitis C, cirrhosis, non-alcoholic steatohepatitis), porphyria cutanea tarda, post-portoaortic shunt, metabolic hyperactivity syndrome, iron tablet overdose (such as may be caused by a child taking adult iron tablets), or other causes of acute or chronic iron overload.
[0140] In some embodiments, the iron overload disorder, disease, and / or condition is hemochromatosis type 1. In some embodiments, the iron overload disorder, disease, and / or condition is hemochromatosis type 2a. In some embodiments, the iron overload disorder, disease, and / or condition is hemochromatosis type 2b. In some embodiments, the iron overload disorder, disease, and / or condition is hemochromatosis type 3.
[0141] In some embodiments, the iron overload disorder, disease, and / or condition is hepcidin deficiency. In some embodiments, the iron overload disorder, disease, and / or condition is transfusional iron overload. In some embodiments, the iron overload disorder, disease, and / or condition is African iron overload. In some embodiments, the iron overload disorder, disease, and / or condition is iron overload cardiomyopathy.
[0142] In some embodiments, the present invention provides a method for treating one or more iron-loaded anemias, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the iron-loaded anemia is β thalassemia, HbE / β thalassemia, or other variants thereof, including, but not limited to, thalassemia major, thalassemia intermediate, thalassemia minor, non-transfusion-dependent thalassemia, and transfusion-dependent thalassemia. In some embodiments, the iron-loaded anemia is associated with or caused by α thalassemia. In some embodiments, the iron-loaded anemia is congenital dyserythroid anemia type I and / or type II. In some embodiments, the iron-loaded anemia is pyruvate kinase deficiency. In some embodiments, the iron-loaded anemia is myelodysplastic syndrome (MDS), including, but not limited to, myelodysplasia, including, but not limited to, RARS and / or SF3B1 associated with MDS.
[0143] In some embodiments, the present invention provides a method of treating one or more hematological diseases, disorders, and / or conditions, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the hematological disease, disorder, and / or condition is sickle cell disease. In some embodiments, the hematological disease, disorder, and / or condition is sickle cell anemia. In some embodiments, the hematological disease, disorder, and / or condition is polycythemia vera. In some embodiments, the hematological disease, disorder, and / or condition is sideroblastic anemia. In some embodiments, the hematological disease, disorder, and / or condition is bone marrow transplantation.
[0144] In some embodiments, the present invention provides a method of treating one or more liver diseases, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the liver disease is hepatitis B. In some embodiments, the liver disease is hepatitis C or other forms of viral hepatitis. In some embodiments, the liver disease is alcoholic liver disease. In some embodiments, the liver disease is cirrhosis. In some embodiments, the liver disease is hepatocellular carcinoma. In some embodiments, the liver disease is nonalcoholic steatohepatitis (NASH).
[0145] In some embodiments, the present invention provides a method of treating one or more metabolic disorders, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the metabolic disorder is metabolic syndrome. In some embodiments, the metabolic disorder is insulin resistance. In some embodiments, the metabolic disorder is type II diabetes. In some embodiments, the metabolic disorder is porphyria. In some embodiments, the metabolic disorder is porphyria cutanea tarda. In some embodiments, the metabolic disorder is Wilson's disease. In some embodiments, the metabolic disorder is acute iron overload.
[0146] In some embodiments, the present invention provides a method of treating one or more neurodegenerative diseases, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof. In some embodiments, the neurodegenerative disease is selected from the group consisting of Huntington's disease (HD), Parkinson's disease (PD), amyotrophic sclerosis (ALS), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), and multiple sclerosis (MS).
[0147] In some embodiments, the present invention provides a method of treating one or more infectious diseases, comprising administering to a patient in need thereof a compound of the present invention or a pharmaceutically acceptable composition thereof, hi some embodiments, the infectious disease is a siderophilic infection.
[0148] The compounds and compositions of the present invention may be administered in an amount and via an administration route effective to treat or reduce the severity of diseases, disorders, and / or conditions with low hepcidin levels, or in an amount and via an administration route effective to enhance hepcidin production by the liver. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease or condition, the particular drug, its mode of administration, and the like. The compounds of the present invention are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The term "unit dosage form" as used herein refers to a physically discrete unit of drug appropriate for the patient being treated. However, it will be understood that the total daily usage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The specific effective dosage level for a particular patient or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, weight, general condition, sex, and diet of the patient; the number of doses, route of administration, and rate of excretion of the specific compound employed; the duration of treatment; drugs used in combination or concomitantly with the specific compound employed, and similar factors well known in the medical arts. The term "patient," as used herein, means an animal, preferably a mammal, and most preferably a human.
[0149] The pharmaceutically acceptable compositions of the invention can be administered to humans or other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, etc., depending on the severity of the disease or disorder being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally, one or more times daily, at dosage levels of from about 0.01 mg / kg to about 50 mg / kg, preferably from about 1 mg / kg to about 25 mg / kg of subject body weight per day, to obtain the desired therapeutic effect.
[0150] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to the active compound, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions may also contain auxiliary agents, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings, and fragrances.
[0151] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The preparation may be a sterile injectable solution, suspension, or emulsion in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, USP, and isotonic sodium chloride solution. Additionally, sterile, fixed oils are conventionally employed as solvents or suspending media. For this purpose, any grade of fixed oil, including synthetic monoglycerides or diglycerides, may be employed. Additionally, fatty acids, such as oleic acid, are used in injectable preparations.
[0152] Injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0153] To prolong the effects of compounds of the present invention, it is often desirable to slow their absorption from subcutaneous or intramuscular injection. This may be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of compound absorption then depends on the rate of dissolution, which may in turn depend on crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered compound forms can be achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. The rate of compound release can be controlled depending on the ratio of compound to polymer and the nature of the particular polymer employed. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0154] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing a compound of the present invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ordinary temperatures but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.
[0155] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, such as glycerol; (d) disintegrants, such as agar-agar, calcium carbonate, and jasmine. They are mixed with (e) solution-retaining agents such as paraffin, (f) absorption promoters such as quaternary ammonium compounds, (g) wetting agents such as cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain buffering agents.
[0156] Solid compositions of a similar type may also be employed as fillers in soft and hard capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents, and may be used to aid in the absorption of certain parts of the intestinal tract. They can also be of a composition that releases only or preferentially the active ingredient(s) in minutes, optionally with a delay. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can also be employed as fillers in soft and hard capsules, using excipients such as lactose or milk sugar as well as high molecular weight polyethylene glycols, etc.
[0157] The active compound may also be in microencapsulated form with one or more excipients, as mentioned above. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms may also contain commonly used additional substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. They may optionally contain opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally with a delay. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0158] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers, as needed. Ophthalmic formulations, ear drops, and eye drops are also contemplated as being within the scope of the present invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0159] In some embodiments, the present invention relates to a method of inhibiting the activity of matriptase 2, or a variant thereof, in a biological sample, comprising contacting the biological sample with a compound of the present invention or a composition comprising said compound.
[0160] The term "biological sample" as used herein includes, but is not limited to, cell cultures or extracts thereof; biopsies or extracts thereof obtained from mammals; and blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.
[0161] Depending on the particular condition, or disease, being treated, additional therapeutic agents, which are normally administered to treat that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated."
[0162] In some embodiments, the present invention provides methods for treating the disclosed diseases or conditions, comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering, simultaneously or sequentially, an effective amount of one or more additional therapeutic agents. In some embodiments, the method comprises co-administering one additional therapeutic agent. In some embodiments, the method comprises co-administering two or more additional therapeutic agents. In some embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically. In some embodiments, the additional The therapeutic agent is an iron-chelating compound or a pharmaceutically acceptable salt thereof, hi some embodiments, the iron-chelating compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of deferasirox, deferiprone, and deferoxamine.
[0163] In some embodiments, the present invention provides a method of treating a disclosed disease or condition, comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and an iron-chelating compound or a pharmaceutically acceptable salt thereof. In some embodiments, the patient is a patient with iron overload. In some embodiments, the patient is a patient with cardiac iron overload or iron-overload-associated cardiomyopathy. In some embodiments, the iron-chelating compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of deferasirox, deferiprone, and deferoxamine. [Example]
[0164] General synthesis method As shown in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures: While the general methods are directed to the synthesis of specific compounds of the invention, it will be appreciated that the following general methods, and other methods known to those skilled in the art, are applicable to all of the compounds as described herein and to each of their respective subclasses and species.
[0165] General mode of preparation The general synthetic methods used in each general procedure follow and include descriptions of compounds synthesized using the specified general procedure. Any specific conditions and reagents mentioned herein should not be construed as limiting the scope of the invention, but are provided for illustrative purposes only.
[0166] The compounds of the invention may be made by synthetic chemical processes, examples of which are given herein, it being understood that the order of steps in the processes may be varied, reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and vulnerable moieties may be protected and deprotected as necessary.
[0167] Unless otherwise stated, workup included partitioning the reaction mixture between organic and aqueous phases as indicated in parentheses, separating the layers and drying the organic layer over anhydrous sodium sulfate, filtration and distillation of the solvent under reduced pressure. Purification included purification by silica gel chromatography, typically using a preferred polar ethyl acetate / petroleum ether mixture as the mobile phase, unless otherwise noted.
[0168] The following abbreviations have the following definitions:
[0169] ACN, acetonitrile; br, wide; °C, degrees Celsius; CHCl3, chloroform; CD3OD, deuterated methanol; DMSO-d 6 , deuterated dimethyl sulfoxide; DCM - dichloromethane; DIPEA - diisopropylethylamine; DMF, N,N-dimethylformamide; d, doublet; dd, doublet of doublets; EDC.HCl, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; mg, milligram; g, gram; h, hour; 1H, proton; HCl, hydrochloric acid; HPLC, high-performance liquid chromatography; H2, hydrogen; HOBt, 1-hydroxybenzotriazole; K2CO3, potassium carbonate; LCMS, liquid chromatography mass spectrometry; LiOH.H2O, lithium hydroxide monohydrate; M, mole; MHz, megahertz (frequency); MeOH, methanol; mL, milliliter; min, minute; mol, mole; M + , molecular ion; M, multiplet; N2, nitrogen; NH3, ammonia; NBS, N-bromosuccinimide; NCS, N-chlorosuccinimide NMR, nuclear magnetic resonance; NaOH, sodium hydroxide; RT, room temperature; s, singlet; t, triplet; TLC, thin layer chromatography; TFA, trifluoroacetic acid; TEA, triethylamine; THF, tetrahydrofuran; %, percentage; μ, micron; and δ, delta; Zn, zinc; mmol, millimole.
[0170] Analysis of the compounds of the invention was carried out by conventional methods well known to those skilled in the art, unless otherwise noted. The invention has been described with reference to certain preferred embodiments, but other embodiments will become apparent to those skilled in the art from consideration of this specification. The invention is further defined by reference to the following examples, which describe in detail the analysis of the compounds of the invention.
[0171] Unless otherwise stated, LCMS data were recorded in +ve mode.
[0172] It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of this invention.
[0173] General synthetic scheme 1 [ka]
[0174] Example 1: Synthesis of Compound I-1 N-(6-aminopyridin-3-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide [ka]
[0175] Step 1: 6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole Ethyl 2-carboxylate
[0176] Ethyl 6-cyano-1H-indole-2-carboxylate (5.0 g, 23.34 mmol) dissolved in 150 mL of N,N-dimethylformamide was added to 1-(bromomethyl)-4-(trifluoromethyl)benzene (6.14 g, 25.67 mmol) and potassium carbonate (3.55 g, 25.67 mmol) and stirred at room temperature for 8 hours. After completion of the reaction, the mixture was quenched with ice-cold water, and the precipitated product was filtered off. The solid thus obtained was further washed with water and dried under vacuum to give the crude compound, which was purified by column chromatography using silica gel as adsorbent and eluted with 30-40% ethyl acetate / hexane to give the title compound (7.4 g). LCMS: 373.1 (M+1). +
[0177] Step 2: 6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxylic acid
[0178] The product of Step 1 of Example 1 (7.0 g, 18.8 mmol) was dissolved in 100 mL of a mixture of tetrahydrofuran / methanol / water (1:1:1), and lithium hydroxide (1.57 g, 65.8 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 4 hours. The mixture was acidified with a saturated aqueous solution of citric acid, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and then the solvent was evaporated under vacuum to give the title compound (5.2 g). LCMS: 345.1 (M+1). +
[0179] Step 3: tert-butyl (5-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamido)pyridin-2-yl)carbamate
[0180] The product of Step 2 of Example 1 (350 mg, 1.01 mmol) was dissolved in 5 mL of N,N-dimethylformamide, and butyl (5-aminopyridin-2-yl)carbamate (234 mg, 1.1 mmol), EDCI.HCl (292 mg, 1.52 mmol), HOBt (137 mg, 1.01 mmol), and DIEA (526 mg, 4.066 mmol) were added to the reaction mixture, and the resulting solution was stirred at RT overnight. The reaction mixture was quenched with water and extracted with ethyl acetate, then washed with brine and water, and dried over sodium sulfate. Evaporation of the solvent under vacuum gave the crude compound, which was purified by column chromatography using silica gel as an adsorbent and eluted with 20% ethyl acetate / hexane to give the title compound (380 mg). LCMS: 536.2 (M+1). +
[0181] Step 4: 2-((6-aminopyridin-3-yl)carbamoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0182] The product of Step 3 of Example 1 (350 mg, 0.65 mmol) was dissolved in 50 mL of ethanolic HCl (ethanol saturated with HCl gas at -20°C) and kept at RT in a sealed glass test tube for 12 hours. After completion of the reaction, the solvent was evaporated under vacuum to give the title compound (205 mg). LCMS: 482.2 (M+1). +
[0183] Step 5: N-(6-aminopyridin-3-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0184] The product of Step 4 of Example 1 (200 mg, 0.41 mmol) was dissolved in 50 mL of ethanolic ammonia (ethanol saturated with ammonia gas at -70°C) and kept overnight in a steel bomb at RT. After completion of the reaction, the solvent was evaporated under vacuum to give the crude compound, which was purified by preparative high-performance liquid chromatography equipped with an Agilent XDB C18 reverse-phase column (21.2 x 150 mm, 5 microns). The mobile phase was 30% acetonitrile in water (0.1% TFA) to 100% acetonitrile (0.1% TFA), which gave the title compound (110 mg). LCMS: 452.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ5.98(s,2H),6.93(d,2H),7.22(d,1H),7.51(m,4H),7.81(brs, 1H),8.05(m,2H),8.41(s,1H),8.41(s,1H),9.11(brs,2H),9.25(brs,2H),10.75(brs,1H)
[0185] The following compounds listed in Tables 1, 2 and 3 were prepared according to Scheme 1 by following similar procedures as described above for Example 1 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0186] [Table 133] [Table 134] [Table 135] [Table 136] [Table 137] [Table 138]
[0187] [Table 139] [Table 140] [Table 141]
[0188] [Table 142] [Table 143]
[0189] Example 2: Synthesis of Compound I-6 N-(1-(3-aminopropyl)piperidin-4-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H indole-2-carboxamide [ka]
[0190] Step 1: tert-butyl 4-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamido)-piperidine-1-carboxylate
[0191] The product of Step 2 of Example 1 and tert-butyl 4-aminopiperidine-1-carboxylate were treated together to give the title compound according to the procedure described in Step 3 of Example 1. LCMS: 527.2 (M+1). +
[0192] Step 2: 6-cyano-N-(piperidin-4-yl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0193] The product of Step 1 of Example 2 (884 mg, 1.68 mmol) was treated with 30 mL of ethanolic HCl according to the procedure described in Step 4 of Example 1, except that the reaction was carried out at 0° C. for 2 hours to give 665 mg of the title compound. LCMS: 427.2 (M+1). +
[0194] Step 3: tert-butyl (3-(4-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamido)-piperidin-1-yl)propyl)carbamate
[0195] The product of Step 2 of Example 2 (550 mg, 1.28 mmol) was treated with tert-butyl (3-bromopropyl)carbamate (305 mg, 1.28 mmol) to give 525 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS :584.3(M+1) +
[0196] Step 4: 2-((1-(3-aminopropyl)piperidin-4-yl)carbamoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0197] The product of Step 3 of Example 2 (450 mg, 0.77 mmol) was treated with 50 mL of ethanolic HCl to give 215 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 530.3 (M+1). +
[0198] Step 5: N-(1-(3-aminopropyl)piperidin-4-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0199] The product of Step 4 of Example 2 (200 mg, 0.37 mmol) was treated with 30 mL of ethanolic NH3 to give 95 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 501.2 (M+1).+ , 1 H-NMR (300MHz, DMSO-d6): δ1.72(m,2H),1.91(m,4H),2.83(m,2H),3.45(m,2H),3.92(m,1H),5.95(s,2H),7.21(d,2H),7.35(s,1H),7.52 (d,1H),7.62(d,2H),7.91(m,4H),8.21(s,1H),8.82(d,1H),9.15(brs,2H),9.24(brs,2H),9.89(brs,1H);HPLC:95.18%(retention time = 6.081 minutes).
[0200] Example 3: Synthesis of Compound I-7 6-Carbamimidoyl-N-(1-(3-guanidinopropyl)piperidin-4-yl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide [ka]
[0201] Step 1: N-(1-(3-aminopropyl)piperidin-4-yl)-6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0202] The product of Step 3 of Example 2 (550 mg, 1.28 mmol) was treated with 20 mL of ethanolic HCl to give 520 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 484.2 (M+1). +
[0203] Step 2: 6-cyano-N-(1-(3-guanidinopropyl)piperidin-4-yl)- 1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0204] The product of Step 1 of Example 3 (498 mg, 1.03 mmol) was dissolved in 15 mL of N,N-dimethylformamide and treated with 1H-pyrazole-1-carboxamidine hydrochloride (329 mg, 2.25 mmol) and N,N-diisopropylethylamine (452 mg, 3.50 mmol), and the resulting mixture was stirred at room temperature for 24 hours. Evaporation of the solvent under vacuum gave 250 mg of the title compound, which was used without further purification. LCMS: 526.2 (M+1). +
[0205] Step 3: 2-((1-(3-guanidinopropyl)piperidin-4-yl)carbamoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0206] The product of Step 2 of Example 3 (250 mg, 0.47 mmol) was treated with 50 mL of ethanolic HCl to give 180 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 572.3 (M+1). +
[0207] Step 4: 6-Carbamimidoyl-N-(1-(3-guanidinopropyl)piperidin-4-yl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0208] The product of Step 3 of Example 3 (170 mg, 0.29 mmol) was treated with 30 mL of ethanolic NH to give 40 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 543.3 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ1.72(m,6H),3.01(m,3H),3.18(m,3H),2.98(m,3H),3.96(brs,2H),5.95(s,2H),7.21(d,2H),7.35(s ,1H),7.52(d,1H),7.62(d,2H),7.88(m,1H),7.9(d,1H),8.21(s,1H),8.85(d,1H),9.05(brs,2H),9.24(brs,2H),9.89(brs,1H)
[0209] Example 4: Synthesis of Compound I-8 N-(1-(3-aminopropanoyl)piperidin-4-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide [ka]
[0210] Step 1: tert-butyl (3-(4-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamido)-piperidin-1-yl)-3-oxopropyl)carbamate
[0211] The product of Step 2 of Example 2 (553 mg, 1.3 mmol) and 3-((tert-butyl 2-methyl-2-propanol) This was treated with 245 mg (1.3 mmol) of 2,4-dimethoxycarbonylaminopropanoic acid and 380 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 598.3 (M+1). +
[0212] Step 2: 2-((1-(3-aminopropanoyl)piperidin-4-yl)carbamoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0213] The product of Step 1 of Example 4 (304 mg, 0.51 mmol) was treated with 50 mL of ethanolic HCl to give 65 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 544.2 (M+1). +
[0214] Step 3: N-(1-(3-aminopropanoyl)piperidin-4-yl)-6-carbamimidoyl-1-(4-(trifluoromethyl)-benzyl)-1H-indole-2-carboxamide
[0215] The product of Step 2 of Example 4 (167 mg, 0.28 mmol) was treated with 30 mL of ethanolic NH3 to give 80 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 515.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.35(m,2H),1.75(m,2H),2.72(m,4H),2.95(m,4H),3.78(m,1H),5.95(s,2H),7.23(d,2H),7.35(s,1 HPLC: 92.34% (retention time = 6.841 minutes)
[0216] Example 5: Synthesis of Compound I-9 6-Carbamimidoyl-N-((1r,4r)-4-(picolinamido)cyclohexyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide [ka]
[0217] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide) cyclohexyl)carbamate
[0218] The product of Step 2 of Example 1 (430 mg, 1.25 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (268 mg, 1.25 mmol) were treated together to give 520 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 541.2 (M+1). +
[0219] Step 2: N-((1r,4r)-4-aminocyclohexyl)-6-cyano-1-(4- (Trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0220] The product of Step 1 of Example 5 (275 mg, 0.51 mmol) was treated with 20 mL of ethanolic HCl to give 115 mg of the title compound according to the procedure described in Step 2 of Example 6. LCMS: 441.2 (M+1). +
[0221] Step 3: 6-cyano-N-((1r,4r)-4-(picolinamido)cyclohexyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0222] The product of Step 2 of Example 5 (572 mg, 1.3 mmol) and picolinic acid (160 mg, 1.3 mmol) were treated together to give 420 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 546.3 (M+1). +
[0223] Step 4: 2-(((1r,4r)-4-(picolinamido)cyclohexyl)carbamoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0224] The product of Step 3 of Example 5 (275 mg, 0.51 mmol) was treated with 50 mL of ethanolic HCl to give 95 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 592.2 (M+1). +
[0225] Step 5: 6-Carbamimidoyl-N-((1r,4r)-4-(picolinamido)cyclohexyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxamide
[0226] The product of Step 4 of Example 5 (95 mg, 0.16 mmol) was treated with 30 mL of ethanolic NH3 to give 20 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 563.2 (M+1). + , 1 H-NMR(300MHz,CD3OD):δ1.48(m,4H),1.93(m,4H),3.82(m,2H),5.93(s,2H),7.18(d, 3H),7.52(m,4H),7.91(m,2H),8.22(m,2H),8.61(m,1H);HPLC:97.78%(retention time = 8.714 minutes)
[0227] Example 6: Synthesis of Compound I-20 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzoic acid [ka]
[0228] Step 1: 6-cyano-1H-indole-2-carboxylic acid
[0229] Ethyl 6-cyano-1H-indole-2-carboxylate (710 mg, 3.31 mmol) and lithium hydroxide (486 mg, 11.58 mmol) were treated together to give 480 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 187.1 (M+1). +
[0230] Step 2: tert-butyl ((1r,4r)-4-(6-cyano-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0231] The product of Step 1 of Example 6 (480 mg, 2.56 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)-carbamate (547 mg, 2.56 mmol) were treated together to give 325 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 383.2 (M+1). +
[0232] Step 3: 4-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzoic acid
[0233] The product of Step 2 of Example 6 (325 mg, 0.84 mmol) and 4-(bromomethyl)benzoic acid (179 mg, 0.84 mmol) were treated together to give 198 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 517.2 (M+1). +
[0234] Step 4: 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-(ethoxy(imino)methyl)-1H-indol-1-yl)methyl)benzoic acid
[0235] The product of Step 3 of Example 6 (198 mg, 0.38 mmol) was treated with 30 mL of ethanolic HCl to give 82 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 463.2 (M+1). +
[0236] Step 5: 4-((3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzoic acid
[0237] The product of Step 4 of Example 6 (80 mg, 0.17 mmol) was treated with 20 mL of ethanolic NH3 to give 14 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 434.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.32(m,4H),1.83(m,4H),2.95(m,1H),3.63(m,1H),5.91(s,2H),7.11(d,2H),7.27(s,1H),7.52 (d,1H),7.80(m,5H),8.19(s,1H),8.62(d,1H),9.11(brs,2H),9.25(brs,2H),12.91(brs,1H);HPLC:90.14%(retention time=4.327 minutes)
[0238] Example 7: Synthesis of Compound I-21 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)-benzoic acid methyl ester [ka]
[0239] Step 1: methyl 4-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzoate
[0240] The product of Step 2 of Example 6 (300 mg, 0.78 mmol) and methyl 4-(bromomethyl)benzoate (177 mg, 0.78 mmol) were treated together to give 380 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 531.2 (M+1). +
[0241] Step 2: methyl 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-(ethoxy(imino)methyl)-1H-indol-1-yl)methyl)benzoate
[0242] The product of Step 1 of Example 7 (350 mg, 0.65 mmol) was treated with 50 mL of ethanolic HCl to give 153 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 477.2 (M+1). +
[0243] Step 3: methyl 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzoate
[0244] The product of Step 2 of Example 7 (150 mg, 0.28 mmol) was treated with 30 mL of ethanolic NH3 to give 42 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 448.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.32(m,4H),1.82(m,4H),2.96(m,1H),3.52(m,1H),3.81(m,3H),5.96(s,2H),7.13(d, 2H),7.32(s,1H),7.55(d,1H),7.82(m,5H),8.19(s,1H),8.65(d,1H),9.24(brs,3H);HPLC:96.693%(retention time = 5.524 minutes)
[0245] Example 8: Synthesis of Compound I-22 Ethyl 4-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)-benzoate [ka]
[0246] This compound was prepared according to the procedure described in Steps 1 to 3 of Example 7 using ethyl 4-(bromomethyl)benzoate. LCMS: 462.2 (M+1) + , 1H-NMR(300MHz,DMSO-d6):δ1.32(m,3H),1.41(m,4H),1.82(m,4H),2.96(m,1H),3.52(m,1H),4.26(m,2H),5.96(s, 2H),7.13(d,2H),7.32(s,1H),7.86(m,6H),8.21(s,1H),8.62(d,1H),9.24(brs,3H);HPLC:96.18%(retention time = 4.601 minutes)
[0247] Example 9: Synthesis of Compound I-23 Ethyl 4-((3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)-methyl)benzoate [ka]
[0248] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-3-nitro-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0249] The product of Step 2 of Example 6 (535 mg, 1.39 mmol) was dissolved in 10 mL of acetic acid and cooled to 0° C. Copper(II) nitrate trihydrate (401 mg, 1.66) was added and stirred for 3 hours. The reaction mixture was quenched with cold water and extracted with ethyl acetate, then washed with brine and dried over sodium sulfate. Evaporation of the solvent gave the crude product, which was purified by column chromatography using silica gel as adsorbent and eluting with hexane:ethyl acetate (7:3) to give the title compound. LCMS: 428.2 (M+1). +
[0250] Step 2: 4-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-3-nitro-1H-indol-1-yl)methyl)benzoate ethyl
[0251] The product of Step 1 of Example 9 (310 mg, 0.72 mmol) and 4-(bromomethyl ) and ethyl benzoate (174 mg, 0.72 mmol) according to the procedure described in Step 1 of Example 1 to give 213 mg of the title compound. LCMS: 590.2 (M+1) +
[0252] Step 3: ethyl 4-((3-amino-2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzoate
[0253] The product of Step 2 of Example 9 (200 mg, 0.33 mmol) was dissolved in 10 mL of glacial acetic acid, and zinc (107 mg, 1.65 mmol) was added portionwise at room temperature. The reaction mixture was stirred at RT for 6 h. The contents were filtered through a pad of Celite, and the filtrate was concentrated under vacuum to give the crude compound, which was purified by column chromatography using silica gel as adsorbent and eluting with hexane:ethyl acetate (6:4) to give the title compound (152 mg). LCMS: 560.3 (M+1). +
[0254] Step 4: ethyl 4-((3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-(ethoxy(imino)methyl)-1H-indol-1-yl)methyl)benzoate
[0255] The product of Step 3 of Example 9 (150 mg, 0.27 mmol) was treated with 40 mL of ethanolic HCl to give 111 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 506.3 (M+1). +
[0256] Step 5: ethyl 4-((3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzoate
[0257] The product of Step 4 of Example 9 (108 mg, 0.21 mmol) was treated with 30 mL of ethanolic NH3 to give 29 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 477.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.32(m,3H),1.41(m,5H),1.85(m,4H),3.0(m,1H),3.62(m,2H),4.26(m,2H),3 .62(m,2H),7.12(d,2H),7.42(m,1H),7.76(m,5H),7.88(d,1H),8.42(m,2H),8.85(brs,2H),9.19(brs,2H)
[0258] Example 10: Synthesis of Compound I-28 N-(1-(2-aminoethyl)piperidin-4-yl)-6-carbamimidoyl-1-phenethyl-1H-indole-2-carboxamide [ka]
[0259] Step 1: ethyl 6-cyano-1-phenethyl-1H-indole-2-carboxylate
[0260] " Ethyl 6-cyano-1H-indole-2-carboxylate (2500 mg, 11.67 mmol) and (2-bromoethyl)benzene (2160 mg, 11.67 mmol) were treated together to give 3100 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 319.1 (M+1). +
[0261] Step 2: 6-cyano-1-phenethyl-1H-indole-2-carboxylic acid
[0262] The product of Step 1 of Example 10 (3000 mg, 9.42 mmol) and lithium hydroxide (792 mg, 32.97 mmol) were treated together to give 2100 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 291.1 (M+1). +
[0263] Step 3: tert-butyl 4-(6-cyano-1-phenethyl-1H-indole-2-carboxamido)piperidine-1-carboxylate
[0264] The product of Step 2 of Example 10 (390 mg, 1.34 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (205 mg, 1.5 mmol) were treated together to give 378 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 473.2 (M+1). +
[0265] Step 4: 6-cyano-1-phenethyl-N-(piperidin-4-yl)-1H-indole-2-carboxamide
[0266] The product of Step 3 of Example 10 (350 mg, 0.73 mmol) was treated with 20 mL of ethanolic HCl to give 212 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 373.2 (M+1). +
[0267] Step 5: tert-butyl (2-(4-(6-cyano-1-phenethyl-1H-indole-2-carboxamido)piperidin-1-yl)ethyl)carbamate
[0268] The product of Step 4 of Example 10 (200 mg, 0.53 mmol) and tert-butyl (2-bromoethyl)carbamate (118 mg, 0.53 mmol) were treated together to give 226 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 516.3 (M+1). +
[0269] Step 6: ethyl 2-((1-(2-aminoethyl)piperidin-4-yl)carbamoyl)-1-phenethyl-1H-indole-6-carbimidate
[0270] The product of Step 5 of Example 10 (220 mg, 0.42 mmol) was treated with 50 mL of ethanolic HCl to give 105 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 462.3 (M+1). +
[0271] Step 7: N-(1-(2-aminoethyl)piperidin-4-yl)-6-carbamimidoyl-1-phenethyl-1H-indole-2-carboxamide
[0272] The product of Step 6 of Example 10 (105 mg, 0.22 mmol) was treated with 50 mL of ethanolic NH3 to give 43 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 433.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.62(m,2H),1.19(m,2H),2.12(m,3H) ,3.00(m,4H),3.33(m,4H),3.62(m,2H),4.12(m,1H),4.81(m,2H),7.35(m,3H),7.51(d,1H),7.85(d,1 HPLC: 94.7% (retention time = 4.194 minutes)
[0273] Example 11: Synthesis of Compound I-29 N-(1-(3-aminopropyl)piperidin-4-yl)-6-carbamimidoyl-1-phenethyl-1H-indole-2-carboxamide [ka]
[0274] Step 1: tert-butyl (3-(4-(6-cyano-1-phenethyl-1H-indole-2-carboxamido)piperidin-1-yl)propyl)carbamate
[0275] The product of Step 4 of Example 10 (380 mg, 1.01 mmol) and tert-butyl (3-bromopropyl)carbamate (239 mg, 1.01 mmol) were treated together to give 350 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 530.3 (M+1). +
[0276] Step 2: ethyl 2-((1-(3-aminopropyl)piperidin-4-yl)carbamoyl)-1-phenethyl-1H-indole-6-carbimidate
[0277] The product of Step 1 of Example 11 (350 mg, 0.66 mmol) was treated with 50 mL of ethanolic HCl to give 253 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 476.3 (M+1). +
[0278] Step 3: N-(1-(3-aminopropyl)piperidin-4-yl)-6-carbamimidoyl-1-phenethyl-1H-indole-2-carboxamide
[0279] The product of Step 2 of Example 11 (250 mg, 0.55 mmol) was treated with 50 mL of ethanolic NH3 to give 135 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 447.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.62(m,2H),1.19(m,4H),2.85(m,4H),3.05(m,6H),4.05(m,1H),4.73(m,2H),7. 15(m,5H),7.51(d,1H),7.85(m,3H),8.15(d,1H),8.70(d,1H),9.07(brs,2H),9.24(brs,2H),9.69(brs,1H)
[0280] Example 12: Synthesis of Compound I-33 3-Amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(4-(trifluoromethyl)-phenethyl)-1H-indole-2-carboxamide [ka]
[0281] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-3-nitro-1-(4-(trifluoromethyl)phenethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0282] The product of Step 1 of Example 9 (580 mg, 1.35 mmol) and 1-(2-bromoethyl)-4-(trifluoromethyl)benzene (340 mg, 1.35 mmol) were treated together to give 550 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 600.2 (M+1). +
[0283] Step 2: tert-butyl ((1r,4r)-4-(3-amino-6-cyano-1-(4-(trifluoromethyl)phenethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0284] The product of Step 1 of Example 12 (455 mg, 0.75 mmol) and zinc (246 mg, 3.79 mmol) were treated together to give 345 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 570.3 (M+1). +
[0285] Step 3: Ethyl-3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-(4-(trifluoromethyl)-phenethyl)-1H-indole-6-carbimidate
[0286] The product of Step 2 of Example 12 (345 mg, 0.60 mmol) was treated with 50 mL of ethanolic HCl to give 180 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 516.2 (M+1). +
[0287] Step 4: 3-amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(4-(trifluoromethyl)-phenethyl)-1H-indole-2-carboxamide
[0288] The product of Step 3 of Example 12 (180 mg, 0.34 mmol) was treated with 50 mL of ethanolic NH to give 65 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 487.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.38(m,4H),1.92(m,4H),2.93(m,3H),3.05(m,1H),3.75(m,3H),3.72(m,1H),4.65(m,2 HPLC: 95.67% (retention time = 4.682 minutes)
[0289] Example 13: Synthesis of Compound I-36 N-((1r,4r)-4-aminocyclohexyl)-1-((3-(3-aminopropanamido)phenyl)sulfonyl)-6-carbamimidoyl-1H-indole-2-carboxamide [ka]
[0290] Step 1: ethyl 6-cyano-1-((3-nitrophenyl)sulfonyl)-1H-indole-2-carboxylate
[0291] Ethyl 6-cyano-1H-indole-2-carboxylate (780 mg, 3.64 mmol) and 3-nitrobenzene-1-sulfonyl chloride (2011 mg, 9.1 mmol) were treated together to give 660 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 401.1 (M+1). +
[0292] Step 2: 6-cyano-1-((3-nitrophenyl)sulfonyl)-1H-indole-2-carboxylic acid
[0293] The product of Step 1 of Example 13 (550 mg, 1.37 mmol) and lithium hydroxide (201 mg, 4.79 mmol) were treated together to give 425 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 372.1 (M+1). +
[0294] Step 3: tert-butyl ((1r,4r)-4-(6-cyano-1-((3-nitrophenyl)sulfonyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0295] The product of Step 2 of Example 13 (400 mg, 1.07 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (230 mg, 1.07 mmol) were treated together to give 368 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 568.2 (M+1). +
[0296] Step 4: tert-butyl ((1r,4r)-4-(1-((3-aminophenyl)sulfonyl)-6-cyano-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0297] The product of Step 3 of Example 13 (360 mg, 0.63 mmol) was treated with zinc (205 mg, 3.16 mmol) according to the procedure described in Step 3 of Example 9 to give 210 mg of the title compound. LCMS: 538.2 (M+1).+
[0298] Step 5: ((1r,4r)-4-(1-((3-(3-(tert-butylcarbamic acid)-propanamido)phenyl)sulfonyl)-6-cyano-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0299] The product of Step 4 of Example 13 (200 mg, 0.37 mmol) and 3-((tert This was treated with 185 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 709.3 (M+1). +
[0300] Step 6: Ethyl-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-((3-(3-aminopropanamido)phenyl)-sulfonyl)-1H-indole-6-carbimidate
[0301] The product of Step 5 of Example 1 (185 mg, 0.26 mmol) was treated with 50 mL of ethanolic HCl to give 88 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 555.2 (M+1). +
[0302] Step 7: N-((1r,4r)-4-aminocyclohexyl)-1-((3-(3-aminopropanamido)phenyl)sulfonyl)-6-carbamimidoyl-1H-indole-2-carboxamide
[0303] The product of Step 6 of Example 13 (85 mg, 0.15 mmol) was treated with 50 mL of ethanolic NH to give 18 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 526.2 (M+1). +
[0304] General synthetic scheme 2 [ka]
[0305] Example 14: Synthesis of Compound I-40 6-Carbamimidoyl-1-(2-(phenylsulfonyl)ethyl)-N-(3-(trifluoromethyl)phenyl)-1H-indole-2-carboxamide [ka]
[0306] Step 1: ethyl 6-cyano-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxylate
[0307] Ethyl 6-cyano-1H-indole-2-carboxylate (3.5 g, 16.33 mmol) and ((2-bromoethyl)sulfonyl)benzene (4.68 mg, 16.33 mmol) were treated together to give 5.2 g of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 383.1 (M+1). +
[0308] Step 2: 6-cyano-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxylic acid
[0309] The product of Step 1 of Example 14 (5.1 g, 13.33 mmol) and lithium hydroxide (1.12 g, 46.65 mmol) were treated together to give 4.1 g of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 355.1 (M+1). +
[0310] Step 3: 6-cyano-1-(2-(phenylsulfonyl)ethyl)-N-(3-(trifluoromethyl)phenyl)-1H-indole-2-carboxamide
[0311] The product of Step 2 of Example 14 (578 mg, 1.63 mmol) and 3-(trifluoromethyl)aniline (262 mg, 1.63 mmol) were treated together to give 645 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 498.1 (M+1). +
[0312] Step 4: 6-(N'-hydroxycarbamimidoyl)-1-(2-(phenylsulfonyl)ethyl)-N-(3-(trifluoromethyl)-phenyl)-1H-indole-2-carboxamide
[0313] The product of Step 3 of Example 14 (550 mg, 1.10 mmol) was dissolved in 10 mL of ethanol, an aqueous solution of hydroxylamine (1.3 mL) was added, and the resulting mixture was refluxed at 80° C. for 4 hours. The solvent was evaporated in vacuo to give the title compound (425 mg), which was used in the next step without further purification. LCMS: 531.1 (M+1). +
[0314] Step 5: 6-(N'-acetoxycarbamimidoyl)-1-(2-(phenylsulfonyl)ethyl)-N-(3-(trifluoromethyl)phenyl)-1H-indole-2-carboxamide
[0315] The product of Step 4 of Example 14 (570 mg, 1.07 mmol) was dissolved in 5 mL of acetic acid, acetic anhydride (0.87 mg, 8.56 mmol) was added, and the resulting mixture was stirred at RT for 2 h. The solvent was evaporated in vacuo to give the title compound (560 mg), which was further purified. It was used in the next step without further purification. LCMS: 573.1 (M+1) +
[0316] Step 6: 6-Carbamimidoyl-1-(2-(phenylsulfonyl)ethyl)-N-(3-(trifluoromethyl)phenyl)-1H-indole-2-carboxamide
[0317] The product of Step 5 of Example 14 (450 mg, 0.78 mmol) was dissolved in 5 mL of acetic acid, zinc (408 mg, 6.24 mmol) was added portionwise, and the resulting mixture was stirred at RT for 6 h. The reaction mixture was filtered through a pad of Celite, and the resulting filtrate was concentrated in vacuo to give the crude product, which was purified by reverse-phase preparative HPLC to give the title compound (275 mg). LCMS: 573.1 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ4.00(m,2H),4.92(m,2H),7.45(s,1H),7.49(m,2H),7.59(m,3H),7.63(m,1H),7.9 0(m,3H),7.96(m,2H),8.21(s,1H),9.09(brs,2H),9.32(brs,2H),10.76(s,1H);HPLC:97.32%(retention time = 3.595 minutes)
[0318] The following compounds listed in Table 4 were prepared according to Scheme 2 by following analogous procedures as described for Example 14 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0319] [Table 144] [Table 145]
[0320] Example 15: Synthesis of Compound I-55 N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide [ka]
[0321] Step 1: tert-butyl-((1r,4r)-4-(6-cyano-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0322] The product of Step 1 of Example 9 (688 mg, 1.60 mmol) and ((2-bromoethyl)sulfonyl)benzene (395 mg, 1.60 mmol) were treated together to give 780 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 596.2 (M+1). +
[0323] Step 2: Ethyl-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-6-carbimidate
[0324] The product of Step 1 of Example 15 (650 mg, 1.09 mmol) was treated with 60 mL of ethanolic HCl to give 380 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 542.2 (M+1). +
[0325] Step 3: N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide
[0326] The product of Step 2 of Example 15 (250 mg, 0.46 mmol) was treated with 50 mL of ethanolic NH3 to give 135 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 513.2 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ1.21(m,2H),1.38(m,2H),1.85(m,4H),3.05(m,1H),3.55(m,1H),4.01(m,2H),4. 55(m,2H),7.65(m,2H),7.81(m,6H),8.20(brs,1H),8.52(d,1H),9.12(d,1H),8.25(brs,2H),9.45(brs,2H).
[0327] Example 16: Synthesis of Compound I-56 3-Amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide [ka]
[0328] Step 1: tert-butyl ((1r,4r)-4-(3-amino-6-cyano-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0329] The product of Step 1 of Example 15 (335 mg, 0.56 mmol) and zinc (182 mg, 2.80 mmol) were treated together to give 180 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 566.2 (M+1). +
[0330] Step 2: ethyl 3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-6-carbimidate
[0331] The product of Step 1 of Example 16 (175 mg, 0.30 mmol) was treated with 40 mL of ethanolic HCl to give 105 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 512.2 (M+1). +
[0332] Step 3: tert-butyl ((1r,4r)-4-(3-amino-6-carbamimidoyl-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0333] The product of Step 2 of Example 16 (105 mg, 0.20 mmol) was treated with 30 mL of ethanolic NH3 to give 43 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 483.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.45(m,4H),1.91(m,4H),3.08(m,1H),3.52(m,1H),3.79(m,2H),4.67(m ,2H),7.37(d,1H),7.65(m,2H),7.73(m,2H),7.83(m,6H),7.91(d,1H),9.12(brs,2H),9.28(brs,2H)
[0334] Example 17: Synthesis of Compound I-17 Ethyl (2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-((Z)-N'-hydroxycarbamimidoyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indol-3-yl)carbamate [ka]
[0335] Step 1: ((1r,4r)-4-(3-(ethylcarbamate)-6-cyano-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0336] The product of Step 1 of Example 16 (630 mg, 1.11 mmol) and ethyl chloroformate (119 mg, 1.11 mmol) were treated together to give 553 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 638.3 (M+1). +
[0337] Step 2: ((1r,4r)-4-(3-(ethyl carbamate)-6-((Z)-N'-hydroxycarbamimidoyl)-1-(2-(phenylsulfonyl)-ethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0338] The product of Step 1 of Example 17 (540 mg, 0.84 mmol) and aqueous hydroxylamine (2.7 mL) were treated together to give 329 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 671.3 (M+1). +
[0339] Step 3: (2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-((Z)-N'-hydroxycarbamimidoyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indol-3-yl)carbamate
[0340] The product of Step 2 of Example 17 (315 mg, 0.46 mmol) was treated with 30 mL of ethanolic HCl to give 180 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 571.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.45(m,7H),1.91(m,4H),3.08(m,1H),3.52(m,1H),3.89(m,2H),4.67(m,2H),7.37(d,1H),7.56 (m,3H),7.73(m,2H),7.83(m,5H),8.05(d,1H),8.93(brs,1H),11.11(brs,1H),12.80(brs,1H);HPLC:90.09%(retention time=4.488 minutes)
[0341] Example 18: Synthesis of Compound I-58 3-Amino-6-carbamimidoyl-N-(cyclohexylmethyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide [ka]
[0342] Step 1: 6-cyano-N-(cyclohexylmethyl)-1H-indole-2-carboxamide
[0343] The product of Step 1 of Example 6 (1.0 g, 5.34 mmol) and cyclohexylmethanamine (603 mg, 5.34 mmol) were treated together to give 1.25 g of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 282.2 (M+1). +
[0344] Step 2: 6-cyano-N-(cyclohexylmethyl)-3-nitro-1H-indole-2-carboxamide
[0345] The product of Step 1 of Example 18 (610 mg, 2.16 mmol) and copper(II) nitrate trihydrate (622 mg, 2.59 mmol) were treated together to give 352 mg of the title compound according to the procedure described in Step 1 of Example 9. LCMS: 327.1 (M+1). +
[0346] Step 3: 6-cyano-N-(cyclohexylmethyl)-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide
[0347] The product of Step 2 of Example 18 (345 mg, 1.05 mmol) and ((2-bromoethyl)sulfonyl)benzene (389 mg, 1.57 mmol) were treated together to give 356 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 495.2 (M+1). +
[0348] Step 4: 3-amino-6-cyano-N-(cyclohexylmethyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carboxamide
[0349] The product of Step 3 of Example 18 (350 mg, 0.70 mmol) and zinc (229 mg, 3.5 mmol) were treated together to give 195 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 465.2 (M+1). +
[0350] Step 5: 3-amino-2-((cyclohexylmethyl)carbamoyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-6-carbimidate ethyl ester
[0351] The product of Step 4 of Example 18 (190 mg, 0.40 mmol) was treated with ethanolic HCl to give 133 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 511.2 (M+1). +
[0352] Step 6: 3-amino-6-carbamimidoyl-N-(cyclohexylmethyl)-1-( 2-(Phenylsulfonyl)ethyl)-1H-indole-2-carboxamide
[0353] The product of Step 5 of Example 18 (125 mg, 0.24 mmol) was treated with ethanolic NH to give 38 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 482.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.92(m,2H),1.11(m,3H),1.52(m,1H),1.66(m,4H),3.08(m,2H),3.77(m,2H),4.67(m,2H),5.03(brs,2H),7 .37(d,1H),7.60(m,2H),7.73(m,2H),7.83(m,2H),7.91(d,2H),8.10(m,1H),8.92(brs,2H),9.25(brs,2H);HPLC:93.49%(retention time = 6.417 minutes)
[0354] Example 19: Synthesis of Compound I-59 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(4-fluorophenyl)-1H-indole-2-carboxamide [ka]
[0355] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-1H-indole-2-carboxylate ethyl
[0356] Ethyl 6-cyano-1H-indole-2-carboxylate (4.0 g, 18.67 mmol) and 4-(bromomethyl)benzamide (4.8 g, 22.4 mmol) were treated together to give 5.26 g of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 348.1 (M+1). +
[0357] Step 2: 1-(4-carbamoylbenzyl)-6-cyano-1H-indole-2-carboxylic acid
[0358] The product of Step 1 of Example 19 (1.2 g, 3.44 mmol) and lithium hydroxide (505 mg, 12.04 mmol) were treated together to give 882 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 320.1 (M+1). +
[0359] Step 3: 1-(4-carbamoylbenzyl)-6-cyano-N-(4-fluorophenyl)-1H-indole-2-carboxamide
[0360] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 4-fluoroaniline (174 mg, 1.56 mmol) were treated together to give 385 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 413.1 (M+1). +
[0361] Step 4: 1-(4-carbamoylbenzyl)-N-(4-fluorophenyl)-6-(N'-hydroxycarbamimidoyl)-1H-indole-2-carboxamide
[0362] The product of Step 3 of Example 19 (360 mg, 0.87 mmol) and aqueous hydroxylamine (1.8 mL) were treated together to give 310 mg of the title compound according to the procedure described in Step 4 of Example 40. LCMS: 446.2 (M+1). +
[0363] Step 5: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(4-fluorophenyl)-1H-indole-2-carboxamide
[0364] The product of Step 4 of Example 19 (285 mg, 0.64 mmol) and acetic anhydride (261 mg, 2.56 mmol) were treated together to give 240 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 488.2 (M+1). +
[0365] Step 6: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(4-fluorophenyl)-1H-indole-2-carboxamide
[0366] The product of Step 5 of Example 19 (230 mg, 0.47 mmol) and zinc (125 mg, 1.89 mmol) were treated together to give 128 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 430.2 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ5.94(s,2H),7.10(d,2H),7.18(m,2H),7.34(brs,1H),7.52(brs,1H),7.57(d,1H),7.74(m,4 HPLC: 98.09% (retention time = 3.018 minutes)
[0367] The following compounds listed in Tables 5 and 6 were prepared according to Scheme 2 by following similar procedures as described above for Example 19 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0368] [Table 146] [Table 147] [Table 148] [Table 149] [Table 150] [Table 151] [Table 152] [Table 153] [Table 154] [Table 155] [Table 156] [Table 157] [Table 158] [Table 159] [Table 160] [Table 161] [Table 162] [Table 163]
[0369] [Table 164] [Table 165] [Table 166]
[0370] Example 20: Compound I-103 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-indole-2-carboxamide [ka]
[0371] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-indole-2-carboxamide
[0372] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and N,1-dimethylpyrrolidin-3-amine (178 mg, 1.56 mmol) were treated together to give 385 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 413.1 (M+1). +
[0373] Step 2: 1-(4-carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-indole-2-carboxamide
[0374] The product of Step 1 of Example 20 (360 mg, 0.87 mmol) and aqueous hydroxylamine (1.7 mL) were treated together and purified according to the procedure described in Step 4 of Example 14. This gave 310 mg of the title compound. LCMS: 448.2 (M+1) +
[0375] Step 3: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-indole-2-carboxamide
[0376] The product of Step 2 of Example 20 (280 mg, 0.62 mmol) and acetic anhydride (260 mg, 2.54 mmol) were treated together to give 240 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 491.2 (M+1). +
[0377] Step 4: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(4-fluorophenyl)-1H-indole-2-carboxamide
[0378] The product of Step 3 of Example 20 (230 mg, 0.46 mmol) and zinc (125 mg, 1.89 mmol) were treated together to give 108 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 433.2 (M+1). +, 1 H-NMR(300MHz,DMSO-d6):δ1.94(m,2H),2.40(m,2H),2.60(m,2H),2.94(s,3H),3.05(s,3H),5.76(m,2H),7.00(d, 1H),7.20(d,2H),7.26(brs,1H),7.58(d,1H),7.83(d,2H),7.92(d,1H),8.17(m,1H);HPLC:94.31%(retention time = 4.429 minutes)
[0379] Example 21: Synthesis of Compound I-117 1-(4-carbamoylbenzyl)-N 2 -(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2,6-dicarboxamide [ka]
[0380] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0381] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 3-(pyrrolidin-1-yl)aniline (254 mg, 1.56 mmol) were treated together to give 520 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 464.2 (M+1). +
[0382] Step 2: 1-(4-carbamoylbenzyl)-N 2 -(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2,6-dicarboxamide
[0383] To a solution of the product of Step 1 of Example 21 (250 mg, 0.53 mmol) in 5 mL of a 1:1 mixture of methanol and water was added solid sodium hydroxide (65 mg, 1.6 mmol). The reaction was stirred at 50°C. Upon completion of the reaction, the reaction mixture was concentrated to methanol. The solvent was removed and acidified with 2N HCl. The aqueous mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The solvent was evaporated under vacuum to give the crude product, which was purified by reverse phase preparative HPLC to give 120 mg of the title compound. LCMS: 482.2 (M+1) + , 1 H-NMR (300MHz, DMSO-d6): δ1.93(m,4H),3.20(m,4H),5.94(s,2H),6.30(d,2H),6.99(m,6H),7.22(d,2H),7.42 (s,1H),7.69(m,4H),7.87(brs,1H),7.97(brs,1H),8.11(s,1H),10.26(brs,1H);HPLC:98.46%(retention time = 6.85 minutes).
[0384] General synthetic scheme 2A [ka]
[0385] Example 22: Compound I-118 Methyl ((1-(4-carbamoylbenzyl)-2-((4-(pyrrolidin-1-yl)phenyl)carbamoyl)-1H-indol-6-yl)(imino)methyl)carbamate [ka]
[0386] Step 1: ((1-(4-carbamoylbenzyl)-2-((4-(pyrrolidin-1-yl)phenyl)carbamoyl)-1H-indol-6-yl)(imino)methyl)carbamate methyl
[0387] Compound I-90 (300 mg, 0.64 mmol) and potassium carbonate (355 mg, 2.57 mmol) were dissolved in 10 mL of DMF. Methyl carbonochloridate (95 mg, 0.96 mmol) was added dropwise at 0 °C, and the mixture was stirred at RT for 8 h. After completion of the reaction, the mixture was quenched with ice-cold water, extracted with ethyl acetate, then brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under vacuum to give the crude product, which was purified by reverse-phase HPLC to give the title compound (120 mg, 70%-80% yield). LCMS: 539.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.92(m,4H),3.18(m,4H),3.61(s,3H),5.96(s,2H),6.49(d,2H),7.07(d,2H),7 .30(brs,1H),7.39(s,1H),7.50(d,2H),7.73(d,2H),7.80(s,2H),7.87(brs,1H),8.24(s,1H),9.20(brs,2H) ),10.22(brs,1H);HPLC:97.37%(retention time=3.765 minutes)
[0388] The following compounds listed in Table 7 were prepared according to Scheme 2 followed by Scheme 2A by following similar procedures as described above for Example 22 using the appropriate reagents with suitable modifications known to one of skill in the art.
[0389] [Table 167] [Table 168] [Table 169]
[0390] Example 23: Synthesis of Compound I-135 1-(4-Carbamoylbenzyl)-6-(N'-(2-(dimethylamino)acetoxy)carbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide [ka]
[0391] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0392] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 3-(pyrrolidin-1-yl)aniline (254 mg, 1.56 mmol) were treated together to give 520 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 464.2 (M+1). +
[0393] Step 2: 1-(4-carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0394] The product of Step 1 of Example 23 (500 mg, 0.24 mmol) and aqueous hydroxylamine (0.063 mL) were treated together to give 350 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 497.2 (M+1). +
[0395] Step 3: 1-(4-carbamoylbenzyl)-6-(N'-(2-(dimethylamino)acetoxy)carbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0396] To a solution of N,N-dimethylglycine (45 mg, 0.44 mmol) and triethylamine (66 mg, 0.66 mmol) in 10 mL of tetrahydrofuran was added isobutyl chloroformate (60 mg, 0.44 mmol) at 0°C and stirred for 2 hours. Then, the product of Step 2 of Example 23 (220 mg, 0.44 mmol) was added and stirred at RT for 8 hours. After completion of the reaction, the solvent was evaporated under vacuum to give the crude product, which was purified by reverse-phase HPLC to give the title compound (85 mg, 20%-30% yield). LCMS: 582.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.95(m,4H),2.54(s,6H),3.18(m,6H),5.84(brs,2H),5.92(s,2H),6.29(d,2H),7.02(m,2H),7.09(m,3 HPLC: 93.11% (retention time = 3.869 minutes)
[0397] Example 24: Synthesis of Example I-136 1-(4-carbamoylbenzyl)-N 2 -(3-(pyridin-2-yl)phenyl)-1H-indole-2,6-dicarboxamide [ka]
[0398] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-(pyridin-2-yl)phenyl)-1H-indole-2-carboxamide
[0399] The product of Step 2 of Example 19 (1.2 g, 3.76 mmol) and 3-(pyridin-2-yl)aniline (640 mg, 3.76 mmol) were treated together to give 1230 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 472.2 (M+1). +
[0400] Step 2: 1-(4-carbamoylbenzyl)-N 2 -(3-(pyridin-2-yl)phenyl)-1H-indole-2,6-dicarboxamide
[0401] The product of Step 1 of Example 24 (150 mg, 0.31 mmol) and sodium hydroxide (38 mg, 0.93 mmol) were treated together to give 300 mg of the title compound according to the procedure described in Step 2 of Example 21. LCMS: 490.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ5.98(s,2H),7.10(d,2H),7.30(brs,1H),7.35(brs,1H),7.40(m,1H),7.50(m,1H),7.54( HPLC: 99.42% (retention time = 6.151 minutes)
[0402] Example 25: Synthesis of Compound I-149 1-(4-carbamoylbenzyl)-6-(N'-methoxycarbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide [ka]
[0403] Step 1: 1-(4-carbamoylbenzyl)-6-(N'-methoxycarbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0404] To a solution of the product of Step 2 of Example 23 (300 mg, 0.6 mmol) in 10 mL of dioxane, 0.7 N aqueous sodium hydroxide (25 mg, 0.6 mmol) was added dropwise at 0° C. and stirred for 10 minutes. Then, dimethyl sulfate (1860 mg, 10 mmol) was added dropwise at the same temperature, and the reaction mixture was stirred at 0° C. for 4 hours. The solvent was evaporated under vacuum to give the crude product, which was purified by reverse-phase preparative HPLC to give 35 mg of the title compound. LCMS: 511.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.95(m,4H),3.16(m,7H),5.95(s,2H),6.29(d,1H),7.80(br,2H) ,7.00(s,1H),7.06(m,2H),7.20(m,3H),7.29(s,1H),7.75(d,3H),7.84(m,2H),10.22(s,1H)
[0405] Example 26: Synthesis of Compound I-157 (R)-tert-butyl (1-(((amino(1-(4-carbamoylbenzyl)-2-((3-(pyrrolidin-1-yl)phenyl)-carbamoyl)-1H-indol-6-yl)methylene)amino)oxy)-3-methyl-1-oxobutan-2-yl)carbamate
[0406] Step 1: (R)-tert-butyl (1-(((amino(1-(4-carbamoylbenzyl)-2-((3-(pyrrolidin-1-yl)phenyl)-carbamoyl)-1H-indol-6-yl)methylene)amino)oxy)-3-methyl-1-oxobutan-2-yl)carbamate
[0407] The product of Step 2 of Example 23 (230 mg, 0.46 mmol) and (R)-2-((tert-butoxycarbonyl)-amino)-3-methylbutanoic acid (100 mg, 0.46 mmol) were treated together to give 60 mg of the title compound according to the procedure described in Step 3 of Example 23. LCMS: 696.3 (M+1). + , 1 H-NMR (300M Hz,DMSO-d6):δ0.90(m,6H),1.41(s,9H),1.95(m,4H),3.18(m,4H),4.04(m,1H) ),5.95(s,2H),6.28(d,1H),6.84(brs,1H),6.97(s,1H),7.06(d,1H),7.11(m,2 H),7.28(brs,1H),7.34(d,1H),7.43(s,1H),7.51(d,1H),7.72(d,2H),7.81(d ,1H),7.85(brs,1H),9.26(brs,2H),10.21(s,1H);HPLC:90.92%(retention time=4.537 minutes)
[0408] Example 27: Synthesis of Compound I-158 (S)-tert-butyl (1-(((amino(1-(4-carbamoylbenzyl)-2-((3-(pyrrolidin-1-yl)phenyl)carbamoyl)-1H-indol-6-yl)methylene)amino)oxy)-1-oxopropan-2-yl)carbamate [ka]
[0409] Step 1: (S)-tert-butyl (1-(((amino(1-(4-carbamoylbenzyl)-2-((3-(pyrrolidin-1-yl)phenyl)-carbamoyl)-1H-indol-6-yl)methylene)amino)oxy)-1-oxopropan-2-yl)carbamate
[0410] The product of Step 2 of Example 23 (0.2 mg, 0.4 mmol) and (S)-Boc alanine were treated together to give 45 mg of the title compound according to the procedure described in Step 3 of Example 23.
[0411] Example 28: Synthesis of Compound I-183 Ethyl ((1-(4-carbamoylbenzyl)-2-((6-(pyrrolidin-1-yl)pyridin-2-yl)carbamoyl)-1H-indol-6-yl)(imino)methyl)carbamate [ka]
[0412] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(6-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0413] The product of Step 2 of Example 19 (950 mg, 2.97 mmol) and 6-(pyrrolidin-1-yl)pyridin-2-amine (485 mg, 2.97 mmol) were treated together to give 685 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 465.2 (M+1). +
[0414] Step 2: 1-(4-carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(6-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0415] The product of Step 1 of Example 28 (685 mg, 1.47 mmol) and aqueous hydroxylamine (0.4 mL) were treated together to give 520 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 498.2 (M+1). +
[0416] Step 3: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(6-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0417] The product of Step 2 of Example 28 (520 mg, 1.04 mmol) and acetic anhydride (213 mg, 2.08 mmol) were treated together to give 465 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 540.2 (M+1). +
[0418] Step 4: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(6-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0419] The product of Step 3 of Example 28 (460 mg, 0.85 mmol) and zinc (112 mg, 1.7 mmol) were treated together to give 60 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 482.2 (M+1). +
[0420] Step 5: ((1-(4-carbamoylbenzyl)-2-((6-(pyrrolidin-1-yl)pyridin-2-yl)carbamoyl)-1H-indol-6-yl)(imino)methyl)ethyl carbamate
[0421] The product of Step 4 of Example 28 (350 mg, 0.72 mmol) and ethyl carbonochloridate (78 mg, 0.72 mmol) were treated together to give 70 mg of the title compound according to the procedure described in Step 1 of Example 22. LCMS: 554.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.19(m,3H),1.92(m,4H),3.38(m,4H),4.04(m ,2H),4.12(m,1H),5.95(s,2H),6.18(d,1H),7.05(d,2H),7.22(d,1H),7.2 9(brs,1H),7.46(m,1H),7.59(m,1H),7.72(d,2H),7.80(s,1H),7.85(s,1H) ),8.24(s,1H),9.01(brs,2H),10.4(brs,1H);HPLC:97.47%(retention time=5.938 minutes)
[0422] Example 29: Synthesis of Compound I-199 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(3-fluoroadamantan-1-yl)-1H-indole-2-carboxamide [ka]
[0423] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-((2-methoxyethoxy)methoxy)adamantan-1-yl)-1H-indole-2-carboxamide
[0424] The product of Step 2 of Example 19 (800 mg, 2.5 mmol) and 3-((2-methoxyethoxy)methoxy)adamantan-1-amine (640 mg, 2.5 mmol) were treated together to give 635 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 557.3 (M+1). +
[0425] Step 2: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-hydroxyadamantan-1-yl)-1H-indole-2-carboxamide
[0426] The product of Step 1 of Example 29 (650 mg, 1.07 mmol) was treated with 50 mL of ethanolic HCl to give 320 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 469.2 (M+1). +
[0427] Step 3: 1-(4-carbamoylbenzyl)-6-cyano-N-(3-fluoroadamantan-1-yl)-1H-indole-2-carboxamide
[0428] The product of Step 2 of Example 29 (320 mg, 0.68 mmol) was dissolved in 10 mL of dichloromethane and cooled to −78° C. Diethylaminosulfur trifluoride (165 mg, 1.02 mmol) was added, and the reaction mixture was stirred at −30° C. for 1 hour. The mixture was quenched with ice-cold water, extracted with dichloromethane, dried over sodium sulfate, and the solvent was evaporated under vacuum to give 180 mg of the title compound, which was used in the next step without further purification. LCMS: 471.2 (M+1). +
[0429] Step 4: 1-(4-carbamoylbenzyl)-N-(3-fluoroadamantan-1-yl)-6-(N'-hydroxycarbamimidoyl)-1H-indole-2-carboxamide
[0430] The product of Step 3 of Example 29 (180 mg, 0.38 mmol) and aqueous hydroxylamine (0.1 mL) were treated together to give 150 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 504.2 (M+1). +
[0431] Step 5: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(3-fluoroadamantan-1-yl)-1H-indole-2-carboxamide
[0432] The product of Step 4 of Example 29 (150 mg, 0.29 mmol) and acetic anhydride (60 m g, 0.6 mmol) were treated together to give 120 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 546.2 (M+1) +
[0433] Step 6: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-((1r,3r)-3-((2-methoxyethoxy)methoxy)-adamantan-1-yl)-1H-indole-2-carboxamide
[0434] The product of Step 5 of Example 29 (120 mg, 0.21 mmol) and zinc (30 mg, 0.45 mmol) were treated together to give 25 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 488.2 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ1.51(s,2H),1.80(m,4H),1.94(s,4H),2.17(m,2H),2.29(m,2H),5.84(s,2H),7.15(m,3H) ),7.33(brs,1H),7.52(d,1H),7.75(d,2H),7.87(m,2H),8.19(brs,1H),8.27(brs,1H),8.93(brs,2H),9.22(brs,2H)
[0435] Example 30: Synthesis of Compound I-210 3-Amino-6-carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka]
[0436] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(cyclohexylmethyl)-1H-indole-2-carboxamide
[0437] The product of Step 2 of Example 18 (780 mg, 2.76 mmol) and 4-(bromomethyl)benzamide (592 mg, 2.76 mmol) were treated together to give 645 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 413.1 (M+1). +
[0438] Step 2: 1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-6-(N'-hydroxycarbamimidoyl)-3-nitro-1H-indole-2-carboxamide
[0439] The product of Step 1 of Example 30 (645 mg, 1.56 mmol) and aqueous hydroxylamine (0.5 mL) were treated together to give 470 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 493.2 (M+1). +
[0440] Step 3: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-3-nitro-1H-indole-2-carboxamide
[0441] The product of Step 2 of Example 30 (470 mg, 0.95 mmol) and acetic anhydride (194 mg, 1.9 mmol) were treated together to give 385 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 535.2 (M+1). +
[0442] Step 4: 3-amino-6-carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide
[0443] The product of Step 3 of Example 30 (385 mg, 0.71 mmol) and zinc (187 mg, 2.87 mmol) were treated together to give 55 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 447.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.83(m,2H),1.06(m,3H),1.45(m,2H),1.55(m,6H),3.07(m,2H),5.08(brs,2H), 5.68(s,2H),6.98(d,2H),7.30(brs,1H),7.39(d,1H),7.69(d,2H),7.86(brs,1H),7.92(d,1H),8.06(m,2H).
[0444] Example 31: Synthesis of Compound I-211 3-amino-1-(4-carbamoylbenzyl)-N 2 -(Cyclohexylmethyl)-1H-indole-2,6-dicarboxamide [ka]
[0445] Step 1: 1-(4-carbamoylbenzyl)-N2-(cyclohexylmethyl)-3-nitro-1H-indole-2,6-dicarboxamide
[0446] The product of Step 1 of Example 81 (340 mg, 0.82 mmol) and sodium hydroxide (65 mg, 1.64 mmol) were treated together to give 165 mg of the title compound according to the procedure described in Step 2 of Example 21. LCMS: 478.2 (M+1). +
[0447] Step 2: 3-amino-1-(4-carbamoylbenzyl)-N 2 -(Cyclohexylmethyl)-1H-indole-2,6-dicarboxamide
[0448] The product of Step 1 of Example 81 (165 mg, 0.34 mmol) and zinc (45 mg, 0.69 mmol) were treated together to give 300 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 448.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.76(m,2H),1.06(m,3H),1.38(m,1H),1.48(m,5H),3.03(m,2H),5.08(brs,2H),5.73(s,2H),7 .00(d,1H),7.12(brs,1H),7.25(brs,1H),7.41(d,1H),7.78(d,1H),7.98(d,1H),8.04(m,2H),8.95(brs,2H),9.19(brs,2H) );HPLC:96.22%(retention time=6.176 minutes)
[0449] Example 32: Synthesis of Compound I-212 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-3-hydroxy-1H-indole-2-carboxamide [ka]
[0450] Step 1: Ethyl 3-acetoxy-6-cyano-1H-indole-2-carboxylate
[0451] Ethyl 6-cyano-1H-indole-2-carboxylate (1.46 g, 6.82 mmol), (diacetoxyiodo)benzene (2.85 g, 8.86 mmol), and palladium(II) acetate (75 mg, 0.34 mmol) were dissolved in 150 mL of acetic acid in a sealed tube, and the mixture was slowly heated to 100 °C for 3 h. The reaction mixture was diluted with ethyl acetate, filtered through a pad of Celite, and the filtrate was washed with water and dried over sodium sulfate. The solvent was evaporated under vacuum to give the crude compound, which was purified by column chromatography using silica gel as an adsorbent and eluted with hexane:ethyl acetate (7:3) to give 645 mg of the title compound. LCMS: 273.1 (M+1). +
[0452] Step 2: 3-acetoxy-1-(4-carbamoylbenzyl)-6-cyano-1H-indole-2-carboxylate ethyl
[0453] The product of Step 1 of Example 212 (645 mg, 2.37 mmol) and 4-(bromomethyl)benzamide (507 mg, 2.37 mmol) were treated together to give 745 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 406.1 (M+1). +
[0454] Step 3: 1-(4-carbamoylbenzyl)-6-cyano-3-hydroxy-1H-indole-2-carboxylate ethyl
[0455] The product of Step 2 of Example 32 (745 mg, 1.83 mmol) was dissolved in 150 mL of toluene and treated with silica gel (165 mg, 2.75 mmol), 4-methylbenzenesulfonic acid (380 mg, 2.2 mmol), and water (72 mg, 4.02 mmol). The mixture was heated to 80° C. for 6 hours. The reaction mixture was quenched with cold water and extracted with ethyl acetate, then washed with water and dried over sodium sulfate. Evaporation of the solvent under vacuum gave the crude compound, which was purified by column chromatography using silica gel as adsorbent and eluting with hexane:ethyl acetate (6:4) to give 540 mg of the title compound. LCMS: 364.1 (M+1). +
[0456] Step 4: 1-(4-carbamoylbenzyl)-6-cyano-3-((4-methoxybenzyl)oxy)-1H-indole-2-carboxylate ethyl
[0457] The product of Step 3 of Example 32 (540 mg, 1.48 mmol) was dissolved in 50 mL of tetrahydrofuran, and 1-(bromomethyl)-4-methoxybenzene (298 mg, 1.48 mmol) and sodium hydride (60 mg, 1.48 mmol) were added at 0° C. The reaction mixture was stirred at room temperature for 6 hours. The mixture was quenched with cold water and extracted with ethyl acetate, then washed with brine and dried over sodium sulfate. The solvent was evaporated under vacuum to give the crude compound, which was purified by column chromatography using silica gel as an adsorbent and eluted with hexane:ethyl acetate (8:2) to give 610 mg of the title compound. LCMS: 484.2 (M+1). +
[0458] Step 5: 1-(4-carbamoylbenzyl)-6-cyano-3-((4-methoxybenzyl)oxy)-1H-indole-2-carboxylic acid
[0459] The product of Step 4 of Example 32 (610 mg, 1.26 mmol) and lithium hydroxide (60 mg, 2.52 mmol) were treated together to give 385 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 456.2 (M+1). +
[0460] Step 6: 1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-6-cyano-3-((4-methoxybenzyl)oxy)-1H-indole-2-carboxamide
[0461] The product of Step 5 of Example 32 (385 mg, 0.84 mmol) and cyclohexylmethanamine (95 mg, 0.84 mmol) were treated together to give 310 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 551.3 (M+1). +
[0462] Step 7: 1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-6-(N'-hydroxycarbamimidoyl)-3-((4-methoxybenzyl)oxy)-1H-indole-2-carboxamide
[0463] The product of Step 6 of Example 32 (310 mg, 0.56 mmol) and aqueous hydroxylamine (0.2 mL) were treated together to give 165 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 584.3 (M+1). +
[0464] Step 8: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-3-((4-methoxybenzyl)oxy)-1H-indole-2-carboxamide
[0465] The product of Step 7 of Example 32 (165 mg, 0.28 mmol) and acetic anhydride (58 mg, 0.56 mmol) were treated together to give 145 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 626.3 (M+1). +
[0466] Step 9: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-3-hydroxy-1H-indole-2-carboxamide
[0467] The product of Step 8 of Example 32 (145 mg, 0.23 mmol) was dissolved in 20 mL of methanol and treated with 10% palladium on carbon (24 mg, 0.23 mmol) under nitrogen at room temperature for 4 hours. The mixture was filtered through a pad of Celite, and the filtrate was concentrated to give the crude product, which was purified by reverse-phase preparative column chromatography to give 20 mg of the title compound. LCMS: 448.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.95(m,2H),1.06(m,3H),1.38(m,1H),1. 48(m,5H),3.18(m,2H),5.92(s,2H),7.01(d,2H),7.32(brs,1H),7.43(d,1H),7.72(d,2H),7.88(d,1H) ,7.88(brs,1H),7.98(m,2H),8.09(s,1H),8.89(brs,2H),9.22(brs,2H);HPLC:95.18%(retention time = 3.216 minutes).
[0468] General synthetic scheme 3 [ka]
[0469] Example 33: Synthesis of Compound 213 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-3-chloro-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka]
[0470] Step 1: Ethyl 3-chloro-6-cyano-1H-indole-2-carboxylate
[0471] Ethyl 6-cyano-1H-indole-2-carboxylate (1.25 g, 5.84 mmol) was dissolved in 125 mL of dimethylformamide, and N-chlorosuccinimide (932 mg, 7.0 mmol) was added portionwise at 0° C., and the mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with water and extracted with ethyl acetate, then washed with brine and dried over sodium sulfate. The solvent was evaporated under vacuum and the resulting crude residue was purified by column chromatography using silica gel as adsorbent and eluting with hexane:ethyl acetate (9:1) to give 820 mg of the title compound. LCMS: 249.1 (M+1). +
[0472] Step 2: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-3-chloro-1H-indole-2-carboxylate ethyl
[0473] The product of Step 1 of Example 33 (820 mg, 3.29 mmol) and 4-(bromomethyl)benzamide (704 mg, 3.29 mmol) were treated together to give 1150 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 399.1 (M+1). +
[0474] Step 3: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-3-chloro-1H-indole-2-carboxylic acid
[0475] The product of Step 2 of Example 33 (1150 mg, 2.88 mmol) and lithium hydroxide (138 mg, 5.76 mmol) were treated together to give 735 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 371.1 (M+1).+
[0476] Step 4: 1-(4-carbamoylbenzyl)-3-chloro-6-cyano-N-(cyclohexylmethyl)-1H-indole-2-carboxamide
[0477] The product of Step 3 of Example 33 (735 mg, 1.98 mmol) and cyclohexylmethanamine (223 mg, 1.98 mmol) were treated together to give 630 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 449.2 (M+1). +
[0478] Step 5: 1-(4-carbamoylbenzyl)-3-chloro-2-((cyclohexylmethyl)carbamoyl)-1H-indole-6-carbimidate ethyl ester
[0479] The product of Step 4 of Example 33 (630 mg, 1.4 mmol) was treated with 50 mL of ethanolic HCl to give 385 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 495.2 (M+1). +
[0480] Step 6: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-3-chloro-N-(cyclohexylmethyl)-1H-indole-2-carboxamide
[0481] The product of Step 5 of Example 33 (385 mg, 0.77 mmol) was treated with 50 mL of ethanolic NH to give 75 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 466.2 (M+1). + , 1H-NMR(300MHz,DMSO-d6):δ0.84(m,2H),1.07(m,3H),1.56(m,6H),3.05(m,2H),5.75(s,2H),7.12(d,2H),7.36(brs,1H),7.6 3(d,1H),7.77(m,3H),7.93(brs,1H),8.26(brs,1H),8.78(m,1H),9.02(brs,2H),9.29(brs,2H);HPLC:98.64%(retention time = 3.759 minutes)
[0482] The following compounds listed in Table 8 can be synthesized by following procedures similar to those described above for Example 33 using appropriate reagents with suitable modifications known to those skilled in the art: The solution was prepared according to Method 3.
[0483] [Table 170] [Table 171]
[0484] Example 34: Synthesis of Compound I-215 6-Carbamimidoyl-N-(cyclohexylmethyl)-1-(4-(methylcarbamoyl)benzyl)-1H-indole-2-carboxamide [ka]
[0485] Step 1: Methyl 4-((6-cyano-2-((cyclohexylmethyl)carbamoyl)-1H-indol-1-yl)methyl)benzoate
[0486] The product of Step 1 of Example 18 (950 mg, 3.36 mmol) and methyl 4-(bromomethyl)benzoate (771 mg, 3.36 mmol) were treated together to give 1.16 g of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 430.2 (M+1). +
[0487] Step 2: 4-((6-cyano-2-((cyclohexylmethyl)carbamoyl)-1H- Indol-1-yl)methyl)benzoic acid
[0488] The product of Step 1 of Example 34 (1.16 g, 2.7 mmol) and lithium hydroxide (130 mg, 5.41 mmol) were treated together to give 835 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 417.2 (M+1). +
[0489] Step 3: 6-cyano-N-(cyclohexylmethyl)-1-(4-(methylcarbamoyl)benzyl)-1H-indole-2-carboxamide
[0490] The product of Step 2 of Example 34 (830 mg, 1.99 mmol) and methanamine (62 mg, 1.99 mmol) were treated together to give 445 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 429.2 (M+1). +
[0491] Step 4: 2-((cyclohexylmethyl)carbamoyl)-1-(4-(methylcarbamoyl)benzyl)-1H-indole-6-carbimidate ethyl ester
[0492] The product of Step 3 of Example 34 (445 mg, 1.03 mmol) was treated with 50 mL of ethanolic HCl to give 265 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 475.3 (M+1). +
[0493] Step 5: 6-Carbamimidoyl-N-(cyclohexylmethyl)-1-(4-(methylcarbamoyl)benzyl)-1H-indole-2-carboxamide
[0494] The product of Step 4 of Example 34 (265 mg, 0.55 mmol) was treated with 30 mL of ethanolic NH3 to give 80 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 446.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.84(m,2H),1.09(m,3H),1.58(m,6H),2.73(d,3H),3.03(m,2H),5.91(s,2H),7.06(d,2H),7.24(brs,1H),7.5 3(d,1H),7.69(d,2H),7.90(d,1H),8.18(brs,1H),8.33(m,1H),8.72(m,1H),8.90(brs,2H),9.22(brs,2H);HPLC:91.68%(retention time = 3.622 minutes).
[0495] Example 35: Synthesis of Compound I-216 6-Carbamimidoyl-N-(cyclohexylmethyl)-1-(4-(dimethylcarbamoyl)benzyl)-1H-indole-2-carboxamide [ka]
[0496] This compound was synthesized following a similar procedure as described in Steps 3 to 5 of Example 34. Prepared by reacting the product of Step 2 of Example 34 with dimethylamine. LCMS: 460.2 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.84(m,2H),1.11(m,3H),1.61(m,6H),2.85(s,3H),2.93(s,3H),3.05(m,2H),5.90(s,2H),7.0 6(d,2H),7.25(m,3H),7.55(d,1H),8.19(s,1H),8.72(m,1H),8.87(brs,1H),9.23(brs,2H);HPLC:91.37%(retention time = 3.758 minutes).
[0497] Example 36: Synthesis of Compound I-217 6-Carbamimidoyl-N-(cyclohexylmethyl)-1-(4-(cyclopropylcarbamoyl)benzyl)-1H-indole-2-carboxamide [ka]
[0498] This compound was prepared by reacting the product of Step 2 of Example 34 with cyclopropylamine following a similar procedure as described in Steps 3 to 5 of Example 34. LCMS: 472.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.49(m,2H),0.64(m,2H),0.84(m,2H),1.11(m ,3H),1.61(m,6H),2.75(m,1H),3.03(m,2H),5.90(s,2H),7.05(d,2H),7.2 4(s,1H),7.53(d,1H),7.68(d,1H),7.90(d,1H),8.17(brs,1H),8.34(m,1H ),8.71(m,1H),8.88(brs,2H),9.22(brs,2H);HPLC:95.16%(retention time=3.363 minutes)
[0499] Example 37: Synthesis of Compound I-218 6-Carbamimidoyl-1-(4-(dimethylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0500] Step 1: 6-cyano-N-(4-methylcyclohexyl)-1H-indole-2-carboxylate Voxamide
[0501] The product of Step 1 of Example 6 (850 mg, 4.54 mmol) and 4-methylcyclohexanamine (513 mg, 4.54 mmol) were treated together to give 530 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 282.2 (M+1). +
[0502] Step 2: Methyl 4-((6-cyano-2-((4-methylcyclohexyl)carbamoyl)-1H-indol-1-yl)methyl)benzoate
[0503] The product of Step 1 of Example 37 (530 mg, 1.87 mmol) and methyl 4-(bromomethyl)benzoate (430 mg, 1.87 mmol) were treated together to give 565 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 430.2 (M+1). +
[0504] Step 3: 4-((6-cyano-2-((4-methylcyclohexyl)carbamoyl)-1H-indol-1-yl)methyl)benzoic acid
[0505] The product of Step 2 of Example 37 (550 mg, 1.27 mmol) and lithium hydroxide (60 mg, 2.54 mmol) were treated together to give 410 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 416.2 (M+1). +
[0506] Step 4: 6-cyano-1-(4-(dimethylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide
[0507] The product of Step 3 of Example 37 (410 mg, 0.98 mmol) and dimethylamine (45 mg, 0.98 mmol) were treated together to give 270 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 443.2 (M+1). +
[0508] Step 5: 1-(4-(dimethylcarbamoyl)benzyl)-2-((4-methylcyclohexyl)carbamoyl)-1H-indole-6-carbimidate ethyl ester
[0509] The product of Step 4 of Example 37 (270 mg, 0.6 mmol) was treated with 50 mL of ethanolic HCl to give 160 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 489.3 (M+1). +
[0510] Step 6: 6-Carbamimidoyl-1-(4-(dimethylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide
[0511] The product of Step 5 of Example 37 (160 mg, 0.32 mmol) was treated with 30 mL of ethanolic NH to give 35 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 460.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.85(d,3H),1.34(m,6H),1.60(m,4H),2.84(s,3H),2.93(s,3H),3.85(m,1H),5.87(d,2H),7.08(m,2 HPLC: 93.97% (retention time = 6.536 minutes)
[0512] Example 38: Synthesis of Compound I-219 6-Carbamimidoyl-1-(4-(cyclopropylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0513] This compound was prepared by reacting the product of Step 3 of Example 37 with cyclopropylamine following a similar procedure as described in Steps 4 to 6 of Example 37. LCMS: 472.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.50(m,2H),0.63(m,2H),0.88(m,3H),1.34(m,3H),1.49(m,3H),1.62(m,3H),2.78(m,1H),3.81(m,1H),5.87(s ,2H),7.15(d,2H),7.23(d,1H),7.51(d,1H),7.67(d,2H),7.84(m,1H),8.14(m,1H),8.33(d,1H),8.42(d,1H);HPLC:88.81%(retention time = 6.469 minutes)
[0514] Example 39: Synthesis of Compound I-220 6-Carbamimidoyl-1-(4-(methylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0515] This compound was prepared by reacting the product of Step 3 of Example 37 with methylamine following a similar procedure as described in Steps 4 to 6 of Example 37. LCMS: 446.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.86(d,3H),1.32(m,3H),1.46(m,3H),1.62(m,3H),2.73(d,3H),3.3.78(m,1H),5.88(d,2H),7.12(d,2H),7.25(d, 1H),7.53(d,1H),7.70(d,2H),7.88(m,1H),8.16(m,1H),8.34(m,1H),8.44(d,1H),8.91(brs,2H),9.22(brs,2H);HPLC:89.03%(retention time = 6.274 minutes)
[0516] Example 40: Synthesis of Compound I-221 6-Carbamimidoyl-1-(4-(ethylcarbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0517] This compound was prepared by reacting the product of Step 3 of Example 37 with ethylamine following a similar procedure as described in Steps 4 to 6 of Example 37. LCMS: 460.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.90(d,3H),1.05(m,3H),1.34(m,6H),1.61(m,3H),3.23(m,2H),3.85(m,1H),5.87(s,2H),7.12(d,2H),7 .26(s,1H),7.53(d,1H),7.70(d,2H),7.89(m,1H),8.17(s,1H),8.37(m,1H),8.44(d,1H),8.92(brs,2H);HPLC:97.38%(retention time = 3.915 minutes)
[0518] Example 41: Synthesis of Compound I-222 6-Carbamimidoyl-N-(cyclohexylmethyl)-1-(4-((2-hydroxyethyl)carbamoyl)benzyl)-1H-indole-2-carboxamide [ka]
[0519] This compound was prepared by reacting the product of Step 2 of Example 34 with 2-((2-methoxyethoxy)methoxy)ethanamine following a similar procedure as described in Steps 3-5 of Example 34. LCMS: 476.3 (M+1) + , 1H-NMR(300MHz,DMSO-d6):δ0.82(m,2H),1.09(m,3H),1.61(m,6H),3.03(m,2H),3.25(m,2H),3.43(m,2H),5.91(s,2H),7.06(d,2H),7.24(s,1H) ),7.53(d,1H),7.72(d,2H),7.90(d,1H),8.17(brs,1H),8.36(m,1H),8.72(m,1H),8.86(brs,2H),9.22(brs,2H);HPLC:91.88%(retention time = 6.012 minutes).
[0520] Example 42: Synthesis of Compound I-223 6-Carbamimidoyl-1-(4-((2-hydroxyethyl)carbamoyl)benzyl)-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0521] This compound was prepared by reacting the product of Step 3 of Example 37 with 2-((2-methoxyethoxy)methoxy)ethanamine following a similar procedure as described in Steps 4-6 of Example 39. LCMS: 476.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.90(m,3H),1.37(m,2H),1.46(m,4H),1.63(m,3H),3.25(m,2H),3.44(m,2H),3.91(m,1H),5.90(s,2H),7.14(d,2) HPLC: 96.87% (retention time = 6.14 minutes)
[0522] Example 43: Synthesis of Compound I-224 1-(4-((2-aminoethyl)carbamoyl)benzyl)-6-carbamimidoyl-N-(4-methylcyclohexyl)-1H-indole-2-carboxamide [ka]
[0523] This compound was prepared by reacting the product of Step 3 of Example 37 with tert-butyl (2-aminoethyl)carbamate following a similar procedure as described in Steps 4 to 6 of Example 37. LCMS: 475.3 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ0.91(m,3H),1.34(m,2H),1.47(m,4H),1.63( m,3H),2.93(m,2H),3.35(m,2H),3.88(m,1H),5.89(s,2H),7.16(d,2H),7 .28(d,1H),7.54(d,2H),7.74(m,3H),7.90(m,1H),8.15(s,1H),8.45(m,1 H),8.54(m,1H),8.97(s,2H),9.23(brs,2H);HPLC:92.46%(retention time=5.517 minutes)
[0524] Example 44: Synthesis of Compound I-225 1-(4-((2-aminoethyl)carbamoyl)benzyl)-6-carbamimidoyl-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka]
[0525] This compound was prepared by reacting the product of Step 2 of Example 34 with tert-butyl (2-aminoethyl)carbamate following a similar procedure as described in Steps 3 to 5 of Example 34. LCMS: 475.3 (M+1) + , 1H-NMR(300MHz,DMSO-d6):δ0.83(m,2H),1.07(m,4H),1.47(m,1H),1.60(m ,4H),2.94(m,2H),3.05(m,2H),3.34(m,2H),5.92(s,2H),7.11(d,2H),7.2 7(s,1H),7.54(d,2H),7.73(m,3H),7.90(m,1H),8.16(s,1H),8.56(m,1H) ,8.74(m,1H),9.03(brs,2H),9.23(brs,2H);HPLC:95.19%(retention time=5.421 minutes).
[0526] Example 45: Synthesis of Compound I-232 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-N-methyl-1H-indole-2-carboxamide [ka]
[0527] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(cyclohexylmethyl)-N-methyl-1H-indole-2-carboxamide
[0528] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 1-cyclohexyl-N-methylmethanamine (198 mg, 1.56 mmol) were treated together to give 395 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 429.2 (M+1). +
[0529] Step 2: 1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-6-(N'-hydroxycarbamimidoyl)-N-methyl-1H-indole-2-carboxamide
[0530] The product of Step 1 of Example 50 (380 mg, 0.88 mmol) and aqueous hydroxylamine (1.7 mL) were treated together to give 300 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 462.2 (M+1). +
[0531] Step 3: 6-(N'-acetoxycarbamimidoyl)-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-N-methyl-1H-indole-2-carboxamide
[0532] The product of Step 2 of Example 50 (250 mg, 0.54 mmol) and acetic anhydride (260 mg, 2.54 mmol) were treated together to give 180 mg of the title compound according to the procedure described in Step 5 of Example 14. LCMS: 504.2 (M+1). +
[0533] Step 4: 6-Carbamimidoyl-1-(4-carbamoylbenzyl)-N-(cyclohexylmethyl)-N-methyl-1H-indole-2-carboxamide
[0534] The product of Step 3 of Example 50 (160 mg, 0.31 mmol) and zinc (80 mg, 1.24 mmol) were treated together to give 65 mg of the title compound according to the procedure described in Step 6 of Example 14. LCMS: 446.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.76(m,2H),1.08(m,3H),1.38(m,1H),1.48(m,6H),2.90(s,3H),3.23(d,2H),5.65(d,2H),6.99(s,1H),7.04(d,1H) ,7.35(brs,1H),7.56(d,1H),7.79(d,2H),7.86(d,1H),7.92(brs,1H),8.23(d,1H),9.05(brs,2H),9.24(brs,2H);HPLC:96.43%(retention time = 3.663 minutes)
[0535] Example 46: Synthesis of Compound I-226 6-Carbamimidoyl-1-(4-carbamoyl-phenethyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka] The synthesis of Example I-226 was achieved following a procedure similar to Step 1 of Example 45 and Example 19, using Steps 1 to 4, where N-methylcyclohexylmethylamine was replaced with cyclohexylmethylamine. LCMS: 446.2 (M+1)+ 1 H-NMR(300MHz,DMSO-d6):δ0.85(m,2H),1.17(m,4H),1.51(m,1H),1.63(m,4H),2.03(m,3H),3.06(m,2H),3.15(m, 1H), 6.33 (m, 1H), 7.09 (s, 1H), 7.27 (d, 1H), 7.41 (m, 2H), 7.56 (brs, 1H), 7.78 (m, 3H); HPLC: 84.28% (retention time = 6.495 minutes)
[0536] Example 47: Synthesis of Compound I-227 6-Carbamimidoyl-1-(2-fluoro-4-carbamoyl-benzyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka] The synthesis of the compound of Example I-227 was achieved following a procedure similar to that of Example 45 and Step 1 of Example 19, using Steps 1 to 4, where N-methylcyclohexylmethylamine was replaced with cyclohexylmethylamine. LCMS: 450.2 (M+1)+ 1H-NMR(300MHz,DMSO-d6):δ0.82(m,2H),1.08(m,3H),1.47(m,1H),1.60(m,5H),3.01(m,2H),5.96(s,2H),6.46(m,1H),7 .28(s,1H),7.48(m,3H),7.67(d,1H),7.89(d,1H),7.99(brs,1H),8.16(s,1H),8.72(m,1H);HPLC:98.05%(retention time = 3.057 minutes)
[0537] Example 48: Synthesis of Compound I-228 6-Carbamimidoyl-1-(2-chloro-4-carbamoyl-benzyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka] The synthesis of Example I-228 was achieved following a procedure similar to that of Example 45 using steps 1 to 4, where N-methylcyclohexylmethylamine was replaced with cyclohexylmethylamine, and step 1 of Example 19 using the corresponding 2-chloro derivative. LCMS: 466.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.76(m,2H),1.05(m,3H),1.40(m,1H),1.52(m,5H),2.98(m,2H),5.97(s,2H),6.08(d,1H),6.37(s,1H),7.48(b rs,1H),7.58(m,2H),7.95(m,2H),8.03(brs,1H),8.14(brs,1H),8.77(m,1H),9.11(brs,2H),9.24(brs,2H);HPLC:97.51%(retention time = 6.278 minutes).
[0538] Example 49: Synthesis of Compound I-229 6-Carbamimidoyl-1-(3-chloro-4-carbamoyl-benzyl)-N-(cyclohexylmethyl)-1H-indole-2-carboxamide [ka] The synthesis of Example I-229 was achieved following a procedure similar to that of Example 45 using steps 1 to 4, where N-methylcyclohexylmethylamine was replaced with cyclohexylmethylamine, and step 1 of Example 19 using the corresponding 3-chloro derivative. LCMS: 466.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δδ0.88(m,2H),1.10(m,3H),1.52(m,1H),1.61(m,5H),3.07(m,2H),5.88(s,2H),7.06(d,1H),7. 16(s,1H),7.27(m,2H),7.53(m,2H),7.78(brs,1H),7.86(d,1H),8.15(brs,1H),8.77(m,1H);HPLC:94.47%(retention time = 2.907 minutes)
[0539] Example 50: Synthesis of Compound I-230 6-Carbamimidoyl-1-(3-carbamoylbenzyl)-N-(4-difluorocyclohexyl)-1H-indole-2-carboxamide [ka] The synthesis of Example I-230 was achieved following a procedure similar to that of Example 45 using steps 1 to 4, where N-methylcyclohexylmethylamine was replaced with 4,difluorocyclohexylamine, and step 1 of Example 19 using the corresponding 3-carbamoyl derivative. LCMS: 454.2 (M+1). + ,1.56(m,2H),1.80(m,3H),1.95(m,3H),3.59(m,1H),5.90(s,2H),7.08(s,1H),7.19(m,2H),7.26(s,1H),7.30(m,2H),7.55(d,1H) ),7.65(s,1H),7.70(d,1H),7.89(m,1H),8.30(brs,1H),8.66(d,1H),8.99(brs,2H),9.33(brs,2H);HPLC:95.37%(retention time=3.356 minutes)
[0540] Example 51: Synthesis of Compound I-241 6-Carbamimidoyl-N-((1r,4r)-4-guanidinocyclohexyl)-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide [ka]
[0541] Step 1: 6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxylate ethyl
[0542] Ethyl 6-cyano-1H-indole-2-carboxylate (3.2 g, 14.95 mmol) and 1-(bromomethyl)-4-phenoxybenzene (3.93 g, 14.95 mmol) were treated together to give 4.65 g of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 397.2 (M+1). +
[0543] Step 2: 6-cyano-1-((4'-ethoxy-[1,1'-biphenyl]-3-yl)methyl)-1H-indole-2-carboxylic acid
[0544] The product of Step 1 of Example 51 (4.5 g, 11.33 mmol) and lithium hydroxide (544 mg, 22.67 mmol) were treated together to give 3.28 g of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 367.2 (M+1). +
[0545] Step 3: tert-butyl ((1r,4r)-4-(6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0546] The product of Step 2 of Example 51 (650 mg, 1.77 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (378 mg, 1.77 mmol) were treated together to give 485 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 565.3 (M+1). +
[0547] Step 4: N-((1r,4r)-4-aminocyclohexyl)-6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide
[0548] The product of Step 3 of Example 51 (840 mg, 1.48 mmol) was treated with 50 mL of ethanolic HCl to give 645 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 465.2 (M+1). +
[0549] Step 5: 6-cyano-N-((1r,4r)-4-guanidinocyclohexyl)-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide
[0550] The product of Step 4 of Example 51 (640 mg, 1.37 mmol) dissolved in 10 mL of N,N-dimethylformamide was treated with 1H-pyrazole-1-carboxamidine hydrochloride (405 mg, 2.76 mmol) and N,N-diisopropylethylamine (535 mg, 4.11 mmol) to give 320 mg of the title compound according to the procedure described in Step 2 of Example 3. LCMS: 507.3 (M+1). +
[0551] Step 6: 2-(((1r,4r)-4-guanidinocyclohexyl)carbamoyl)-1-(4-phenoxybenzyl)-1H-indole-6-carbimidate ethyl ester
[0552] The product of Step 5 of Example 51 (320 mg, 0.63 mmol) was treated with 50 mL of ethanolic HCl to give 175 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 553.3 (M+1). +
[0553] Step 7: 6-Carbamimidoyl-N-((1r,4r)-4-guanidinocyclohexyl)-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide
[0554] The product of Step 6 of Example 51 (150 mg, 0.28 mmol) was treated with 30 mL of ethanolic NH3 to give 80 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 524.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.32(m,4H),1.82(m,4H),2.45(m,2H),3.71(m,2H),5.82(s,2H),6.88(m,4H),7.12(m,3 H),7.22(brs,1H),7.33(m,2H),7.53(m,2H),7.88(d,1H),8.31(s,1H),8.65(d,1H),9.12(brs,2H),9.32(brs,2H).
[0555] Example 52: Synthesis of Compound I-242 N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide [ka]
[0556] Step 1: tert-butyl (3-(((1r,4r)-4-(6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)-amino)-3-oxopropyl)carbamate
[0557] The product of Step 4 of Example 51 (730 mg, 1.56 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (296 mg, 1.56 mmol) were treated together to give 425 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 636.3 (M+1). +
[0558] Step 2: 2-(((1r,4r)-4-(3-aminopropanamido)cyclohexyl)carbamoyl)-1-(4-phenoxybenzyl)-1H-indole-6-carbimidate ethyl ester
[0559] The product of Step 1 of Example 52 (425 mg, 0.66 mmol) was treated with 50 mL of ethanolic HCl to give 195 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 582.3 (M+1). +
[0560] Step 3: N-((1r,4r)-4-(3-aminopropanamido)cyclohexyl)-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide
[0561] The product of Step 2 of Example 52 (195 mg, 0.33 mmol) was treated with 30 mL of ethanolic NH3 to give 62 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 553.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.32(m,4H),1.82(m,4H),2.45(m,2H),2.95(m,2H),3.71(m,2H),5.82(s,2H),6.88(m,3H),7.12(m,3H),7. 22(m,2H),7.33(m,2H),7.53(d,1H),7.81(m,3H),8.21(d,1H),8.28(d,1H),9.12(brs,2H),9.32(brs,2H);HPLC:93.49%(retention time = 7.133 minutes)
[0562] Example 53: Synthesis of Compound I-252 3-Amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide [ka]
[0563] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-3-nitro-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0564] The product of Step 1 of Example 9 (980 mg, 2.29 mmol) and 1-(bromomethyl)-4-phenoxybenzene (605 mg, 2.29 mmol) were treated together to give 760 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 610.3 (M+1). +
[0565] Step 2: ((1r,4r)-4-(3-amino-6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamic acid te rt-butyl
[0566] The product of Step 1 of Example 53 (750 mg, 1.22 mmol) and zinc (160 mg, 2.45 mmol) were treated together to give 430 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 580.3 (M+1). +
[0567] Step 3: 3-amino-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-(4-phenoxybenzyl)-1H-indole-6-carbimidate ethyl ester
[0568] The product of Step 2 of Example 53 (430 mg, 0.74 mmol) was treated with 50 mL of ethanolic HCl to give 155 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 526.3 (M+1). +
[0569] Step 4: 3-amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamide
[0570] The product of Step 3 of Example 53 (155 mg, 0.29 mmol) was treated with 30 mL of ethanolic NH to give 15 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 497.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.31(m,4H),1.83(m,4H),2.95(m,1H),3.71(m,1H),5.63(s,2H),6.85(d,4H),7.12(m, 1H),7.21(d,2H),7.36(m,3H),7.81(m,3H),7.94(d,1H),8.13(d,1H),8.18(brs,1H),9.10(brs,2H),9.21(brs,2H)
[0571] Example 54: Synthesis of Compound I-253 ((1r,4r)-4-(3-amino-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamic acid [ka]
[0572] Step 1: ((1r,4r)-4-(3-amino-6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamic acid
[0573] The product of Step 2 of Example 53 (510 mg, 0.87 mmol) and sodium hydroxide (52 mg, 1.3 mmol) were treated together to give 180 mg of the title compound according to the procedure described in Step 2 of Example 1, without using lithium hydroxide as the base. LCMS: 524.2 (M+1). +
[0574] Step 2: ((1r,4r)-4-(3-amino-6-(ethoxy(imino)methyl)-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamic acid
[0575] The product of Step 1 of Example 53 (180 mg, 0.51 mmol) was treated with 30 mL of ethanolic HCl to give 65 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 570.3 (M+1). +
[0576] Step 3: ((1r,4r)-4-(3-amino-6-carbamimidoyl-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamic acid
[0577] The product of Step 2 of Example 53 (65 mg, 0.11 mmol) was treated with 20 mL of ethanolic NH3 to give 10 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 541.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.21(m,2H),1.36(m,2H),1.79(m,4H),2.95(m,1H),3.71(m,1H),5.63(s,2H),6.85(d,4H),7.12(m,3H),7.32(m,3H) ,7.52(m,1H),7.71(d,1H),7.82(m,2H),8.19(d,1H),8.31(brs,1H),9.10(brs,2H),9.21(brs,2H),9.65(brs,1H);HPLC:87.13%(retention time = 6.683 minutes)
[0578] Example 55: Synthesis of Compound I-254 Ethyl (2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-((Z)-N'-hydroxycarbamimidoyl)-1-(4-phenoxybenzyl)-1H-indol-3-yl)carbamate [ka]
[0579] Step 1: ((1r,4r)-4-(3-ethylcarbamate-6-cyano-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0580] The product of Step 2 of Example 53 (650 mg, 1.12 mmol) and ethyl carbonochloridate (121 mg, 1.12 mmol) were treated together to give 370 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 652.3 (M+1). +
[0581] Step 2: ((1r,4r)-4-(ethyl 3-carbamate-6-((Z)-N'-hydroxycarbamimidoyl)-1-(4-phenoxybenzyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0582] The product of Step 1 of Example 55 (370 mg, 0.56 mmol) and aqueous hydroxylamine (0.2 mL) were treated together to give 230 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 613.3 (M+1). +
[0583] Step 3: (2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-((Z)-N'-hydroxycarbamimidoyl)-1-(4-phenoxybenzyl)-1H-indol-3-yl)carbamate ethyl
[0584] The product of Step 2 of Example 55 (230 mg, 0.37 mmol) was treated with 30 mL of ethanolic HCl to give 65 mg of the title compound according to the procedure described in Step 2 of Example 2. LCMS: 585.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.21(m,7H),1.81(m,4H),2.96(m,1H),3.52(m,1H),4.09(m,2H),5.83(s,2H),6.89(m,4H),7.11(m,3H),7.32( HPLC: 97.32% (retention time = 4.97 minutes).
[0585] Example 56: Synthesis of Compound I-256 1-(3-aminobenzyl)-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1H-indole-2-carboxamide [ka]
[0586] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-1-(3-nitrobenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0587] The product of Step 2 of Example 6 (1200 mg, 3.13 mmol) and 1-(bromomethyl)-3-nitrobenzene (676 mg, 3.13 mmol) were treated together to give 850 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 518.2 (M+1). +
[0588] Step 2: ((1r,4r)-4-(1-(3-aminobenzyl)-6-cyano-1H-indole-2-carboxamido)cyclohexyl)-carbamate tert-butyl
[0589] The product of Step 1 of Example 56 (850 mg, 1.64 mmol) and zinc (213 mg, 3.28 mmol) were treated together and reacted according to the procedure described in Step 3 of Example 9. Obtained 410 mg of the title compound. LCMS: 488.3 (M+1) +
[0590] Step 3: 1-(3-aminobenzyl)-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1H-indole-6-carbimidate ethyl ester
[0591] The product of Step 2 of Example 56 (410 mg, 0.84 mmol) was treated with 50 mL of ethanolic HCl to give 235 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 434.2 (M+1). +
[0592] Step 4: 1-(3-aminobenzyl)-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1H-indole-2-carboxamide
[0593] The product of Step 3 of Example 56 (235 mg, 0.54 mmol) was treated with 30 mL of ethanolic NH to give 35 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 405.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.42(m,4H),1.81(m,4H),2.95(m,1H),3.45(m,1H),5.83(s,2H),6.41(m,3H),6.97(m,1H),7.2 2(s,1H),7.52(d,1H),7.82(m,4H),8.15(brs,1H),8.61(d,1H),9.05(brs,2H),9.25(brs,2H);HPLC:94.55%(retention time = 4.255 minutes)
[0594] Example 57: Synthesis of Compound I-257 N-((1r,4r)-4-aminocyclohexyl)-1-(3-(3-aminopropanamido)benzyl)-6-carbamimidoyl-1H-indole-2-carboxamide [ka]
[0595] This compound was prepared by treating the product of Step 2 of Example 56 with 3-((tert-butoxycarbonyl)amino)propanoic acid following a similar procedure as described in Steps 3-5 of Example 1. LCMS: 476.3 (M+1) + , 1 H-NMR (300MHz, DMSO-d6): δ1.32(m,4H),1.83(m,4H),2.63(m,2H),3.11(m,3H),3.71(m,1H),5.84(s,2H),7.14(m,1H),7.27(s,1H),7. 32(brs,1H),7.48(m,2H),7.84(m,4H),7.93(m,2H),8.18(s,1H),8.58(d,1H),9.22(d,3H),10.18(brs,1H);HPLC:97.1%(retention time = 4.042 minutes)
[0596] Example 58: Synthesis of Compound I-258 N-((1r,4r)-4-aminocyclohexyl)-1-(3-(azetidine-3-carboxamido)benzyl)-6-carbamimidoyl-1H-indole-2-carboxamide Samid [ka]
[0597] This compound was prepared by treating the product of Step 2 of Example 56 with 1-((tert-butoxycarbonyl)azetidine-3-carboxylic acid following a similar procedure as described in Steps 3-5 of Example 1. LCMS: 488.3 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ1.42(m,4H),1.81(m,4H),2.95(m,2H),3.55(m,3H),4.05(m,2H),5.83(s,2H),6.71(d,1H),7.22(m,2H),7.51( HPLC: 94.31% (retention time = 4.177 minutes).
[0598] Example 59: Synthesis of Compound I-259 3-(3-((2-(((1r,4r)-4-amiocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzamido)propanoic acid [ka]
[0599] Step 1: methyl 3-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzoate
[0600] The product of Step 2 of Example 6 (1.2 g, 3.13 mmol) and methyl 3-(bromomethyl)benzoate (717 mg, 3.13 mmol) were treated together to give 930 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 531.2 (M+1). +
[0601] Step 2: 3-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzoic acid
[0602] The product of Step 1 of Example 59 (930 mg, 1.75 mmol) and lithium hydroxide (85 mg, 3.5 mmol) were treated together to give 630 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 517.2 (M+1). +
[0603] Step 3: methyl 3-(3-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzamido)propanoate
[0604] The product of Step 2 of Example 59 (630 mg, 1.21 mmol) and methyl 3-aminopropanoate (125 mg, 1.21 mmol) were treated together to give 340 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 602.3 (M+1). +
[0605] Step 4: 3-(3-((2-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-6-cyano-1H-indol-1-yl)methyl)benzamido)propanoic acid
[0606] The product of Step 3 of Example 59 (340 mg, 0.56 mmol) and lithium hydroxide (55 mg, 2.26 mmol) were treated together to give 210 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 588.3 (M+1). +
[0607] Step 5: 3-(3-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-(ethoxy(imino)methyl)-1H-indol-1-yl)methyl)benzamido)propanoic acid
[0608] The product of Step 4 of Example 59 (200 mg, 0.34 mmol) was treated with 50 mL of ethanolic HCl to give 75 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 534.3 (M+1). +
[0609] Step 6: 3-(3-((2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)benzamido)propanoic acid
[0610] The product of Step 5 of Example 59 (70 mg, 0.13 mmol) was treated with 20 mL of ethanolic NH to give 23 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 505.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.32(m,4H),1.83(m,4H),2.33(m,3H),2.95(m ,1H),3.45(m,2H),5.84(s,2H),6.82(s,1H),7.17(d,1H),7.28(s,1H),7.3 6(m,2H),7.52(m,3H),7.81(m,2H),8.21(s,1H),8.45(m,1H),8.65(d,1H), 9.02 (brs, 2H), 9.25 (brs, 2H), 13.24 (brs, 1H); HPLC: 96.04% (retention time = 4.45 minutes)
[0611] Example 60: Synthesis of Compound I-260 1-(3-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0612] Step 1: ethyl 6-cyano-1-(3-nitrobenzyl)-1H-indole-2-carboxylate [ka]
[0613] Ethyl 6-cyano-1H-indole-2-carboxylate (1.45 g, 6.77 mmol) and 1-(bromomethyl)-3-nitrobenzene (1.46 g, 6.77 mmol) were treated together to give 1.05 g of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 350.1 (M+1). +
[0614] Step 2: 6-cyano-1-(3-nitrobenzyl)-1H-indole-2-carboxylic acid
[0615] The product of Step 1 of Example 60 (1.05 g, 3.0 mmol) and lithium hydroxide (145 mg, 6.0 mmol) were treated together to give 680 mg of the title compound according to the procedure described in Step 2 of Example 1. LCMS: 322.1 (M+1). +
[0616] Step 3: 6-cyano-N-(4,4-difluorocyclohexyl)-1-(3-nitrobenzyl)-1H-indole-2-carboxamide
[0617] The product of Step 2 of Example 60 (680 mg, 2.11 mmol) and 4,4-difluorocyclohexanamine (285 mg, 2.11 mmol) were treated together to give 570 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 439.2 (M+1). +
[0618] Step 4: 1-(3-aminobenzyl)-6-cyano-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0619] The product of Step 3 of Example 60 (570 mg, 1.29 mmol) and zinc (170 mg, 2.62 mmol) were treated together to give 410 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 409.2 (M+1). +
[0620] Step 5: tert-butyl (3-((3-((6-cyano-2-((4,4-difluorocyclohexyl)carbamoyl)-1H-indol-1-yl)-methyl)phenyl)amino)-3-oxopropyl)carbamate
[0621] The product of Step 4 of Example 60 (410 mg, 1.0 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (190 mg, 1.0 mmol) were treated together Following the procedure described in Step 3 of Example 1, 365 mg of the title compound was obtained. LCMS: 580.3 (M+1) +
[0622] Step 6: 2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-(3-((2-aminoethyl)carbamoyl)-benzyl)-1H-indole-6-carbimidate ethyl ester
[0623] The product of Step 5 of Example 60 (350 mg, 0.6 mmol) was treated with 50 mL of ethanolic HCl to give 115 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 526.3 (M+1). +
[0624] Step 7: 1-(3-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0625] The product of Step 6 of Example 60 (115 mg, 0.21 mmol) was treated with 30 mL of ethanolic NH3 to give 34 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 497.3 (M+1). + , 1H-NMR(300MHz,DMSO-d6):δ1.61(m,2H),1.83(m,3H),2.03(m,3H),2.63(m,2H) ,3.04(m,2H),3.95(m,1H),5.83(s,2H),6.71(d,1H),7.17(m,1H),7.28(s,1H) ,7.36(brs,1H),7.47(d,1H),7.54(m,1H),7.74(brs,3H),7.90(d,1H),8.18(s ,1H),8.59(d,1H),9.02(brs,2H),9.25(brs,2H);HPLC:89.25%(retention time=5.796 minutes)
[0626] Example 61: Synthesis of Compound I-261 1-(4-aminobenzyl)-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1H-indole-2-carboxamide [ka]
[0627] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-1-(4-nitrobenzyl)-1H-indole-2-carboxamido)-cyclohexyl)carbamate
[0628] The product of Step 2 of Example 6 (1.2 g, 3.13 mmol) and 1-(bromomethyl)-4-nitrobenzene (676 mg, 3.13 mmol) were treated together to give 970 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 518.2 (M+1). +
[0629] Step 2: ((1r,4r)-4-(1-(3-aminobenzyl)-6-cyano-1H-indole-2-carboxamido)cyclohexyl)-carbamate tert-butyl
[0630] The product of Step 1 of Example 61 (970 mg, 1.87 mmol) and zinc (244 mg, 3.74 mmol) were treated together to give 530 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 488.3 (M+1). +
[0631] Step 3: 1-(4-aminobenzyl)-2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1H-indole-6-carbimidate ethyl ester
[0632] The product of Step 2 of Example 61 (340 mg, 0.69 mmol) was treated with 50 mL of ethanolic HCl to give 150 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 434.2 (M+1). +
[0633] Step 4: 1-(4-aminobenzyl)-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1H-indole-2-carboxamide
[0634] The product of Step 3 of Example 61 (150 mg, 0.34 mmol) was treated with 30 mL of ethanolic NH to give 22 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 405.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.41(m,4H),1.75(m,4H),2.96(m,1H),3.62(m,1H),5.67(s,2H),6.67(brs,2H),6.97(d,2H),7. 13(s,1H),7.52(d,1H),7.85(d,1H),7.95(m,3H),8.25(s,1H),9.00(brs,2H),9.24(brs,2H);HPLC:91.55%(retention time = 5.551 minutes).
[0635] Example 62: Synthesis of Compound I-262 N-((1r,4r)-4-aminocyclohexyl)-1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-1H-indole-2-carboxamide [ka]
[0636] Step 1: tert-butyl ((1r,4r)-4-(1-(4-(3-((tert-butoxycarbonyl)amino)propanamido)benzyl)-6-cyano-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0637] The product of Step 2 of Example 61 (640 mg, 1.31 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (248 mg, 1.31 mmol) were treated together to give 430 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 659.3 (M+1). +
[0638] Step 2: 2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-( 4-(3-aminopropanamido)benzyl)-1H-indole-6-carbimidate ethyl ester
[0639] The product of Step 1 of Example 62 (430 mg, 0.65 mmol) was treated with 50 mL of ethanolic HCl to give 170 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 505.3 (M+1). +
[0640] Step 3: N-((1r,4r)-4-aminocyclohexyl)-1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-1H-indole-2-carboxamide
[0641] The product of Step 2 of Example 62 (170 mg, 0.33 mmol) was treated with 30 mL of ethanolic NH3 to give 28 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 476.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.48(m,4H),1.83(m,4H),2.15(m,2H),3.10(m,2H),3.70(m,1H),5.88(s,2H),7.08(d,2H),7.22(s,1H),7.45(d,2H) ),7.53(d,2H),7.73(brs,3H),7.88(m,3H),8.18(s,1H),8.61(d,1H),9.09(brs,2H),9.23(brs,2H),10.13(s,1H);HPLC:85.85%(retention time=4.127 minutes)
[0642] Example 63: Synthesis of Compound I-263 1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide [ka]
[0643] Step 1: ethyl 6-cyano-1-(4-nitrobenzyl)-1H-indole-2-carboxylate
[0644] The product of Step 2 of Example 6 (1.35 g, 3.52 mmol) and 1-(bromomethyl)-4-nitrobenzene (761 mg, 3.52 mmol) were treated together to give 955 mg of the title compound according to the procedure described in Step 1 of Example 1. LCMS: 350.1 (M+1). +
[0645] Step 2: 6-cyano-1-(4-nitrobenzyl)-1H-indole-2-carboxylic acid
[0646] The product of Step 1 of Example 63 (950 mg, 2.71 mmol) and lithium hydroxide (130 mg, 5.42 mmol) were treated together and purified using the procedure described in Step 2 of Example 1. Following this procedure gave 710 mg of the title compound. LCMS: 322.1 (M+1) +
[0647] Step 3: 6-cyano-N-(4,4-difluorocyclohexyl)-1-(4-nitrobenzyl)-1H-indole-2-carboxamide
[0648] The product of Step 2 of Example 63 (650 mg, 2.01 mmol) and 4,4-difluorocyclohexanamine (272 mg, 2.01 mmol) were treated together to give 512 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 439.2 (M+1). +
[0649] Step 4: 1-(4-aminobenzyl)-6-cyano-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0650] The product of Step 3 of Example 63 (510 mg, 1.16 mmol) and zinc (151 mg, 2.32 mmol) were treated together to give 365 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 409.2 (M+1). +
[0651] Step 5: tert-butyl (3-((4-((6-cyano-2-((4,4-difluorocyclohexyl)carbamoyl)-1H-indol-1-yl)-methyl)phenyl)amino)-3-oxopropyl)carbamate
[0652] The product of Step 4 of Example 63 (365 mg, 0.89 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (120 mg, 0.89 mmol) were treated together to give 280 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 580.3 (M+1).+
[0653] Step 6: 1-(4-(3-aminopropanamido)benzyl)-2-((4,4-difluorocyclohexyl)carbamoyl)-1H-indole-6-carbimidate ethyl ester
[0654] The product of Step 5 of Example 63 (280 mg, 0.48 mmol) was treated with 50 mL of ethanolic HCl to give 125 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 526.3 (M+1). +
[0655] Step 7: 1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0656] The product of Step 6 of Example 63 (125 mg, 0.23 mmol) was treated with 30 mL of ethanolic NH to give 22 mg of the title compound according to the procedure described in Step 5 of Example 1. LCMS: 497.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.21(m,2H),1.83(m,3H),2.03(m,3H),2.63(m,2H),3.04(m,2H),3.95(m,1H),5.88(s,2H),7.08(d,2H),7.22(s,1H) ),7.45(d,2H),7.53(d,2H),7.73(brs,3H),7.88(d,1H),8.61(d,1H),9.04(brs,2H),9.25(brs,2H),10.13(s,1H);HPLC:92.28%(retention time=5.091 minutes)
[0657] Example 64: Synthesis of Compound I-264 1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(cyclohex-3-en-1-yl)-1H-indole-2-carboxamide [ka]
[0658] Step 1: 6-cyano-N-(cyclohex-3-en-1-yl)-1-(4-nitrobenzyl)-1H-indole-2-carboxamide
[0659] The product of Step 2 of Example 63 (500 mg, 1.55 mmol) and cyclohex-3-enamine (150 mg, 1.55 mmol) were treated together to give 360 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 401.2 (M+1). +
[0660] Step 2: 1-(4-aminobenzyl)-6-cyano-N-(cyclohex-3-en-1-yl)-1H-indole-2-carboxamide
[0661] The product of Step 1 of Example 64 (360 mg, 0.89 mmol) and zinc (116 mg, 1.8 mmol) were treated together to give 265 mg of the title compound according to the procedure described in Step 3 of Example 9. LCMS: 371.2 (M+1). +
[0662] Step 3: tert-butyl (3-((4-((6-cyano-2-(cyclohex-3-en-1-ylcarbamoyl)-1H-indol-1-yl)methyl)phenyl)amino)-3-oxopropyl)carbamate
[0663] The product of Step 2 of Example 64 (260 mg, 0.7 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (132 mg, 0.7 mmol) were treated together to give 200 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 542.3 (M+1). +
[0664] Step 4: 1-(4-(3-aminopropanamido)benzyl)-2-(cyclohex-3-en-1-ylcarbamoyl)-1H-indole-6-carbimidate ethyl ester
[0665] The product of Step 3 of Example 64 (200 mg, 0.36 mmol) was treated with 30 mL of ethanolic HCl to give 85 mg of the title compound according to the procedure described in Step 4 of Example 1. LCMS: 488.3 (M+1). +
[0666] Step 5: 1-(4-(3-aminopropanamido)benzyl)-6-carbamimidoyl-N-(4,4-difluorocyclohexyl)-1H-indole-2-carboxamide
[0667] The product of Step 4 of Example 64 (85 mg, 0.17 mmol) was treated with 20 mL of ethanolic NH3 to produce 14 mg of the title compound according to the procedure described in Step 5 of Example 1. The compound was obtained. LCMS: 459.2 (M+1) + , 1 H-NMR(300MHz,DMSO-d6):δ1.51(m,1H),1.81(m,1H),2.01(m,3H),2.25(m,1H) ,2.63(m,2H),3.02(m,2H),3.91(m,1H),5.65(brs,2H),5.79(s,2H),7.09(d,1 H),7.23(s,1H),7.45(d,2H),7.52(m,1H),7.71(m,3H),7.88(d,1H),8.60(d,1 H),8.96(brs,2H),9.24(brs,2H),10.12(s,1H);HPLC:81.94%(retention time=5.292 minutes).
[0668] Example 65: Synthesis of Compound I-267 1-(4-Carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(3-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide [ka]
[0669] The crude product of Step 2 of Example 23 was purified by preparative high performance liquid chromatography with an Agilent XDB reverse phase column (21.2 x 150 mm, 5 microns). The mobile phase was 30% acetonitrile in water (0.1% TFA) to 100% acetonitrile (0.1% TFA), which gave the title compound (25 mg). LCMS: 497.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.94(m,4H),3.19(m,4H),5.93(s,2H),6.28(d,2H),6.96(s,1H),7.01(d,1H),7.07(m,3H),7.31 (brs,1H),7.44(m,2H),7.73(m,2H),7.87(brs,1H),7.91(d,2H),8.03(s,1H),10.34(brs,1H);HPLC:94.73%(retention time=3.839 minutes)
[0670] Example 66: Compound I-268 1-(4-Carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(4-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide [ka]
[0671] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(4-pyrrolidine-1 -yl)phenyl)-1H-indole-2-carboxamide
[0672] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 4-(pyrrolidin-1-yl)aniline (252 mg, 1.56 mmol) were treated together to give 375 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 464.2 (M+1). +
[0673] Step 2: 1-(4-carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(4-(pyrrolidin-1-yl)phenyl)-1H-indole-2-carboxamide
[0674] The product of Step 1 of Example 66 (370 mg, 0.79 mmol) and aqueous hydroxylamine (1.3 mL) were treated together to give 180 mg of the title compound according to the procedure described in Step 4 of Example 14. LCMS: 497.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ1.92(m,4H),3.21(m,4H),5.93(s,2H),6.49(d,2H),7.11(d,2H),7.31(brs ,1H),7.43(m,4H),7.73(d,2H),7.87(m,2H),8.01(s,1H),10.24(brs,1H);HPLC:99.76%(retention time = 3.663 minutes)
[0675] Example 67: Synthesis of Compound I-269 1-(4-Carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(4-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide [ka]
[0676] Step 1: 1-(4-carbamoylbenzyl)-6-cyano-N-(4-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0677] The product of Step 2 of Example 19 (500 mg, 1.56 mmol) and 4-(pyrrolidin-1-yl)pyridin-2-amine (254 mg, 1.56 mmol) were treated together to give 285 mg of the title compound according to the procedure described in Step 3 of Example 1. LCMS: 465.2 (M+1). +
[0678] Step 2: 1-(4-carbamoylbenzyl)-6-(N'-hydroxycarbamimidoyl)-N-(4-(pyrrolidin-1-yl)pyridin-2-yl)-1H-indole-2-carboxamide
[0679] The product of Step 1 of Example 67 (250 mg, 0.53 mmol) and aqueous hydroxylamine (1.2 mL) were treated together and purified according to the procedure described in Step 4 of Example 14. This gave 110 mg of the title compound. LCMS: 498.2 (M+1) + , 1 HNMR(300MHz,DMSO-d6):δ2.02(m,4H),3.42(m,4H),5.93(s,2H),6.69(m,2H),7.08(d,2H),7.34(brs,1H),7 .53(d,1H),7.70(s,1H),7.78(d,2H),7.88(m,1H),7.92(m,2H),11.85(brs,1H);HPLC:98.17%(retention time = 2.79 minutes)
[0680] General synthetic scheme 4 [ka]
[0681] A first general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 4. Ethyl 6-cyano-1H-indole-2-carboxylate was treated with various alkylating agents in the presence of a suitable base (KCO) and a suitable solvent (DMF) to give alkylated derivatives. Hydrolysis of the C(2) ethyl ester with aqueous LiOH, followed by coupling with an amine using EDCI and HOBt, gave amides. The cyano group in the resulting amide derivative was converted to the amine analog by treatment with ethanolic HCl, and the intermediate imidate ester was quenched with ammonia to form compounds of formula (I).
[0682] Example 68: Synthesis of Compound I-270 2-(4-fluoropiperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carboximidamide [ka]
[0683] Step 1: ethyl 6-cyano-1-isopentyl-1H-indole-2-carboxylate
[0684] Ethyl 6-cyano-1H-indole-2-carboxylate (10.0 g, 46.71 mmol) dissolved in 250 mL of N,N-dimethylformamide (DMF) was added with 1-bromo-3-methylbutane (7.0 g, 46.71 mmol) and potassium carbonate (K2CO3) (7.73 g, 56.0 mmol) and stirred at room temperature for 8 hours. After completion of the reaction, the mixture was quenched with ice-cold water, and the precipitated product was filtered off. The solid thus obtained was further washed with water and dried under vacuum to give the crude compound, which was purified by column chromatography using silica gel as adsorbent and eluted with 10-20% ethyl acetate / hexane to give the title compound (6.2 g). LCMS: 285.1 (M+1). +
[0685] Step 2: 6-cyano-1-isopentyl-1H-indole-2-carboxylic acid
[0686] The product of Step 1 of Example 68 (5.8 g, 19.64 mmol) was dissolved in 100 mL of a mixture of tetrahydrofuran / methanol / water (1:1:1), and lithium hydroxide (LiOH) (1.9 g, 78.6 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 4 to 6 hours. The mixture was acidified with a saturated aqueous solution of citric acid, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and then the solvent was evaporated under vacuum to give the title compound (3.65 g). LCMS: 257.1 (M+1). +
[0687] Step 3: 2-(4-fluoropiperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carbonitrile
[0688] The product of Step 2 of Example 68 (650 mg, 2.53 mmol) was dissolved in 10 mL of N,N-dimethylformamide, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (392 mg, 2.53 mmol), hydroxybenzotriazole (HOBt) (341 mg, 2.53 mmol), and N,N-diisopropylethylamine (DIPEA) (327 mg, 2.53 mmol) were added and stirred at RT for 15 minutes. 4-Fluoropiperidine (260 mg, 2.53 mmol) dissolved in 5 mL of DMF was added to the reaction mixture, and the resulting solution was stirred at RT overnight. The reaction mixture was quenched with water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. Evaporation of the solvent under vacuum gave the crude compound, which was purified by column chromatography using silica gel as adsorbent and eluting with 10% ethyl acetate / hexane to give the title compound (510 mg). LCMS: 342.2 (M+1). +
[0689] Step 4: 2-(4-fluoropiperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carbimidate ethyl ester
[0690] The product of Step 3 of Example 68 (450 mg, 1.31 mmol) was dissolved in 50 mL of ethanolic HCl (ethanol was saturated with HCl gas at -20°C) and kept at RT in a sealed glass tube for 12 hours. After completion of the reaction, the solvent was evaporated under vacuum to give the title compound (235 mg). LCMS: 388.2 (M+1). +
[0691] Step 5: 2-(4-fluoropiperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carboximidamide
[0692] The product of Step 4 of Example 68 (220 mg, 0.56 mmol) was dissolved in 50 mL of ethanolic NH3 (ethanol saturated with NH3 gas at -70 °C) and kept overnight at RT in a steel bomb. After completion of the reaction, the solvent was evaporated under vacuum to give the crude product, which was then purified by column chromatography on an Agilent XDB C18 reversed-phase column (21.2 x 150 mm, 5 microns). It was purified by preparative high performance liquid chromatography using a mobile phase of 30% aqueous acetonitrile (0.1% TFA) to 100% acetonitrile (0.1% TFA), thereby giving the title compound (110 mg). LCMS: 359.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.90(m,6H),1.49(m,1H),1.61(m,2H),1.71(m,2H),1.81(m,2H),3.72(m,4H),4.33(m,2H),4.9 0(m,1H),6.84(s,1H),7.51(d,1H),7.81(d,1H),8.11(s,1H),9.06(brs,2H),9.28(brs,2H);HPLC:96.96%(retention time = 3.613 minutes).
[0693] The following compounds listed in Table 9 were prepared according to Scheme 1 by following analogous procedures as described above for Example 68 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0694] [Table 172] [Table 173] [Table 174] [Table 175] [Table 176] [Table 177] [Table 178] [Table 179] [Table 180] [Table 181] [Table 182] [Table 183]
[0695] General synthetic scheme 5 [ka]
[0696] Another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 5. 6-Cyanoindole-2-carboxylic acid derivatives derived from C(2) amides are treated with hydroxylamine to form amidoxime derivatives, which are acylated with AcO and reduced with Zn / AcOH to introduce the amidine functionality. Deprotection of the acid-labile protection with a suitable reagent (TFA / DCM or EtOH.HCl) affords compounds of formula (I).
[0697] Example 69: Synthesis of Compound I-323 3-((6-Carbamimidoyl-2-(3-fluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)benzamide [ka]
[0698] Step 1: 1-(3-carbamoylbenzyl)-6-cyano-1H-indole-2-carboxylate ethyl
[0699] Ethyl 6-cyano-1H-indole-2-carboxylate (3.57 g, 16.71 mmol) and 3-(bromomethyl)benzamide (3.56 g, 16.71 mmol) were treated together to give the title compound according to the procedure described in Step 1 of Example 68. LCMS: 348.1 (M+1). +
[0700] Step 2: 1-(3-carbamoylbenzyl)-6-cyano-1H-indole-2-carboxylic acid
[0701] The product of Step 1 of Example 69 (1.2 g, 3.45 mmol) was treated with lithium hydroxide (331 mg, 13.82 mmol) to give the title compound (770 mg) according to the procedure described in Step 2 of Example 1. LCMS: 320.1 (M+1). +
[0702] Step 3: 3-((6-cyano-2-(3-fluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)benzamide
[0703] The product of Step 2 of Example 69 (700 mg, 2.19 mmol) was treated with 3-fluoropyrrolidine (195 mg, 2.19 mmol) to give the title compound (525 mg) according to the procedure described in Step 3 of Example 1. LCMS: 391.1 (M+1). +
[0704] Step 4: 3-((2-(3-fluoropyrrolidine-1-carbonyl)-6-(N'-hydroxycarbamimidoyl)-1H-indol-1-yl)methyl)benzamide
[0705] The product of Step 3 of Example 69 (500 mg, 1.28 mmol) was dissolved in 20 mL of ethanol, aqueous hydroxylamine (0.3 mL) was added, and the resulting mixture was refluxed at 80° C. for 4-6 hours. Evaporation of the solvent under vacuum gave the title compound (425 mg), which was used in the next step without further purification. LCMS: 424.2 (M+1). +
[0706] Step 5: 3-((6-(N'-acetoxycarbamimidoyl)-2-(3-fluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)benzamide
[0707] The product of Step 4 of Example 69 (400 mg, 0.94 mmol) was dissolved in 10 mL of acetic acid, acetic anhydride (767 mg, 7.52 mmol) was added, and the resulting mixture was stirred at RT for 2 h. Evaporation of the solvent in vacuo gave the title compound (260 mg), which was used in the next step without further purification. LCMS: 466.2 (M+1). +
[0708] Step 6: 3-((6-Carbamimidoyl-2-(3-fluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)benzamide
[0709] The product of Step 5 of Example 69 (250 mg, 0.53 mmol) was dissolved in 5 mL of acetic acid, zinc (275 mg, 4.3 mmol) was added portionwise, and the resulting mixture was stirred at RT for 6-8 h. The reaction mixture was filtered through a pad of Celite, and the resulting filtrate was concentrated in vacuo to give the crude product, which was purified by reverse-phase preparative HPLC to give the title compound (75 mg). LCMS: 408.2 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ2.05(m,3H),3.43(m,2H),3.57(m,2H),5.67(s,2H),7.10(m,2H),7.26(m,3H),7.55(m,2 HPLC: 96.03% (retention time = 5.033 minutes)
[0710] The following compounds listed in Table 10 were prepared according to Scheme 5 by following analogous procedures as described above for Example 69 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0711] [Table 184] [Table 185] [Table 186] [Table 187] [Table 188]
[0712] General synthetic scheme 6 [ka]
[0713] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 6. Coupling of 6-cyanoindole-2-carboxylic acid with a suitable amine under standard coupling conditions yields the coupled compound, which is then dissolved in acetic acid and treated with copper(II) nitrate trihydrate to give the 3-nitroindole derivative, which upon further treatment with an alkyl halide in the presence of a suitable base (KCO) and a suitable solvent (DMF) yields the N-alkylated analog, which upon reduction with Zn / glacial acetic acid gives the 3-amino derivative. The corresponding 3-amino analog is then treated with ethanolic HCl to give the compound imidate, which is then treated with ethanolic ammonia to give the compound of formula (I).
[0714] Example 70: Synthesis of Compound I-345 3-amino-2-(4-(2-aminoethyl)piperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carboximidamide [ka]
[0715] Step 1: tert-butyl (2-(1-(6-cyano-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0716] 6-Cyano-1H-indole-2-carboxylic acid (1.85 g, 9.94 mmol) and tert-butyl (2-(piperidin-4-yl)ethyl)carbamate (2.26 g, 9.94 mmol) were treated together to give the title compound (1.77 g) according to the procedure described in Step 3 of Example 68. LCMS: 397.2 (M+1). +
[0717] Step 2: tert-butyl (2-(1-(6-cyano-3-nitro-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0718] The product of Step 1 of Example 70 (1.7 g, 4.29 mmol) was dissolved in 30 mL of acetic acid and cooled to 0° C. Copper(II) nitrate trihydrate (401 mg, 5.16) was added and stirred for 3 hours. The reaction mixture was quenched with cold water and extracted with ethyl acetate, then washed with brine and dried over sodium sulfate. Evaporation of the solvent gave the crude product, which was purified by column chromatography using silica gel as the adsorbent and eluting with hexane:ethyl acetate (7:3) to give 610 mg of the title compound. LCMS: 442.2 (M+1). +
[0719] Step 3: tert-butyl (2-(1-(6-cyano-1-isopentyl-3-nitro-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)-carbamate
[0720] The product of Step 2 of Example 70 (600 mg, 1.36 mmol) and 1-bromo-3-methylbutane (204 mg, 1.36 mmol) were treated together to give the title compound (1.52 g) according to the procedure described in Step 1 of Example 1. LCMS: 512.3 (M+1). +
[0721] Step 4: tert-butyl (2-(1-(3-amino-6-cyano-1-isopentyl-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)-carbamate
[0722] The product of Step 3 of Example 70 (510 mg, 0.99 mmol) was dissolved in 10 mL of glacial acetic acid (AcOH), and zinc (383 mg, 5.98 mmol) was added portionwise at room temperature. The reaction mixture was stirred at RT for 6 h. The contents were filtered through a pad of Celite, and the filtrate was concentrated under vacuum to give the crude compound, which was purified by column chromatography using silica gel as an adsorbent and eluting with hexane:ethyl acetate (6:4) to give the title compound (190 mg). LCMS: 482.3 (M+1). +
[0723] Step 5: ethyl 3-amino-2-(4-(2-aminoethyl)piperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carbimidate
[0724] The product of Step 4 of Example 70 (190 mg, 0.39 mmol) was treated with 50 mL of ethanolic HCl to give the title compound (135 mg) according to the procedure described in Step 4 of Example 1. LCMS: 428.3 (M+1). +
[0725] Step 6: 2-(4-fluoropiperidine-1-carbonyl)-1-isopentyl-1H-indole-6-carboximidamide
[0726] The product of Step 5 of Example 70 (130 mg, 0.3 mmol) was treated with 50 mL of ethanolic NH to give the title compound (35 mg) according to the procedure described in Step 5 of Example 1. LCMS: 399.3 (M+1). + , 1 H-NMR (300 MHz, DM SO-d6):δ0.81(m,6H),0.98(m,1H),1.48(m,6H),1.65(m,3H),2.81(m,3H),3.11(m,1H),4.01(m,1H),4.21(m,3H) ,7.38(m,1H),7.71(m,3H),7.82(m,1H),7.93(m,1H),9.00(brs,2H),9.21(brs,2H);HPLC:97.75%(retention time = 4.399 minutes)
[0727] The following compounds listed in Table 11 were prepared according to Scheme 6 by following analogous procedures as described above for Example 70 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0728] [Table 189]
[0729] General synthetic scheme 7 [ka]
[0730] Yet another approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 7. The 3-nitroindole derivatives described in scheme 6 upon treatment with aqueous hydroxylamine gave amidoximes, which upon acylation in the presence of acetic acid and acetic anhydride followed by reduction with Zn / AcOH gave amidine derivatives. The amidine analogs were then deprotected with either HCl or TFA under acidic conditions to give compounds of formula (I).
[0731] Example 71: Synthesis of Compound I-349 3-amino-2-(4-(2-aminoethyl)piperidine-1-carbonyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-6-carboximidamide [ka]
[0732] Step 1: tert-butyl (2-(1-(6-cyano-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0733] 6-Cyano-1H-indole-2-carboxylic acid (1.85 g, 9.94 mmol) and tert-butyl (2-(piperidin-4-yl)ethyl)carbamate (2.26 g, 9.94 mmol) were treated together to give the title compound (1.77 g) according to the procedure described in Step 3 of Example 68. LCMS: 397.2 (M+1). +
[0734] Step 2: (2-(1-(6-cyano-3-nitro-1H-indole-2-carbonyl) Piperidin-4-yl)ethyl)carbamate tert-butyl
[0735] The product of Step 1 of Example 71 (1.7 g, 4.29 mmol) and copper(II) nitrate trihydrate (401 mg, 5.16) were treated together to give the title compound (610 mg) according to the procedure described in Step 2 of Example 70. LCMS: 442.2 (M+1). +
[0736] Step 3: tert-butyl (2-(1-(6-cyano-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0737] The product of Step 2 of Example 71 (600 mg, 1.36 mmol) and ((2-bromoethyl)sulfonyl)benzene (337 mg, 1.36 mmol) were treated together to give the title compound (540 mg) according to the procedure described in Step 1 of Example 1. LCMS: 610.2 (M+1). +
[0738] Step 4: tert-butyl-(2-(1-(6-(N'-hydroxycarbamimidoyl)-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0739] The product of Step 3 of Example 71 (540 mg, 0.88 mmol) was treated with aqueous NHOH (0.3 mL) to give the title compound (410 mg) according to the procedure described in Step 4 of Example 69. LCMS: 643.2 (M+1). +
[0740] Step 5: tert-butyl-(2-(1-(6-(N'-acetoxycarbamimidoyl)-3-nitro-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamic acid
[0741] The product of Step 4 of Example 71 (410 mg, 0.63 mmol) was treated with acetic anhydride (AcO) (521 mg, 5.1 mmol) to give the title compound (325 mg) according to the procedure described in Step 5 of Example 69. LCMS: 685.3 (M+1). +
[0742] Step 6: tert-butyl (2-(1-(3-amino-6-carbamimidoyl-1-(2-(phenylsulfonyl)ethyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0743] The product of Step 5 of Example 71 (325 mg, 0.47 mmol) was treated with zinc (365 mg, 5.7 mmol) according to the procedure described in Step 6 of Example 69 to give the title compound (185 mg). LCMS: 597.3 (M+1). +
[0744] Step 7: 3-amino-2-(4-(2-aminoethyl)piperidine-1-carbonyl)-1-(2-(phenylsulfonyl)ethyl)-1H-indole-6-carboximidamide
[0745] The product of Step 6 of Example 71 (185 mg, 0.31 mmol) was treated with 20 mL of ethanolic HCl to give 65 mg of the title compound according to the procedure described in Step 4 of Example 1, except that the reaction was carried out at 0° C. for 2 hours. LCMS: 497.2 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.98(m,2H),1.40(m,3H),1.61(m,3H),2.81(m,3H),2.99(m,2H), 3.65(m,2H),3.95(m,2H),4.45(brs,2H),4.80(brs,2H),7.32(m,1H),7.61(m,6H),7.82(m,3 H), 9.01(brs,2H), 9.24(brs,2H)
[0746] The following compounds listed in Table 12 were prepared according to Scheme 7 by following analogous procedures as described above for Example 71 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0747] [Table 190]
[0748] General synthetic scheme 8 [ka]
[0749] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 8. Upon reaction with N-chlorosuccinimide in the presence of a suitable solvent (DMF), 6-cyano-indole-2-ethyl carboxylate yielded 3-chloro-6-cyano-indole-2-carboxylate, which upon reaction with a suitable base (KCO) and an appropriate alkylating agent in the presence of a suitable solvent (DMF) afforded the compound N-alkylated derivative. Hydrolysis of the C(2) ethyl ester in the presence of LiOH / HO followed by coupling with the cyclization afforded the corresponding amide upon treatment with ethanolic HCl. This intermediate imidate ester yielded compounds of formula (I) upon further treatment with ethanolic ammonia.
[0750] Example 72: Synthesis of Compound I-353 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-2-(4-fluoro Piperidine-1-carbonyl)-1H-indole-6-carboximidamide [ka]
[0751] Step 1: Ethyl 3-chloro-6-cyano-1H-indole-2-carboxylate
[0752] Ethyl 6-cyano-1H-indole-2-carboxylate (1.25 g, 5.84 mmol) was dissolved in 125 mL of dimethylformamide, and N-chlorosuccinimide (932 mg, 7.0 mmol) was added portionwise at 0° C., and the mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with water and extracted with ethyl acetate, then washed with brine and dried over sodium sulfate. The solvent was evaporated under vacuum and the resulting crude residue was purified by column chromatography using silica gel as adsorbent and eluting with hexane:ethyl acetate (9:1) to give 820 mg of the title compound. LCMS: 249.1 (M+1). +
[0753] Step 2: ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-6-cyano-1H-indole-2-carboxylate
[0754] The product of Step 2 of Example 72 (800 mg, 3.22 mmol) was treated with 4-(bromomethyl)-1,1'-biphenyl (792 mg, 3.22 mmol) to give the title compound (910 mg) according to the procedure described in Step 1 of Example 68. LCMS: 415.1 (M+1). +
[0755] Step 3: 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-6-cyano-1H-indole-2-carboxylic acid
[0756] The product of Step 3 of Example 72 (900 mg, 2.17 mmol) was treated with lithium hydroxide (417 mg, 17.4 mmol) according to the procedure described in Step 2 of Example 68 to give the title compound (640 mg). LCMS: 387.1 (M+1). +
[0757] Step 4: 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-2-(4-fluoropiperidine-1-carbonyl)-1H-indole-6-carbonitrile
[0758] The product of Step 3 of Example 72 (640 mg, 1.65 mmol) and 4-fluoropiperidine (170 mg, 1.65 mmol) were treated together to give the title compound (430 mg) according to the procedure described in Step 3 of Example 68. LCMS: 472.1 (M+1). +
[0759] Step 5: 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-2-(4-fluoropiperidine-1-carbonyl)-1H-indole-6-carbimidate ethyl ester
[0760] The product of Step 4 of Example 72 (430 mg, 0.91 mmol) was treated with 50 mL of ethanolic HCl to give the title compound (225 mg) according to the procedure described in Step 4 of Example 68. LCMS: 518.2 (M+1). +
[0761] Step 6: 1-([1,1'-biphenyl]-4-ylmethyl)-3-chloro-2-(4-fluoropiperidine-1-carbonyl)-1H-indole-6-carboximidamide
[0762] The product of Step 5 of Example 72 (220 mg, 0.42 mmol) was treated with 50 mL of ethanolic NH to give the title compound (65 mg) according to the procedure described in Step 5 of Example 68. LCMS: 489.2 (M+1). + , 1H-NMR (300MHz, DMSO-d6): δ1.52(m,2H),1.66(m,2H),2.96(m,1H),3.13(m,1H),3.46(m,1H),3.79(m,2H),5.33(m,1H),5.72(m,1H),7.21(m,2 HPLC: 97.53% (retention time = 4.135 minutes)
[0763] The following compounds listed in Table 13 can be synthesized using appropriate reagents with suitable modifications known to those skilled in the art: Prepared according to Scheme 8 by following similar procedures as described above for Example 72. [ka]
[0764] [Table 191]
[0765] General synthetic scheme 9 [ka]
[0766] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 9. The previously described N-functionalized 6-cyano-indole dicarboxylic acids were coupled with esters containing cyclic amines to give the corresponding cyclic amides. Hydrolysis of the ester functionality attached to the cyclic amines followed by further coupling with various amines gave diamide derivatives. Treatment of the diamides with ethanolic HCl followed by ethanolic ammonia gave compounds of formula (I).
[0767] Example 73: Synthesis of Compound I-356 N-(3-aminopropyl)-1-(6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)-piperidine-4-carboxamide [ka]
[0768] Step 1: ethyl 6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxylate
[0769] Ethyl 6-cyano-1H-indole-2-carboxylate (10.0 g, 46.71 mmol) and 1-(bromomethyl)-4-(trifluoromethyl)benzene (7.0 g, 46.71 mmol) were treated together to give the title compound (6.2 g) according to the procedure described in Step 1 of Example 68. LCMS: 285.1 (M+1). +
[0770] Step 2: 6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carboxylic acid
[0771] The product of Step 1 of Example 73 (5.8 g, 19.64 mmol) was treated with LiOH (1.89 g, 78.6 mmol) to give the title compound (3.65 g) according to the procedure described in Step 2 of Example 68. LCMS: 257.1 (M+1). +
[0772] Step 3: ethyl 1-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate
[0773] The product of Step 2 of Example 73 (1.55 g, 6.05 mmol) and ethyl piperidine-4-carboxylate (950 mg, 6.05 mmol) were treated together to give the title compound (1.75 g) according to the procedure described in Step 3 of Example 68. LCMS: 484.2 (M+1). +
[0774] Step 4: 1-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid
[0775] The product of Step 3 of Example 73 (1.7 g, 3.51 mmol) was treated with aqueous LiOH (338 mg, 14.0 mmol) according to the procedure described in Step 2 of Example 68 to give the title compound (1.04 g). LCMS: 456.2 (M+1). +
[0776] Step 5: tert-butyl (3-(1-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidine-4-carboxamido)propyl)carbamate
[0777] The product of Step 4 of Example 73 (800 mg, 1.75 mmol) and tert-butyl (3-aminopropyl)carbamate (305 mg, 1.75 mmol) were treated together to give 580 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 612.3 (M+1). +
[0778] Step 6: 2-(4-((3-aminopropyl)carbamoyl)piperidine-1-carbonyl)-1-(4-(trifluoromethyl)-benzyl)-1H-indole-6-carbimidate ethyl ester
[0779] The product of Step 5 of Example 73 (550 mg, 0.9 mmol) was treated with 50 mL of ethanolic HCl to give the title compound (340 mg) according to the procedure described in Step 4 of Example 68. LCMS: 558.3 (M+1). +
[0780] Step 7: N-(3-aminopropyl)-1-(6-carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidine-4-carboxamide
[0781] The product of Step 6 of Example 73 (340 mg, 0.61 mmol) was treated with 50 mL of ethanolic NH to give the title compound (90 mg) according to the procedure described in Step 5 of Example 68. LCMS: 529.2 (M+1). + , 1 HNMR(300MHz,DMSO-d6):δ1.51(m,4H),2.49(m,2H),2.71(m,4H),3.15(m,3H),3.82(m,1H),4.38(m,1H),5.65(s,2H),6.8 3(s,1H),7.23(m,2H),7.52(d,1H),7.78(m,4H),7.94(m,1H),9.13(brs,2H),9.23(brs,2H);HPLC:79.68%(retention time = 6.572 minutes)
[0782] The following compounds listed in Table 14 were prepared according to Scheme 9 by following analogous procedures as described above for Example 73 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0783] [Table 192]
[0784] General synthetic scheme 10 [ka]
[0785] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 10. A suitable base (DIPEA) in a suitable solvent (DMF) Upon treatment with 1H-pyrazole-1-carboxamidine hydrochloride in the presence of, the amino analogs obtained from Scheme 9 provide compounds of formula (I).
[0786] Example 74: Synthesis of Compound I-359 1-(6-Carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)-N-(3-guanidinopropyl)-piperidine-4-carboxamide [ka]
[0787] Step 1: 1-(6-Carbamimidoyl-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)-N-(3-guanidinopropyl)piperidine-4-carboxamide
[0788] The product of Step 7 of Example 73 (90 mg, 0.17 mmol) dissolved in 10 mL of DMF was treated with 1H-pyrazole-1-carboxamidine hydrochloride (50 mg, 0.34 mmol) and DIPEA (88 mg, 0.68 mmol) and stirred at room temperature for 24 hours. Evaporation of the solvent under vacuum gave the crude compound, which was purified by reverse-phase preparative high-performance column chromatography to give 20 mg of the title compound. LCMS: 571.3 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ1.49(m,3H),1.71(m,2H),2.31(m,2H),3.12(m,6H),3.85(m,1H),4.45(m,1H),5.65(s ,2H),6.95(s,1H),7.22(d,2H),7.50(m,2H),7.63(d,2H),7.83(m,2H),8.22(s,1H),8.89(brs,2H),9.25(brs,2H)
[0789] The following compounds listed in Table 15 were prepared according to Scheme 7 by following analogous procedures as described above for Example 74 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0790] [Table 193]
[0791] General synthetic scheme 11 [ka]
[0792] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 11. Upon reduction with Zn in the presence of acetic acid, the nitro derivative yields an amine, which is coupled with a carboxylic acid under standard coupling conditions to give the compound N-1 functionalized amide. Deprotection of the protecting group with ethanolic HCl results in conversion to a nitrile intermediate, which upon treatment with ammonia yields the analog of formula (I).
[0793] Example 75: Synthesis of Compound I-363 3-Amino-N-(3-((2-(4-(2-aminoethyl)piperidine-1-carbonyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)phenyl)propenamide [ka]
[0794] Step 1: ethyl 6-cyano-1-(3-nitrobenzyl)-1H-indole-2-carboxylate
[0795] Ethyl 6-cyano-1H-indole-2-carboxylate (10.0 g, 46.71 mmol) and 1-(bromomethyl)-3-nitrobenzene (10.04 g, 46.71 mmol) were treated together to give 6.8 g of the title compound according to the procedure described in Step 1 of Example 68. LCMS: 350.1 (M+1). +
[0796] Step 2: 6-cyano-1-(3-nitrobenzyl)-1H-indole-2-carboxylic acid
[0797] The product of Step 1 of Example 75 (1.6 g, 4.58 mmol) was treated with lithium hydroxide (440 mg, 18.33 mmol) according to the procedure described in Step 2 of Example 68 to give 930 mg of the title compound. LCMS: 322.1 (M+1). +
[0798] Step 3: ethyl 1-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate
[0799] The product of Step 2 of Example 75 (900 mg, 2.8 mmol) and tert-butyl (2-(piperidin-4-yl)ethyl)-carbamate (638 mg, 2.8 mmol) were treated together to give 740 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 532.2 (M+1). +
[0800] Step 4: tert-butyl (2-(1-(1-(3-aminobenzyl)-6-cyano-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0801] The product of Step 3 of Example 75 (730 mg, 1.37 mmol) was treated with zinc (350 mg, 5.48 mmol) according to the procedure described in Step 4 of Example 70 to give 400 mg of the title compound. LCMS: 502.3 (M+1). +
[0802] Step 5: tert-butyl (2-(1-(1-(3-(3-((tert-butoxycarbonyl)amino)propanamido)benzyl)-6-cyano-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0803] The product of Step 4 of Example 75 (400 mg, 0.59 mmol) and 3-((tert-butoxycarbonyl)-amino)propanoic acid (112 mg, 0.59 mmol) were treated together to give 320 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 673.3 (M+1). +
[0804] Step 6: 2-(4-(2-aminoethyl)piperidine-1-carbonyl)-1-(3-(3-aminopropanamido)benzyl)-1H-indole-6-carbimidate ethyl ester
[0805] The product of Step 5 of Example 75 (320 mg, 0.47 mmol) was treated with 50 mL of ethanolic HCl to give 110 mg of the title compound according to the procedure described in Step 4 of Example 68. LCMS: 519.3 (M+1). +
[0806] Step 7: 3-amino-N-(3-((2-(4-(2-aminoethyl)piperidine-1-carbonyl)-6-carbamimidoyl-1H-indol-1-yl)methyl)phenyl)propanamide
[0807] The product of Step 6 of Example 75 (110 mg, 0.21 mmol) was treated with 50 mL of ethanolic NH3 to give 22 mg of the title compound according to the procedure described in Step 5 of Example 68. LCMS: 490.3 (M+1). + , 1 H-NMR(300MHz,DMSO-d6):δ0.51(m,1H),0.81(m,1H),1.32(m,2H),1.49(m, 2H),1.61(m,1H),2.65(m,4H),2.81(m,1H),3.05(m,2H),3.71(m,2H),4.41( m,1H),5.52(d,2H),6.52(s,1H),6.75(m,2H),7.21(m,1H),7.31(s,1H),7. 52(m,2H),7.81(m,6H),8.35(s,1H),9.12(brs,2H),9.27(brs,2H),10.10(b rs,2H)
[0808] The following compounds listed in Table 16 were prepared according to Scheme 11 by following analogous procedures as described above for Example 75 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0809] [Table 194] [Table 195] [Table 196] [Table 197]
[0810] General synthetic scheme 12 [ka]
[0811] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 12. Appropriately functionalized 6-cyano-indole-2-carboxylic acids were coupled to functionalized cyclic amines using EDC / HOBt to give C(2) amines, which upon treatment with aqueous hydroxylamine and subsequent deprotection of the acid-labile protecting groups with ethanolic HCl gave analogs of general formula (I).
[0812] Example 76: Compound I-379 2-(4-(2-aminoethyl)piperidine-1-carbonyl)-N'-hydroxy-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carboximidamide [ka]
[0813] Step 1: tert-butyl (2-(1-(6-cyano-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0814] The product of Step 2 of Example 73 (753 mg, 2.19 mmol) and tert-butyl (2-(piperidin-4-yl)ethyl)carbamate (500 mg, 2.19 mmol) were treated together to give 575 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 555.3 (M+1). +
[0815] Step 2: tert-butyl-(2-(1-(6-(N'-hydroxycarbamimidoyl)-1-(4-(trifluoromethyl)benzyl)-1H-indole-2-carbonyl)piperidin-4-yl)ethyl)carbamate
[0816] The product of Step 1 of Example 76 (500 mg, 0.9 mmol) was treated with aqueous NHOH (0.3 mL) to give 425 mg of the title compound according to the procedure described in Step 4 of Example 69. LCMS: 588.3 (M+1). +
[0817] Step 3: 2-(4-(2-aminoethyl)piperidine-1-carbonyl)-N'-hydroxy-1-(4-(trifluoromethyl)benzyl)-1H-indole-6-carboximidamide
[0818] The product of Step 2 of Example 76 (420 mg, 0.71 mmol) was treated with 30 mL of ethanolic HCl to give 180 mg of the title compound according to the procedure described in Step 7 of Example 71. LCMS: 488.2 (M+1). + , 1H-NMR(300MHz,DMSO-d6):δ0.66(m,1H),0.95(m,1H),1.31(m,5H),2.61(m,5H),4.21(m,1H),5.61(s,2H),6 .91(s,1H),7.32(d,2H),7.41(d,1H),7.60(m,4H),7.85(d,1H),8.20(s,1H),9.00(brs,2H),11.10(brs,1H)
[0819] The following compounds listed in Table 17 were prepared according to Scheme 12 by following analogous procedures as described above for Example 76 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0820] [Table 198] [Table 199]
[0821] General synthetic scheme 13 [ka]
[0822] Yet another general approach for the synthesis of compounds of general formula (I) is shown in general synthetic scheme 13. Compounds of formula (I) were synthesized according to the procedures described in the above scheme.
[0823] Example 77: Synthesis of Compound I-385 4-((6-Carbamimidoyl-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)-N-ethylbenzamide [ka]
[0824] Step 1: 2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indole-6-carbonitrile
[0825] 6-Cyano-1H-indole-2-carboxylic acid (1.5 g, 8.06 mmol) and 3,3-difluoropyrrolidine (862 mg, 8.06 mmol) were treated together to give 1.27 g of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 276.1 (M+1). +
[0826] Step 2: 4-((6-cyano-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)-benzoate methyl
[0827] The product of Step 1 of Example 77 (1.2 g, 4.34 mmol) was treated with methyl 4-(bromomethyl)benzoate (990 mg, 4.34 mmol) according to the procedure described in Step 1 of Example 68 to give 1.28 g of the title compound. LCMS: 424.1 (M+1). +
[0828] Step 3: 4-((6-cyano-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)benzoic acid
[0829] The product of Step 2 of Example 77 (1.2 g, 2.83 mmol) was treated with LiOH (544 mg, 22.7 mmol) according to the procedure described in Step 2 of Example 68 to give 810 mg of the title compound. LCMS: 410.1 (M+1). +
[0830] Step 4: 4-((6-cyano-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)-N-ethylbenzamide
[0831] The product of Step 3 of Example 77 (800 mg, 1.95 mmol) and tert-butyl (3-aminopropyl)carbamate (340 mg, 1.95 mmol) were treated together to give 530 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 437.2 (M+1). +
[0832] Step 5: 4-((2-(3,3-difluoropyrrolidine-1-carbonyl)-6-(N'-hydroxycarbamimidoyl)-1H-indol-1-yl)methyl)-N-ethylbenzamide
[0833] The product of Step 4 of Example 77 (500 mg, 1.14 mmol) was treated with aqueous NHOH (0.4 mL) and 375 mg of HCl was obtained according to the procedure described in Step 4 of Example 69. The title compound was obtained. LCMS: 470.2 (M+1) +
[0834] Step 6: 4-((6-(N'-acetoxycarbamimidoyl)-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)-N-ethylbenzamide
[0835] The product of Step 5 of Example 77 (250 mg, 0.53 mmol) was treated with AcO (435 mg, 4.26 mmol) to give 180 mg of the title compound according to the procedure described in Step 5 of Example 69. LCMS: 512.2 (M+1). +
[0836] Step 7: 4-((6-Carbamimidoyl-2-(3,3-difluoropyrrolidine-1-carbonyl)-1H-indol-1-yl)methyl)-N-ethylbenzamide
[0837] The product of Step 6 of Example 77 (150 mg, 0.29 mmol) was treated with zinc (150 mg, 2.34 mmol) according to the procedure described in Step 6 of Example 69 to give 35 mg of the title compound. LCMS: 454.2 (M+1). +, 1 H-NMR(300MHz,DMSO-d6):δ1.06(m,3H),2.29(m,2H),3.22(m,2H),3.68(m,2H),3.89(m,2H),5.67(d,2H),7.10(m,3 HPLC: 96.93% (retention time = 3.264 minutes)
[0838] The following compounds listed in Table 18 were prepared according to Scheme 13 by following analogous procedures as described above for Example 77 using the appropriate reagents with suitable modifications known to one skilled in the art. [ka]
[0839] [Table 200] [Table 201]
[0840] Example 78: Synthesis of Compound I-394 1-([1,1'-biphenyl]-4-ylmethyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-indole-6-carboxamide [ka]
[0841] Step 1: ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-6-cyano-1H-indole-2-carboxylate
[0842] Ethyl 6-cyano-1H-indole-2-carboxylate (800 mg, 3.73 mmol) and 4-(bromomethyl)-1,1'-biphenyl (917 mg, 3.73 mmol) were treated together to give 985 mg of the title compound according to the procedure described in Step 1 of Example 68. LCMS: 381.1 (M+1). +
[0843] Step 2: 1-([1,1'-biphenyl]-4-ylmethyl)-6-cyano-1H-indole-2-carboxylic acid
[0844] The product of Step 1 of Example 78 (980 mg, 2.57 mmol) was treated with LiOH (495 mg, 20.63 mmol) according to the procedure described in Step 2 of Example 68 to give 630 mg of the title compound. LCMS: 353.1 (M+1). +
[0845] Step 3: 1-([1,1'-biphenyl]-4-ylmethyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-indole-6-carbonitrile
[0846] The product of Step 2 of Example 78 (600 mg, 1.7 mmol) and 1,2,3,4-tetrahydroisoquinoline (226 mg, 1.7 mmol) were treated together to give 410 mg of the title compound according to the procedure described in Step 3 of Example 68. LCMS: 468.2 (M+1). +
[0847] Step 4: 1-([1,1'-biphenyl]-4-ylmethyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-indole-6-carboxamide
[0848] To a solution of the product of Step 3 of Example 78 (350 mg, 0.75 mmol) in 5 mL of a mixture of MeOH and HO (1:1) was added solid NaOH (240 mg, 6.0 mmol). The reaction was stirred at 50° C. Upon completion of the reaction, the reaction mixture was concentrated to remove methanol and acidified with 2 N HCl. The aqueous mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. Evaporation of the solvent under vacuum gave the crude product, which was purified by reverse-phase preparative HPLC to give 80 mg of the title compound. LCMS: 486.2 (M+1). + , 1 H-NMR (300MHz, DMSO-d6): δ2.61(m,2H),3.6(m,2H),4.74(m,2H),4.71(s,2H),5.81(s,2H),6.90(s,1H),7.07(m,3 HPLC: 89.33% (retention time = 5.639 minutes)
[0849] General synthetic scheme 14 [ka]
[0850] Example 79: Synthesis of Compound I-395 Carbamimidoyl-N-(4-carbamimidoylbenzyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide [ka]
[0851] Step 1: ethyl 6-cyano-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylate
[0852] To a solution of ethyl 6-cyano-1H-indole-2-carboxylate (2.0 g, 8.433 mmol) in DMF (20 mL), potassium carbonate (3.90 g, 28.32 mmol) and a solution of 1-(bromomethyl)naphthalene (3.1 g, 14.15 mmol) in THF (10 mL) were added and stirred at room temperature for 3 hours. After completion of the reaction, THF was distilled off, ice-cold water was added, and the precipitated product was filtered off. The solid thus obtained was dried under vacuum to give the title compound (2.2 g, crude), which was carried on to the next step without further purification. LCMS: 353.1 (M+1). +
[0853] Step 2: 6-cyano-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0854] The product of Step 1 of Example 79 (1.0 g, 2.8 mmol) was dissolved in a mixture of tetrahydrofuran / ethanol / water (10 mL:5 mL:3 mL) at room temperature, and lithium hydroxide monohydrate (155 mg, 2.67 mmol) was added. The resulting mixture was stirred at room temperature for 12 hours. The reaction mixture was evaporated, acidified with 2N HCl, and the precipitated product was filtered off. The solid thus obtained was dried under vacuum to give the title compound (850 mg, crude), which was carried on to the next step. LCMS: 325.2 (M+1) +
[0855] Step 3: 6-cyano-N-(4-cyanobenzyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide
[0856] The product of Step 2 of Example 395 (350 mg, 1.01 mmol) was dissolved in 5 mL of N,N-dimethylformamide at 0°C under a nitrogen atmosphere. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (194 mg, 1.01 mmol), hydroxybenzotriazole (109 mg, 1.01 mmol), 4-(aminomethyl)benzonitrile (136 mg, 0.81 mmol), and N,N-diisopropylethylamine (0.352 mL, 2.02 mmol) were added, and the resulting mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched with ice-cold water, and the precipitated product was filtered off and dried under vacuum. The resulting crude solid was purified by Combiflash on silica gel, eluting with 0.5% methanol in dichloromethane, to give the title compound (235 mg). LCMS: 441.3 (M+1). +
[0857] Step 4: 2-((4-(ethoxy(imino)methyl)benzyl)carbamoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-6-carbimidate ethyl ester
[0858] The product of Step 3 of Example 79 (170 mg, 0.39 mmol) was placed in a sealed glass tube at 0°C. The resulting mixture was dissolved in 10 mL of ethanolic HCl and 5 mL of dioxane HCl and stirred at room temperature for 12 hours. The reaction was not complete. Again, 10 mL of a 4 M solution of HCl in dioxane was added and stirred at room temperature for 2 days. After completion of the reaction, the solvent was evaporated under vacuum to give the title compound (not isolated), and the crude product was carried on to the next step. LCMS: 533.7 (M+1). +
[0859] Step 5: Carbamimidoyl-N-(4-carbamimidoylbenzyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide (TFA salt)
[0860] The product of Step 4 of Example 79 was dissolved in 50 mL of methanolic ammonia in a sealed tube and stirred at room temperature for 12 hours. After completion of the reaction, the solvent was evaporated under vacuum to give the crude product, which was purified by preparative HPLC using a Kinetex EVO C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 30% aqueous acetonitrile (0.1% TFA) to 60% acetonitrile (0.1% TFA), thereby giving the title compound (100 mg) as the TFA salt.
[0861] LCMS:475.2[M+1] + ; 1 H-NMR (400MHz, CD3OD): δ4.52(s,2H),6.20(dd,1H),6.45(s,2H),7.19(dd,1H),7.27-7.34(m,2H),7.37( d,1H),7.50-7.65(m,5H),7.77(d,1H),7.90-8.02(m,3H),8.16-8.22(m,1H).HPLC:99.45%(retention time=4.88 minutes)
[0862] Example 80: Synthesis of Compound I-396 N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(naphthalen-1-ylsulfonyl)-1H-indole-2-carboxamide [ka]
[0863] Step 1: 6-cyano-1H-indole-2-carboxylic acid
[0864] Ethyl 6-cyano-1H-indole-2-carboxylate (700 mg, 3.28 mmol) was treated with lithium hydroxide monohydrate (207 mg, 4.92 mmol) according to the procedure described in Step 2 of Example 79 to give 600 mg of the title compound. LCMS: 184.9 (M-1). +
[0865] Step 2: tert-butyl ((1r,4r)-4-(6-cyano-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0866] The product of Step 1 of Example 80 (600 mg, 3.22 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (700 mg, 3.22 mmol) were treated together to give 1.1 g of the title compound according to the procedure described in Step 3 of Example 79. LCMS: 283.0 (M-100). +
[0867] Step 3: ((1r,4r)-4-(6-cyano-1-(naphthalen-1-ylsulfonyl) )-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0868] To a solution of the product of Step 2 of Example 80 (500 mg, 1.305 mmol) in THF (15 mL) was added potassium tert-butoxide (250 mg, 2.21 mmol) and 18-crown-6 (35 mg, 0.130 mmol) at 0° C., followed by a THF solution (5 mL) of naphthalene-1-sulfonyl chloride (442 mg, 1.958 mmol) at 0° C. The resulting reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, ice water was added and the mixture was extracted with ethyl acetate (2×50 mL). The organic layer was separated and concentrated in vacuo. The crude residue was purified by Combiflash on silica gel eluting with 0.5% methanol in dichloromethane to give the title compound (200 mg). LCMS: 517.4 (M-56). +
[0869] Step 4: 2-(((1r,4r)-4-aminocyclohexyl)carbamoyl)-1-(naphthalen-1-ylsulfonyl)-1H-indole-6-carbimidate ethyl ester
[0870] The product of Step 3 of Example 80 (220 mg, 0.384 mmol) was treated with 10 mL of ethanolic HCl and a 4 M solution of HCl in dioxane at room temperature for 3 days to give 250 mg of the title compound according to the procedure described in Step 4 of Example 79. LCMS: 518.8 (M). + Such crude product was carried on to the next step.
[0871] Step 5: N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(naphthalen-1-ylsulfonyl)-1H-indole-2-carboxamide (TFA salt)
[0872] The product of Step 4 of Example 80 (250 mg (crude), 0.482 mmol) was treated with 10 mL of ethanolic NH at room temperature as described in Step 5 of Example 1 to give a crude product, which was purified by preparative HPLC with a LUNA C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 30% aqueous acetonitrile (0.02% TFA) to 60% acetonitrile (0.02% TFA), thereby giving the title compound (50 mg) as the TFA salt.
[0873] LCMS: 490.3 (M+1) + ; 1 H-NMR(300MHz,CD3OD):δ1.52-1.38(m,4H),2.08-2.05(m,4H),3.08-3.06(m,1H),3.78-3.62(m,1H),7.11(s,1H),7.7 0-7.54(m,4H),7.90-7.87(m,1H),8.04-8.00(m,2H),8.24-8.21(d,1H),8.49-8.40(m,2H);HPLC:99.5%(retention time = 4.55 minutes)
[0874] The following compounds listed in Table 19 were prepared according to Scheme 14 by following analogous procedures as described above for Example 80 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0875] [Table 202]
[0876] General synthetic scheme 15 [ka]
[0877] Example 81: Synthesis of Compound I-398 6-(N'-hydroxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide [ka]
[0878] Step 1: ethyl 6-cyano-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxylate
[0879] Potassium carbonate (612 mg, 4.43 mmol) and 2-(bromomethyl)naphthalene (392 mg, 1.77 mmol) were added to a solution of ethyl 6-cyano-1H-indole-2-carboxylate (380 mg, 1.77 mmol) in DMF (10 ml) at room temperature, and the mixture was stirred at room temperature. Stirred overnight (12 hours). After completion of the reaction, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to give the crude product (720 mg), which was further purified by Combiflash on silica gel (40 g column) eluting with 30% ethyl acetate in hexane to give the title compound (560 mg). LCMS: 355.2 (M+1). +
[0880] Step 2: 6-cyano-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxylic acid
[0881] The product of Step 1 of Example 81 (560 mg, 1.58 mmol) was dissolved in a mixture of tetrahydrofuran / ethanol (7 mL:2 mL), and an aqueous solution of lithium hydroxide monohydrate (66 mg, 1.58 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was evaporated and acidified to pH 4 with dilute HCl, and the precipitated product was filtered off. The solid thus obtained was dried under vacuum to give the title compound (460 mg, crude), which was carried on to the next step.
[0882] Step 3: tert-butyl-4-((6-cyano-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[0883] To a stirred DMF solution of the product of Step 2 of Example 81 (330 mg, 1.01 mmol) was added HATU (403 mg, 1.06 mmol) and N,N-diisopropylethylamine (253 mg, 2.02 mmol) at 0° C. After stirring at RT for 10 minutes, tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (216 mg, 1.01 mmol) was added and stirred at room temperature for 3 hours. After completion of the reaction, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to give the crude product (470 mg), which was further purified by Combiflash on silica gel (24 g column) eluting with 5% methanol in dichloromethane to give the title compound (370 mg). LCMS: 523.69 (M+1). +
[0884] Step 4: tert-butyl-4-((6-(N'-hydroxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[0885] The product of Step 3 of Example 81 (90 mg, 0.172 mmol) was dissolved in 5 mL of ethanol, 50% aqueous hydroxylamine (1.3 mL) was added, and the resulting mixture was refluxed at 90° C. for 2 hours. The solvent was evaporated under vacuum to give the crude product, water was added, and the precipitated solid was filtered off and dried under vacuum to give the title compound (60 mg). LCMS: 556.6 (M+1). +
[0886] Step 5: 6-(N'-hydroxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide (TFA salt)
[0887] To a stirred solution of the product of Step 4 of Example 81 (60 mg, 0.108 mmol) in dichloromethane was added TFA (0.2 mL) at room temperature and stirred for 3 hours. The reaction mixture was evaporated under reduced pressure at room temperature to give the crude product, which was purified by preparative HPLC with a Kinetex C18 reverse-phase column (19 x 150 mm, 5 microns). The mobile phase was 10% aqueous acetonitrile (0.3% TFA) to 40% acetonitrile (0.3% TFA), which gave the title compound (90 mg) as the TFA salt. LCMS: 456.2 (M+1). + ; 1 H-NMR(400MHz,CD3OD):δ1.28-1.09(m,2H),1.54-1.48(d,2H),1.59-1.55(m,1H),2 .51-2.44(m,2H),3.01-2.98(d,2H),3.16-3.14(d,2H),6.03(s,2H),7.14-7.12(d,1H),7.20(s,1H),7.33(s,1H),7 .43-7.42(m,3H),7.69-7.66(m,1H),7.82-7.75(m,2H),7.93-7.91(dd,1H),8.03(s,1H);HPLC:99.8%(retention time = 5.11 minutes)
[0888] The following compounds listed in Table 20 were prepared according to general Scheme 15 by following analogous procedures as described above for Example 81 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0889] [Table 203]
[0890] Example 82: Compound I-402 tert-Butyl ((1r,4r)-4-(6-carbamimidoyl-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate [ka]
[0891] Step 1: tert-butyl ((1r,4r)-4-(6-cyano-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0892] The product of Step 2 of Example 81 (310 mg, 0.950 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (220 mg, 1.1 mmol) were treated together at room temperature for 1 hour to give 370 mg of the title compound according to the procedure described in Step 3 of Example 81. LCMS: 567.15 (M-56). +
[0893] Step 2: tert-butyl ((1r,4r)-4-(6-(-N'-hydroxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0894] The product of Step 1 of Example 82 (370 mg, 0.708 mmol) was treated with 50% aqueous hydroxylamine (10 mL) to give 300 mg of the title compound according to the procedure described in Step 4 of Example 81. LCMS: 555.85 (M+1). +
[0895] Step 3: tert-butyl ((1r,4r)-4-(6-(-N'-acetoxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0896] To a stirred solution of the product of Step 2 of Example 82 (300 mg, 0.540 mmol) in acetic acid (12 mL) was added acetic anhydride (0.6 mL) at room temperature, and the resulting reaction mixture was stirred for 4 hours. The reaction mixture was evaporated under reduced pressure at room temperature. The resulting crude product was basified with aqueous sodium bicarbonate. The precipitated solid was filtered off and dried under vacuum to give the title compound (270 mg, crude). LCMS: 597.91 (M+1). +
[0897] Step 4: tert-butyl ((1r,4r)-4-(6-carbamimidoyl-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0898] To a solution of the product of Step 3 of Example 82 (220 mg, 0.360 mmol) in a mixture of methanol:THF (1:1) (20 mL) was added 10% palladium on carbon (25 mg), and the resulting mixture was stirred under a hydrogen atmosphere (hydrogen gas-filled balloon) at room temperature for 5 hours. After completion of the reaction, the reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by preparative HPLC using a LUNA C18 reverse-phase column (21.2 x 150 mm, 5 microns). The mobile phase was 15% acetonitrile:methanol (1:1) in water to 80% acetonitrile:methanol (1:1) in water, thereby obtaining the title compound (140 mg) as the TFA salt. LCMS: 540.25 (M+1).+ ; 1 H-NMR (400MHz, DMSO-d6): δ1.20-125(m,4H),1.32(s,9H),1.75-178(m,4H),3.14-3. 20(m,1H),3.62-3.70(m,1H),6.00(s,2H),6.75(d,1H),7.20(s,1H),7.29(d,1H),7. 45-7.47(m,2H),7.52-7.57(m,2H),7.74-7.77(m,1H),7.80-7.85(m,3H),8.22(s,1H),8.55(d,1H).HPLC:99.13%(retention time = 6.83 minutes)
[0899] The following compounds listed in Table 21 were prepared according to general Scheme 15 by following analogous procedures as described above for Example 82 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0900] [Table 204]
[0901] Example 83: Synthesis of Compound I-406 6-Carbamimidoyl-1-(naphthalen-2-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide [ka]
[0902] Step 1: Tert-butyl-4-((6-(N'-acetoxycarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[0903] The product of Step 4 of Example 81 (240 mg, 0.432 mmol) and acetic anhydride (0.5 mL) were treated together to give 200 mg of the title compound according to the procedure described in Step 3 of Example 82. LCMS: 598.4 (M+1).+
[0904] Step 2: tert-butyl 4-((6-carbamimidoyl-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[0905] The product of Step 1 of Example 83 (200 mg, 0.335 mmol) was treated with 10% palladium on carbon (40 mg) in the presence of a hydrogen atmosphere for 6 hours to give 200 mg of the title compound according to the procedure described in Step 4 of Example 82. LCMS: 540.9 (M+1). +
[0906] Step 3: 6-Carbamimidoyl-1-(naphthalen-2-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide
[0907] The product of Step 2 of Example 83 (200 mg, 0.335 mmol) was dissolved in ethanol (5 mL) at 0° C., and ethanolic HCl (5 mL) was added, followed by stirring at room temperature for 5 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to give the crude product (218 mg), which was further triturated with pentane and dried under vacuum to give the title compound (130 mg) as the HCl salt. LCMS: 440.4 (M+1). + , 1 H-NMR(400MHz,CD3OD):δ1.17(m,2H),1.52-1.48(m,3H),2.49-2.48(t,2H), 3.01-2.98(d,2H),3.17-3.15(d,2H),6.05(s,2H),7.15-7.12(d,1H),7.21(s ,1H),7.34(s,1H),7.46-7.43(m,2H),7.58-7.55(m,1H),7.70-7.68(m,1H),7 .81-7.76(m,2H),7.94-7.92(d,1H),8.17(s,1H);HPLC:95.22%(retention time=5.08 minutes)
[0908] The following compounds listed in Table 22 were prepared according to general Scheme 15 by following analogous procedures as described above for Example 406 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0909] [Table 205]
[0910] General Synthetic Scheme 15A [ka]
[0911] Example 84: Synthesis of Compound I-411 tert-Butyl ((1r,4r)-4-(6-(N-ethylcarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamido)cyclohexyl)carbamate [ka]
[0912] To a suspension of Example 82 (70 mg, 0.130 mmol) in ethanol (7 mL) was added a 10% solution of ethanolamine in THF, and the resulting mixture was stirred at room temperature for 16 hours. After completion of the reaction, excess solvent was removed under reduced pressure. The resulting crude product was purified by preparative HPLC using a LUNA C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 30% acetonitrile in water (0.02% TFA) to 60% acetonitrile in water (0.02% TFA), thereby yielding the title compound (15 mg) as the TFA salt.
[0913] LCMS: 568.9 (M+1) + ; 1H-NMR(300MHz,CD3OD):δ1.22-1.28(m,4H),1.34(t,3H),1.42(s,9H),1.7 8-1.86(m,4H),3.23-3.26(m,1H),3.48(q,2H),3.68-3.73(m,1H),6.00(s ,2H),7.14(d,1H),7.19-7.23(m,1H),7.39-7.45(m,4H),7.65-7.68(m,1H ),7.73-7.80(m,2H),7.87(d,1H),8.00(s,1H);HPLC:98.33%(retention time=6.11 minutes)
[0914] The following compounds listed in Table 23 were prepared according to general Scheme 15A by following analogous procedures as described above for Example 84 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0915] [Table 206]
[0916] Example 85: Synthesis of Compound I-413 N-((1r,4r)-4-aminocyclohexyl)-6-(N-ethylcarbamimidoyl)-1-(naphthalen-2-ylmethyl)-1H-indole-2-carboxamide [ka]
[0917] Example 84 (10 mg, 0.02 mmol) was treated with TFA (0.1 mL) to give 5 mg of the title compound as a TFA salt according to the procedure described in Step 5 of Example 81. LCMS: 468.04 (M+1) + ; 1H-NMR(400MHz,CD3OD):δ1.27-1.35(m,5H),1.43-1.46(m,2H),1.86-1.89( m,2H),1.98-2.01(m,2H),2.97-3.10(m,1H)3.45-3.47(m,2H),3.71-3.75( m,1H),6.00(s,2H),7.16-7.21(m,2H),7.41-7.45(m,4H),7.63-7.67(m,1H ),7.73-7.76(m,2H),7.87(d,1H),8.01(s,1H);HPLC:96.36%(retention time=4.56 minutes)
[0918] The following compounds listed in Table 24 were prepared according to general Scheme 15A by following analogous procedures as described above for Example 85 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0919] [Table 207]
[0920] General Synthetic Scheme 15B [ka]
[0921] Example 86: Compound I-415 N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(naphthalen-1-yl)-1H-indole-2-carboxamide [ka]
[0922] Step 1: ethyl 6-cyano-1-(naphthalen-1-yl)-1H-indole-2-carboxylate
[0923] To a stirred solution of ethyl 6-cyano-1H-indole-2-carboxylate (2.0 g, 9.34 mmol) in dichloromethane (50 mL) at room temperature was added naphthalen-1-yl boronic acid (3.1 g, 18.69 mmol), copper(II) acetate (3.25 g, 18.69 mmol), and N,N-diisopropylethylamine (3.6 g, 28.038 mmol) were added. The resulting reaction mixture was stirred at room temperature under an atmosphere of oxygen gas (oxygen bubbling) for 16 hours. After completion of the reaction, water was added, the layers were separated, and the organic layer was concentrated under reduced pressure. The crude product obtained above was purified by CombiFlash on silica gel eluting with 10% ethyl acetate in hexane to give the title product (200 mg). LCMS: 340.9 (M) +
[0924] Step 2: 6-cyano-1-(naphthalen-1-yl)-1H-indole-2-carboxylic acid
[0925] The product of Step 1 of Example 86 (200 mg, 0.588 mmol) was treated with lithium hydroxide monohydrate (38 mg, 0.882 mmol) in THF:ethanol:water (3:3:1) to give 150 mg of the title compound according to the procedure described in Step 2 of Example 81, whereupon the reaction mixture was stirred at room temperature for 12 hours. LCMS: 311.2 (M-1). +
[0926] Step 3: tert-butyl ((1r,4r)-4-(6-cyano-1-(naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0927] The product of Step 2 of Example 86 (50 mg, 0.160 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (42 mg, 0.192 mmol) were treated together to give 66 mg of the title compound according to the procedure described in Step 3 of Example 81. LCMS: 453.4 (M-56). +
[0928] Step 4: tert-butyl ((1r,4r)-4-(6-(N'-hydroxycarbamimidoyl)-1-(naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0929] To a stirred ethanolic solution of the product of Step 3 of Example 86 (100 mg, 0.196 mmol) and N,N-diisopropylethylamine (152 mg, 1.176 mmol) was added hydroxylamine hydrochloride at room temperature. The resulting reaction mixture was stirred at 80° C. for 5 hours. After completion of the reaction, excess solvent was distilled off, water was added, and the precipitated solid was filtered off and dried under vacuum to give the title compound as a crude product (100 mg). LCMS: 542.2 [M+1] +
[0930] This step also confirmed the formation of the amide derivative of the title compound as a minor product that could not be separated by TLC: LCMS: 527.3 [M+1] + [ka]
[0931] (((1r,4r)-4-(6-carbamoyl-1-(naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl)
[0932] This crude mixture of compounds was carried forward to the next step without purification.
[0933] Step 5: ((1r,4r)-4-(6-(N'-acetoxycarbamimidoyl)-1- (Naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl
[0934] To a stirred solution of the product of Step 4 of Example 86 (100 mg, 0.184 mmol) in acetic acid (1 mL) was added acetic anhydride (0.2 mL) at room temperature, and the resulting reaction mixture was stirred for 2 hours. The reaction mixture was evaporated under reduced pressure at room temperature, and ice-cold water was added. The precipitated solid was filtered off and dried under vacuum. The resulting crude solid was further purified by Combiflash on silica gel eluting with 0.5% methanol in dichloromethane.
[0935] The isolated non-polar compound was confirmed as the title compound (50 mg). LCMS: 584.2 (M+1) +
[0936] The isolated polar compound was confirmed as the amide derivative formed in step 4 of Example 86 as follows: LCMS: 527.2 (M+1) + [ka]
[0937] ((1r,4r)-4-(6-carbamoyl-1-(naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate tert-butyl) (polar)
[0938] Step 6: tert-butyl ((1r,4r)-4-(6-carbamimidoyl-1-(naphthalen-1-yl)-1H-indole-2-carboxamido)cyclohexyl)carbamate
[0939] The non-polar product of Step 5, Example 86 (50 mg) was treated with 10% palladium on carbon (15 mg) under a hydrogen atmosphere to give 40 mg of the title compound according to the procedure described in Step 4, Example 82, whereupon the reaction mixture was stirred at room temperature for 2 hours. LCMS: 526.4 (M+1). +
[0940] The following compounds listed in Table 25 were prepared according to general Scheme 15B by following analogous procedures as described above for the product of Step 6 of Example 86 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0941] [Table 208]
[0942] Step 7: N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(naphthalen-1-yl)-1H-indole-2-carboxamide
[0943] The product of Step 6 of Example 86 (40 mg, 0.069 mmol) was treated with TFA (0.1 mL) to give 30 mg of the title compound as a TFA salt according to the procedure described in Step 5 of Example 81. LCMS: 426.3 (M+1). + ; 1 H-NMR(300MHz,CD3OD):δ1.41-1.30(m,4H),1.99-1.75(m,4H),3.02-3.00(m,1H),3.53-3.47(m,1H),7 .05-7.02(d,1H),7.41-7.36(m,3H),7.72-7.51(m,4H),8.11-7.99(m,3H);HPLC:95.53%(retention time=4.60 minutes)
[0944] The following compounds listed in Table 25A were prepared according to general Scheme 15B by following analogous procedures as described above for the product of Step 7 of Example 86 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0945] [Table 209]
[0946] Example 87: Synthesis of Compound I-417 N2-((1r,4r)-4-aminocyclohexyl)-1-(naphthalen-1-yl)-1H-indole-2,6-dicarboxamide [ka]
[0947] The polar product (30 mg, 0.057 mmol) isolated in Step 5 of Example 86 was treated with TFA (0.1 mL) to give 15 mg of the title compound as the TFA salt according to the procedure described in Step 5 of Example 81. LCMS: 427.2 (M+1). + ; 1 HNMR(300MHz,CD3OD):δ1.38-1.28(m,4H),1.97-1.78(m,4H),3.07-2.99(m,1H),3.53-3.51(m,1H),7.05-7.03 (d,1H),7.39-7.32(m,2H),7.71-7.46(m,5H),7.85-7.82(d,1H),8.08-8.00(m,2H);HPLC:99.63%(retention time=5.04 minutes)
[0948] General synthetic scheme 15C [ka]
[0949] Example 88: Synthesis of Compound I-418 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide [ka]
[0950] Step 1: 6-(N'-hydroxycarbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0951] The product of Step 2 of Example 81 (2.7 g, 8.273 mmol) was dissolved in 50 mL of ethanol, 50% aqueous hydroxylamine (20 mL) was added, and the resulting mixture was refluxed at 80° C. for 2 hours. The solvent was evaporated under vacuum to give the crude product, water was added, and the precipitated solid was filtered off. The resulting solid was triturated with cold water followed by n-pentane and dried under vacuum to give the title compound (2.45 g). LCMS: 360.2 (M+1). +
[0952] Step 2: 6-(N'-acetoxycarbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0953] To a stirred solution of the product of Step 1 of Example 88 (2.40 g, 6.678 mmol) in acetic acid (20 mL) at 0° C. was added acetic anhydride (4.09 g, 40.07 mmol). The resulting reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was evaporated under reduced pressure at room temperature. The resulting residue was triturated with diethyl ether and dried under vacuum to give the title compound (2.65 g, crude). LCMS: 402.2 (M+1). +
[0954] Step 3: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0955] To a stirred suspension of the product of Step 2 of Example 88 (2.65 g, 6.601 mmol) in methanol, acetic acid (3.0 mL) and 10% palladium on carbon (wet) (300 mg) were added at room temperature, and the mixture was stirred under a hydrogen atmosphere (hydrogen gas-filled balloon) for 3 hours. After completion of the reaction, the reaction mixture was filtered through a Celite bed, and the filtrate was concentrated under reduced pressure. The resulting crude product was triturated with 50 mL of a mixture of diethyl ether:pentane (1:4), and the resulting solid was dried under vacuum to give the title compound (2.40 g). LCMS: 343.7 (M-1). +
[0956] Step 4: 6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0957] To a stirred suspension of the product of Step 3 of Example 88 (2.40 g, 6.98 mmol) in methanol at 0° C. were added di-tert-butyl dicarbonate (2.28 g, 10.48 mmol) and N,N-diisopropylethylamine (2.44 mL, 13.97 mmol), and the resulting reaction mixture was stirred at room temperature for 20 hours. After completion of the reaction, the reaction mixture was evaporated under reduced pressure. The residue obtained above was redissolved in water and extracted with an equal volume of ethyl acetate. The aqueous layer was acidified with citric acid solution, and the precipitated solid was filtered off and dried to give the title compound (2.40 g). LCMS: 444.4 (M+1). +
[0958] Step 5: 4-(6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1 tert-Butyl 1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamido)piperidine-1-carboxylate
[0959] To a stirred DMF solution of the product of Step 4 of Example 88 (200 mg, 0.441 mmol) was added HATU (251 mg, 0.662 mmol) and N,N-diisopropylethylamine (142 mg, 2.02 mmol) at 0° C. After stirring at room temperature for 10 minutes, tert-butyl 4-aminopiperidine-1-carboxylate (105 mg, 0.529 mmol) was added and stirred at room temperature for 16 hours. After completion of the reaction, ice-cold water was added, and the precipitated solid was filtered off and dried to give the title compound (340 mg). LCMS: 626.4 (M+1). +
[0960] The following compounds listed in Table 26 were prepared according to general Scheme 15C by following analogous procedures as described above for the product of Step 5 of Example 88 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0961] [Table 210] [Table 211]
[0962] Step 6: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-N-(piperidinyl) Zin-4-yl)-1H-indole-2-carboxamide
[0963] To a stirred solution of the product of Step 5 of Example 88 (340 mg, 0.523 mmol) in dichloromethane was added TFA (0.2 mL) at 0° C., and the mixture was stirred at room temperature for 4 hours. The reaction mixture was evaporated under reduced pressure to give the crude compound (490 mg). The resulting crude product was purified by XB The product was purified by preparative HPLC using a ridge C18 reverse-phase column (19 × 150 mm, 5 microns) with a mobile phase of 10% acetonitrile in water (0.02% TFA) to 50% acetonitrile in water (0.02% TFA), which gave the title compound (100 mg) as the TFA salt.
[0964] LCMS: 426.2 (M+1) + ; 1 H-NMR (400MHz, CD3OD): δ1.99-1.69(m,4H),3.36-3.00(m,4H),3.95(m,1H),6.26-6.25(d,1H),6.43(s,2H),7.20-7.17(t ,1H),7.32(s,1H),7.62-7.55(m,3H),7.75-7.73(d,1H),7.58-7.50(m,3H),8.20-8.18(d,1H);HPLC:99.36%(retention time = 4.84 minutes)
[0965] The following compounds listed in Table 27 were prepared according to general Scheme 15C by following analogous procedures as described above for Example 88 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0966] [Table 212] [Table 213] [Table 214] [Table 215] [Table 216]
[0967] Example 89: Synthesis of Compound I-455 1-(Naphthalen-1-ylmethyl)-N2-(piperidin-4-yl)-1H-indole-2,6-dicarboxamide [ka]
[0968] The above title compound (50 mg) was isolated as the TFA salt from the preparative HPLC purification in Step 6 of Example 88. LCMS: 428.0 (M+1) + ; 1 H-NMR(400MHz,CD3OD):δ2.00-1.69(m,4H),3.36-2.96(m,4H),3.93(m,1H),6.242-6.224(d,1H),6.38(s,2H),7.18-7.14(t,1H),7.25(s,1 HPLC: 98.45% (retention time = 5.25 minutes)
[0969] The following compounds listed in Table 27A were isolated with final preparative HPLC purification following similar procedures as described above for Example 89 using the appropriate reagents with suitable modifications known to those skilled in the art.
[0970] [Table 217]
[0971] General synthetic scheme 15D [ka]
[0972] Example 90: Synthesis of Compound I-458 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid [ka]
[0973] Step 1: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0974] A solution of the product of Step 1 of Example 79 (250 mg, 0.766 mmol) in 3 mL of THF cooled to 0° C. and kept under an inert atmosphere was added to a solution of pre-dissolved LiHMDS (solid) (896 mg, 5.367 mmol) in 1 mL of THF at 0° C. under an inert atmosphere. The resulting solution was stirred at room temperature overnight (16 hours). After completion of the reaction, the reaction mixture was quenched with a saturated aqueous solution of ammonium chloride. The precipitated product was filtered off and dried to give the title compound (180 mg). LCMS: 344.0 (M+1). +
[0975] Step 2: 6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0976] To a stirred solution of the product of Step 1 of Example 90 (980 mg, 2.85 mmol) in THF (20 mL) at room temperature was added a 2M aqueous solution of sodium hydroxide (250 mg, 4.28 mmol), followed by di-tert-butyl dicarbonate (932.5 mg, 4.28 mmol), and the resulting reaction mixture was refluxed at 50° C. for 3 hours. After completion of the reaction, the reaction mixture was evaporated under reduced pressure. The resulting residue was diluted with water and adjusted to pH 6-7 with citric acid solution. The precipitated solid was filtered off and dried to give the title compound (1.1 g). LCMS: 443.0 (M+1). +
[0977] Step 2a: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid
[0978] To a stirred solution of the product of Step 2 of Example 90s (85 mg, 0.191 mmol) in dichloromethane (8 mL) was added a solution of predissolved TFA (0.4 mL) in 2 mL of dichloromethane at 0° C., and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was evaporated under reduced pressure, and the resulting crude product was purified by X-Bridge C18 reverse-phase column (19 × 150 mm, 5 microns). The mixture was purified by preparative HPLC using a mobile phase of 10% aqueous acetonitrile (0.1% TFA) to 50% aqueous acetonitrile (0.02% TFA), thereby obtaining the title compound (46 mg) as the TFA salt. LCMS: 342.0 (M-1) + ; 1 H-NMR(600MHz,CD3OD):δ6.16-6.15(d,1H),6.50(s,2H),7.18(t,1H),7.57-7.53(m,3H),7.64(t,1H), 7.74-7.72(d,1H),7.92-7.89(m,2H),7.99-7.97(d,1H),8.24-8.23(d,1H);HPLC:97.95%(retention time = 5.38 minutes)
[0979] The following compounds listed in Table 28 were prepared according to general Scheme 15D by following analogous procedures as described above for Example 90 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0980] [Table 218]
[0981] Example 91: Synthesis of Compound I-460 6-Carbamimidoyl-N-((1-methylpiperidin-4-yl)methyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide [ka]
[0982] Step 1: tert-butyl (imino(2-(((1-methylpiperidin-4-yl)methyl)carbamoyl)-1-(naphthalen-1-ylmethyl)-1H-indol-6-yl)methyl)carbamate
[0983] The product of Step 2 of Example 90 (100 mg, 0.230 mmol) and (1-methylpiperidin-4-yl)methanamine (38 mg, 0.290 mmol) were treated together to give the title compound (110 mg) as a crude product according to the procedure described in Step 3 of Example 79. LCMS: 554.85 (M+1). +
[0984] Step 2: 6-Carbamimidoyl-N-((1-methylpiperidin-4-yl)methyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide
[0985] To a stirred solution of the product of Step 1 of Example 91 (110 mg, 0.200 mmol) in dichloromethane under a nitrogen atmosphere at 0° C., TFA (0.456 mL, 5.96 mmol) was added, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was evaporated under reduced pressure. The crude product obtained was triturated with diethyl ether and dried. The crude product obtained was purified by preparative HPLC using a Kinetex EVO C18 reverse-phase column (21.2×150 mm, 5 microns). The mobile phase was 30% aqueous acetonitrile (0.1% TFA) to 60% aqueous acetonitrile (0.1% TFA), thereby obtaining the title compound (50 mg) as a TFA salt. LCMS: 453.9 (M+1) + ; 1 H-NMR(400MHz,CD3OD):δ1.24-1.30(m,2H),1.67(d,2H),2.64(m,5H),2.89-2 .99(m,1H),3.15(dd,2H),3.29-3.30(m,2H),6.18(dt,1H),6.44(s,2H),7.19( dd,1H),7.28(d,1H),7.56-7.59(m,2H),7.60-7.66(m,1H),7.75(d,1H),7.76- 7.96 (m, 2H), 7.99-8.06 (s, 1H), 8.18-8.26 (m, 1H); HPLC: 99.69% (retention time = 5.11 minutes)
[0986] The following compounds listed in Table 29 were prepared according to general Scheme 15D by following analogous procedures as described above for Example 91 using the appropriate reagents with suitable modifications known to one skilled in the art.
[0987] [Table 219] [Table 220] [Table 221] [Table 222] [Table 223]
[0988] General synthetic scheme 15D-1 [ka]
[0989] Example 92: Synthesis of Compound I-485 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid (1r,4r)-4-aminocyclohexyl [ka]
[0990] Step 1: 6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid (1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl
[0991] To a dichloromethane solution of the product of Step 2 of Example 90 (70 mg, 0.150 mmol) was added 4-dimethylaminopyridine (4 mg, 0.030 mmol) at room temperature, and then N,N'-dicyclohexylcarbodiimide (40 mg, 0.180 mmol) and tert-butyl ((1r,4r)-4-hydroxycyclohexyl)carbamate (40 mg , 0.180 mmol) was added and the resulting reaction mixture was stirred for 2 hours. The reaction mixture was diluted with dichloromethane, washed with water and dried over sodium sulfate. The organic layer was concentrated under reduced pressure to give the title compound (200 mg). LCMS: 641.2 (M+1) +
[0992] Step 2: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid (1r,4r)-4-aminocyclohexyl
[0993] The product of Step 1 of Example 92 (200 mg, 0.300 mmol) was treated with TFA (0.5 mL) to give the crude product according to the procedure described in Step 5 of Example 81.
[0994] The resulting crude product was purified by X-Bridge C18 reversed-phase column (19 × 150 mm, 5 mm The mixture was purified by preparative HPLC using a chromatographic method (Clon) with a mobile phase of 10% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA), thereby giving the title compound (50 mg) as a TFA salt.
[0995] LCMS: 440.85 (M+1) + ; 1 HNMR(400MHz,CD3OD):δ1.37-1.46(m,4H),1.99-2.03(m,4H),3.54-3.58(m,1H),4.78-4.82(m,1H),6.16(d,1H),6.41(s, 2H),7.20(t,1H),7.59-7.61(m,3H),7.68(t,1H),7.78(d,1H),7.95-8.02(m,3H),8.27(d,1H);HPLC:98.35%(retention time = 5.24 minutes)
[0996] General synthetic scheme 15D-2 [ka]
[0997] Example 93: Synthesis of Compound I-486 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid methyl ester [ka]
[0998] Step 1: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylate methyl
[0999] To a stirred solution of the product of Step 2 of Example 90 (200 mg, 0.400 mmol) in methanol (5 mL) was added thionyl chloride (0.160 mL, 2.2 mmol) dropwise at 0°C. The resulting reaction mixture was stirred at 65°C for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure. The resulting residue was basified with aqueous sodium carbonate to pH 9-10. The resulting crude solid was triturated with diethyl ether and dried. The crude product was purified by X-Bridg method. e Purification was carried out by preparative HPLC using a C18 reverse-phase column (19 × 150 mm, 5 microns) with a mobile phase of 10% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA), which gave the title compound (65 mg) as the TFA salt.
[1000] LCMS: 358.0 (M+1) + ; 1 H-NMR(400MHz,CD3OD):δ3.82(s,3H),6.17-6.15(d,1H),6.51(s,2H),7.22-7.19(m,1H ),7.78-7.57(m,5H),8.02-7.94(m,3H),8.28-8.26(d,1H);HPLC:95.95%(retention time=5.21 min)
[1001] Example 94: Synthesis of Compound I-487 2-(hydroxymethyl)-1-(naphthalen-1-ylmethyl)-1H-indole-6-carboximidamide [ka]
[1002] Step 1: 2-(hydroxymethyl)-1-(naphthalen-1-ylmethyl)-1H-indole-6-carboximidamide
[1003] A solution of the product of Step 1 of Example 93 (250 mg, 0.600 mmol) in THF, predissolved in a stirred solution of lithium aluminum hydride (104 mg, 2.6 mmol) in THF (7.5 mL), was added at 0°C under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 4 hours. After completion of the reaction, the reaction mixture was quenched with ethyl acetate (2 mL), water (3 mL), and 15% aqueous NaOH (1 mL) at 0°C and stirred for 10 minutes. The resulting suspension was filtered through a bed of Celite, washed with ethyl acetate, and the filtrate was concentrated to dryness under reduced pressure. The resulting crude product was purified by X-Bridge C18 reverse-phase column (19 x 150 The product was purified by preparative HPLC using a mobile phase of 20% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA), which gave the title compound (50 mg) as the TFA salt.
[1004] LCMS: 330.15 (M+1) + ; 1 H-NMR(400MHz,CD3OD):δ4.72(s,2H),6.16(s,2H),6.28-6.24(d,1H),6.81(s,1H),7.28-7.2 0(m,1H),7.90-7.55(m,6H),7.98-7.94(d,1H),8.30-8.25(d,1H);HPLC:98.69%(retention time=5.33 minutes)
[1005] General synthetic scheme 15D-3 [ka]
[1006] Example 95: Synthesis of Compound I-488 6-Carbamimidoyl-1-(naphthalen-2-yl)-1H-indole-2-carboxylic acid [ka]
[1007] Step 1: ethyl 6-cyano-1-(naphthalen-2-yl)-1H-indole-2-carboxylate
[1008] To a previously degassed (10 min) solution of ethyl 6-cyano-1H-indole-2-carboxylate (2.0 g, 9.34 mmol) in DMSO (25 mL) was added naphthalen-2-ylboronic acid (3.99 g, 0.023 mmol) and trimethylamine (3.77 g, 0.037 mmol) in a sealed tube at room temperature. The mixture was then degassed for 5 min, followed by the addition of copper(II) acetate (6.76 g, 0.373 mmol). The tube was closed under a nitrogen atmosphere and stirred at room temperature for 2 days. Upon completion of the reaction, the reaction mixture was diluted with ethyl acetate and filtered through a Celite bed. The collected filtrate was washed with water, brine, dried over sodium sulfate, and concentrated to give the crude product (2.54 g). The resulting crude product was purified by Combiflash on silica gel (64 g column) eluting with 10% ethyl acetate in hexane to give the title compound (1.45 g). LCMS: 340.75 (M+1) +
[1009] Step 2: 6-cyano-1-(naphthalen-2-yl)-1H-indole-2-carboxylic acid
[1010] The product of Step 1 of Example 95 (1.45 g, 4.2 mmol) was treated with lithium hydroxide monohydrate (179 mg, 4.2 mmol) in THF:ethanol:water to give 590 mg of the title compound as a crude product according to the procedure described in Step 2 of Example 81. LCMS: 311.4 (M-1). +
[1011] Step 3: 6-Carbamimidoyl-1-(naphthalen-2-yl)-1H-indole-2-carboxylic acid
[1012] The product of Step 2 of Example 95 (200 mg, 0.640 mmol) was treated with solid LiHMDS (750 mg, 4.48 mmol) according to the procedure described in Step 1 of Example 90 to give 210 mg of the title compound. LCMS: 328.2 (M-1).+
[1013] Step 4: 6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-2-yl)-1H-indole-2-carboxylic acid
[1014] The product of Step 3 of Example 95 (210 mg, 0.636 mmol) and di-tert-butyl dicarbonate (207 mg, 0.954 mmol) were treated together to give 200 mg of the title compound according to the procedure described in Step 2 of Example 90. LCMS: 428.4 (M-1). +
[1015] Step 4a: 6-Carbamimidoyl-1-(naphthalen-2-yl)-1H-indole-2-carboxylic acid
[1016] The product of Step 4 of Example 95 (70 mg, 0.163 mmol) was treated with TFA (0.2 mL) in dichloromethane to give the first crude product according to the procedure described in Step 2a of Example 90. The resulting crude product was purified by X-Bridge C18 reverse phase column (19 The mixture was purified by preparative HPLC using a 150 mm × 150 mm, 5 micron column. The mobile phase was 20% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA), which gave the title compound (25 mg) as the TFA salt.
[1017] LCMS: 330.15 (M+1) + ; 1 H-NMR (400MHz, CD3OD): δ7.49-7.46(dd,1H),7.64-7.57(m,5H),8.08-7.97(m,5H);HPLC:99.59%(retention time=4.68 minutes)
[1018] The following compounds listed in Table 30 were prepared according to general Scheme 15D-3 by following analogous procedures as described above for Example 95 using the appropriate reagents with suitable modifications known to one skilled in the art.
[1019] [Table 224]
[1020] Example 96: Synthesis of Compound I-490 6-Carbamimidoyl-1-(naphthalen-2-yl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide [ka]
[1021] Step 1: tert-butyl-4-((6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-2-yl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylic acid
[1022] The product of Step 4 of Example 95 (55 mg, 0.128 mmol) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (28 mg, 0.129 mmol) were treated together to give 88 mg of the title compound according to the procedure described in Step 5 of Example 25. LCMS: 626.4 (M+1). +
[1023] Step 2: 6-Carbamimidoyl-1-(naphthalen-2-yl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide
[1024] The product of Step 1 of Example 96 (88 mg, 0.140 mmol) was treated with TFA (0.5 mL) in dichloromethane to give the first crude product according to the procedure described in Step 2a of Example 90. The crude product was purified by preparative HPLC using a Kinetex EVO C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 30% acetonitrile in water (0.05% TFA) to 70% acetonitrile in water (0.05% TFA), which gave the title compound (43 mg) as the TFA salt.
[1025] LCMS:426.2[M+1] + ; 1 H-NMR(400MHz,CD3OD):δ1.25(m,2H),1.75(m,3H),2.75(m,2H),3.32-3.15(m,4H),7.28(s, 1H),7.55(dd,1H),7.60(m,3H),7.75(s,1H),8.13-7.96(m,5H);HPLC:98.11%(retention time = 4.94 minutes)
[1026] The following compounds listed in Table 31 were prepared according to general Scheme 15D-3 by following analogous procedures as described above for Example 96 using the appropriate reagents with suitable modifications known to one skilled in the art.
[1027] [Table 225]
[1028] General synthetic scheme 15E [ka]
[1029] Example 97: Synthesis of Compound I-492 tert-Butyl 4-((6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate [ka]
[1030] Step 1: 6-cyano-1H-indole-2-carboxylic acid
[1031] Ethyl 6-cyano-1H-indole-2-carboxylate (3.5 g, 0.016 mmol) was treated with lithium hydroxide monohydrate (0.86 mg, 0.167 mmol) to give the compound of Example 1. The title compound (2.95 g) was obtained according to the procedure described in Step 2 of 79. LCMS: 185.0 (M-1) +
[1032] Step 2: 6-(N'-hydroxycarbamimidoyl)-1H-indole-2-carboxylic acid
[1033] The product of Step 1 of Example 97 (2.95 g, 15.84 mmol) was treated with 50% aqueous hydroxylamine (10 mL) to give 4.0 g of the title compound according to the procedure described in Step 1 of Example 418. LCMS: 219.9 (M+1). +
[1034] Step 3: 6-(N'-acetoxycarbamimidoyl)-1H-indole-2-carboxylic acid
[1035] The product of Step 2 of Example 97 (4.0 g, 18.26 mmol) was treated with acetic anhydride (5.58 g, 54.79 mmol) to give 7.0 g of the title compound according to the procedure described in Step 2 of Example 10. LCMS: 262.0 (M+1). +
[1036] Step 4: 6-Carbamimidoyl-1H-indole-2-carboxylic acid
[1037] The product of Step 3 of Example 97 (3.5 g, 13.39 mmol) was treated with 10% palladium on carbon (400 mg) under an atmosphere of hydrogen gas to give the title compound (4.0 g) according to the procedure described in Step 3 of Example 88. LCMS: 203.9 (M+1). +
[1038] Step 5: 6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1H-indole-2-carboxylic acid
[1039] The product of Step 4 of Example 97 (4.0 g, 0.019 mmol) was treated with di-tert-butyl dicarbonate (4.29 g, 0.019 mmol) to give the title compound (1.7 g) according to the procedure described in Step 4 of Example 88. LCMS: 304.0 (M+1). +
[1040] Step 6: tert-butyl 4-((6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[1041] The product of Step 5 of Example 97 (250 mg, 0.825 mmol) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (211 mg, 0.990 mmol) were treated together to give 250 mg of the title compound according to the procedure described in Step 5 of Example 88. LCMS: 500.6 (M+1). +
[1042] Step 7: tert-butyl 4-((6-(N-(tert-butoxycarbonyl)carbamimidoyl)-1H-indole-2-carboxamido)methyl)piperidine-1-carboxylate
[1043] To a solution of the product of Step 6 of Example 97 (100 mg, 0.200 mmol) in DMF (3 ml), potassium carbonate (82.96 mg, 0.601 mmol) and 1-(bromomethyl)naphthalene (53.1 mg, 0.240 mmol) were added at room temperature, and the mixture was stirred at 60°C for 5 hours. After completion of the reaction, ice-cold water was added, and the precipitated solid was filtered off and dried. The obtained crude product was purified by preparative TLC (mobile phase: 2% methanol in dichloromethane) to remove impurities. The title compound (25 mg) was obtained as a result of the purification by preparative HPLC using a Gemini-NX C18 reverse phase column (21.2 × 150 mm, 5 microns). The mobile phase was 40% acetonitrile in water (0.02% ammonia) to 90% acetonitrile in water (0.02% ammonia), thereby obtaining the title compound (10 mg).
[1044] LCMS:640.5[M+1] + ; 1 H-NMR(400MHz,CD3OD):δ0.87-0.85(m,2H),1.39-1.29(m,3H),1.41(s,9H),1.45(s ,9H),2.59-2.49(m,2H),3.20-3.06(m,2H),3.86-3.83(m,2H),6.19-6.17(d,1H),6 .39(s,2H),7.18-7.14(t,2H),7.55-7.53(m,3H),7.65-7.63(m,1H),7.81-7.79(d, 1H),7.91-7.89(d,1H),8.04(s,1H),8.22-8.20(d,1H);HPLC:98.23%(retention time = 6.64 minutes)
[1045] The following compounds listed in Table 32 were prepared according to general Scheme 15E by following analogous procedures as described above for Example 97 using the appropriate reagents with suitable modifications known to one skilled in the art.
[1046] [Table 226]
[1047] Example 98: Synthesis of Compound I-496 6-Carbamimidoyl-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide [ka]
[1048] Step 1: 6-Carbamimidoyl-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide
[1049] To a solution of the product of Step 6 of Example 97 (60 mg, 0.120 mmol) in 1,4 dioxane (2 mL) was added HCl in 1,4 dioxane (4 mL) at 0° C. and stirred at room temperature for 3 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain the crude product (60 mg). The crude product obtained above was further purified by preparative HPLC using a Gemini-NX C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 0.5% acetonitrile in water (0.1% TFA) to 25% acetonitrile in water (0.1% TFA), thereby obtaining the title compound (10 mg) as a TFA salt.
[1050] LCMS:300.0[M+1] + ; 1 H-NMR(400MHz,CD3OD):δ1.54-1.28(m,2H),2.03-1.96(m,3H),3.01-2.95(m,2H),3.43-3.32(m,4H),7.19 (s,1H),7.47-7.44(d,1H),7.84-7.82(d,1H),7.97(s,1H),8.78-8.75(m,1H);HPLC:98.94%(retention time=4.21 minutes)
[1051] Example 99: Synthesis of Compound I-497 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide [ka]
[1052] Step 1: 6-Carbamimidoyl-1-(naphthalen-1-ylmethyl)-N-(piperidin-4-ylmethyl)-1H-indole-2-carboxamide
[1053] The product of Step 7 of Example 97 (45 mg, 0.076 mmol) was treated with HCl in 1,4 dioxane to give the crude product according to the procedure described in Example 20. The crude product obtained above was further purified by preparative HPLC using a Kinetex EVO C18 reverse-phase column (21.2 × 150 mm, 5 microns). The mobile phase was 30% acetonitrile in water (0.1% TFA) to 60% acetonitrile in water (0.1% TFA), thereby giving the title compound (19 mg) as the TFA salt.
[1054] LCMS:440.2[M+1] + ; 1 H-NMR(400MHz,CD3OD):δ1.19-1.16(m,2H),1.65-1.58(m,3H),2.71-2.65(m,2H ),3.17-3.14(m,4H),6.18-6.16(d,1H),6.44(s,2H),7.27-7.16(m,1H),7.27(s, 1H),7.59-7.568(m,1H),7.66-7.62(m,1H),7.76-7.74(d,1H),7.96-7.91(m,2H ),8.02(s,1H),8.22-8.21(d,1H),8.85-8.79(m,1H);HPLC:98.97%(retention time=4.68 minutes)
[1055] The following compounds listed in Table 33 were prepared according to general Scheme 15E by following analogous procedures as described above for Example 99 using the appropriate reagents with suitable modifications known to one skilled in the art.
[1056] [Table 227] [Table 228] [Table 229]
[1057] General synthetic scheme 16 [ka]
[1058] Example 100: Synthesis of Compound I-511 3-Amino-N-((1r,4r)-4-aminocyclohexyl)-6-carbamimidoyl-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxamide [ka]
[1059] Step 1: 6-cyano-3-nitro-1H-indole-2-carboxylic acid
[1060] To acetic anhydride (4.5 mL) pre-cooled to -5°C, concentrated nitric acid (0.5 mL) was slowly added. After stirring the reaction mixture at the same temperature (-5°C), the product of Step 1 of Example 97 (0.860 g, 4.62 mmol) was added and the temperature was maintained at -5°C for 30 minutes. The reaction mixture was gradually brought to room temperature and further stirred overnight (about 16 hours). After completion of the reaction, the reaction mixture was poured into water, and the precipitated solid was filtered off, washed with cold water, and dried to give 700 mg of the title compound. LCMS: 230.2 [M-1] +
[1061] Step 2: tert-butyl ((1r,4r)-4-(6-cyano-3-nitro-1H-indole-2-carboxamido)cyclohexyl)carbamate
[1062] The product of Step 1 of Example 100 (650 mg, 2.81 mmol) and tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (662 mg, 3.09 mmol) were treated according to the procedure described in Step 3 of Example 81 to give 365 mg of crude product. The crude compound was further purified by Combiflash on silica gel (24 g column) eluting with 5% methanol in dichloromethane to give the title compound (300 mg). LCMS: 426.0 (M-1). +
[1063] Step 3: tert-butyl ((1r,4r)-4-(6-...
Claims
1. Formula I: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein each X is independently C or N; L 1 is a bond or an optionally substituted divalent C 1-8 A saturated or unsaturated, linear or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently -S(O) 2 substituted by -, -C(O)-, or -O-; R 1 is H or an optionally substituted ring selected from a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic carbocycle, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; L 2 is an optionally substituted divalent C 1-8 A saturated or unsaturated, linear or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally and independently -NR-C(O)-, -C(O)-NR-, -C(O)-, -S(O) 2 -, -C(O)-O-, -OC(O)-, -NR-S(O) 2 -, -S(O) 2 substituted by -NR-, or -Cy-; -Cy- is an optionally substituted divalent ring selected from phenyl, a 4-6 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 4-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 2 is H or an optionally substituted ring selected from a 4-7 membered monocyclic carbocycle, a 4-7 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered bicyclic carbocycle, a 7-10 membered bicyclic heterocarboxylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic ring, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and adamantyl; R 3 is H, -OH, halogen, -CN, -C(O)H, -NH 2 , -NO 2 , -COOH, -CONH 2 , -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 aliphatic compounds, wherein C 1-6 The aliphatic compound is optionally substituted; L 3 is a bond or an optionally substituted divalent C 1-8 a saturated or unsaturated, linear or branched hydrocarbon chain, wherein one, two, or three methylene units of the hydrocarbon chain are optionally replaced by -CO-; R 4 is —NHR, —C(N—R)—NHR, —NH—C(N—R)—NHR, —F, or —OH; and Each R is independently H, OH, -C 1-8 Alkyl, -OC 1-8 Alkyl, —C(O)—C 1-8 Alkyl, —C(O)—OC 1-8 alkyl, 4- to 7-membered monocyclic carbocyclyl, -O-(4- to 7-membered monocyclic carbocyclyl), -C(O)-(4- to 7-membered monocyclic carbocyclyl), -C(O)-O-(4- to 7-membered monocyclic carbocyclyl), phenyl, -O-phenyl, -C(O)-phenyl, -C(O)-O-phenyl, 8- to 10-membered bicyclic aryl, -O-(8- to 10-membered bicyclic aryl), -C(O)-(8- to 10-membered bicyclic aryl), or -C(O)-O-(8- to 10-membered bicyclic aryl), wherein C 1-8 each of alkyl, 4-7 membered monocyclic carbocyclyl, phenyl, and 8-10 membered bicyclic aryl is optionally and independently substituted; However, the compound is 【Chemistry 2】 There is a condition that it is not The compound or a pharma- ceutically acceptable salt thereof.
2. The compound has formula II: 【Chemistry 3】 2. The compound of claim 1, which is:
3. The compound has formula III: 【Chemistry 4】 3. The compound of claim 1 or 2, which is of the formula: or a pharma- ceutically acceptable salt thereof.
4. The compound has formula IV: 【Chemistry 5】 13. A compound according to any one of the preceding claims, which is of the formula: or a pharma- ceutically acceptable salt thereof.
5. L 1 is optionally substituted C 1-8 A divalent hydrocarbon chain, one methylene unit of the hydrocarbon chain being -S(O) 2 13. A compound according to any one of the preceding claims, optionally substituted by -, -C(O)-, or -O-, or a pharma- ceutically acceptable salt thereof.
6. R 1 is an optionally substituted ring selected from a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aromatic carbocycle, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or a pharma- ceutically acceptable salt thereof.
7. R 1 4. A compound according to any one of the preceding claims, wherein is optionally substituted phenyl, or an optionally substituted 8-10 membered bicyclic aromatic carbocycle, or a pharma- ceutically acceptable salt thereof.
8. R 1 is an optionally substituted 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or a pharma- ceutically acceptable salt thereof.
9. L 2 is optionally substituted C 1-8 A divalent hydrocarbon chain, wherein one methylene unit of the hydrocarbon chain is optionally selected from -NR-C(O)-, -C(O)-NR-, -C(O)-, -S(O) 2 -, -C(O)-O-, -OC(O)-, -NR-S(O) 2 -, -S(O) 2 2. A compound according to any one of the preceding claims, substituted by -NR-, or -Cy-, or a pharma- ceutically acceptable salt thereof.
10. 2. The compound of any one of the preceding claims, wherein -Cy- is optionally substituted phenylene, optionally substituted pyridylene, or a 4-6 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or a pharma- ceutically acceptable salt thereof.
11. R 2 5. The compound of any one of the preceding claims, wherein R is an optionally substituted ring selected from a 4-7 membered monocyclic carbocycle, a 4-7 membered monocyclic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered bicyclic carbocycle, a 7-10 membered bicyclic heterocyclic carboxylic acid ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aromatic ring, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and adamantyl, or a pharma- ceutically acceptable salt thereof.
12. R 2 is an optionally substituted ring selected from a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from phenyl, nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aromatic ring, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or a pharma- ceutically acceptable salt thereof.
13. R 3 -OH, halogen, -CN, -C(O)H, -NH 2 , -NO 2 , -COOH, -CONH 2 , -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 an aliphatic compound, 1-6 10. A compound according to any one of the preceding claims, or a pharma- ceutically acceptable salt thereof, wherein the aliphatic compound is optionally substituted.
14. R 3 -OH, -NH 2 , -NO 2 , -COOH, -NH-C(O)-OC 1-6 aliphatic compound, C 1-6 Aliphatic compounds, or -C(O)-C 1-6 an aliphatic compound, 1-6 10. A compound according to any one of the preceding claims, or a pharma- ceutically acceptable salt thereof, wherein the aliphatic compound is optionally substituted.
15. L 3 is a bond or an optionally substituted C 1-8 10. A compound according to any one of the preceding claims, which is a divalent hydrocarbon chain, one methylene unit of said hydrocarbon chain optionally being replaced by -CO-; or a pharma- ceutically acceptable salt thereof.
16. R 4 4. A compound according to any one of the preceding claims, wherein is -NHR, -C(N-R)NHR, or -C(N-OR)-NHR, or a pharma- ceutically acceptable salt thereof.
17. A compound selected from those shown in Table A, or a pharma- ceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, adjuvant or vehicle.
19. 20. A method of treating a disorder, disease and / or condition in a patient in which hepcidin is low, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
20. A method of increasing hepcidin production by the liver in a patient, comprising administering to said patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof. , the method.
21. 20. A method of treating an iron overload disorder, disease and / or condition in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
22. 22. The method of claim 21, wherein the iron overload disorder, disease and / or condition is selected from the group consisting of hemochromatosis types 1, 2a, 2b and 3 (hemochromatosis, Hfe hemochromatosis (type 1), juvenile hemochromatosis (types 2a and 2b)), hepcidin deficiency, transfusional iron overload, African iron overload, and iron overload cardiomyopathy.
23. 20. A method of treating iron-loaded anemia in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
24. 24. The method of claim 23, wherein the iron-loaded anemia is selected from the group consisting of β thalassemia, HbE / thalassemia (thalassemia major, thalassemia intermediate, thalassemia minor, transfusion-independent thalassemia, transfusion-dependent thalassemia), α thalassemia, congenital dyserythroid anemia (types I and II), pyruvate kinase deficiency, and myelodysplasia (e.g., myelodysplastic syndromes and MDS associated with RARS SF3B1).
25. 20. A method of treating a blood disease, disorder and / or condition in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
26. 26. The method of claim 25, wherein the blood disease, disorder and / or condition is selected from the group consisting of sickle cell disease (e.g., sickle cell anemia), polycythemia vera, sideroblastic anemia, and bone marrow transplantation.
27. 20. A method of treating liver disease in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
28. 28. The method of claim 27, wherein the liver disease is selected from the group consisting of hepatitis B, hepatitis C, alcoholic liver disease, cirrhosis of the liver, hepatocellular carcinoma, and nonalcoholic steatohepatitis (NASH).
29. 20. A method of treating a metabolic disease in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
30. 30. The method of claim 29, wherein the metabolic disorder is selected from the group consisting of metabolic syndrome, insulin resistance, type II diabetes, porphyria, porphyria cutanea tarda, Wilson's disease, and acute iron overload.
31. 20. A method of treating a neurodegenerative disease in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
32. 20. A method of treating an infectious disease in a patient, comprising administering to the patient a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.
33. 33. The method of claim 32, wherein the infectious disease is a siderophilic infection.
34. 23. A method of inhibiting matriptase 2 or a mutant form thereof in a biological sample, comprising contacting said sample with a compound according to any one of claims 1 to 17.
Citation Information
Patent Citations
N-benzyl-5 / 6-formyl amino indol-2-carboxylic acid derivative and application thereof
CN105175309A
New use
JP1998067682A
protease inhibitor
JP2002532479A
viral polymerase inhibitor
JP2004537564A
Use of substituted 2,5-diamidoindoles for the treatment of urinary system diseases
JP2006511562A
